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 ABSTRACT 
The use of bioceramic materials for the repair and regeneration of injured or diseased parts of the 
musculoskeletal system is a longstanding area of interest. However, the possibility to extend their 
range of applications, particularly for load-bearing bone defects and shape them into custom-built 
geometries is still an open challenge.  
Beyond the state of the art, this research work focused on the processing and characterisation of 
eight novel silicate, phosphate and borate glass formulations (coded as NCLx, where x=1 to 8), 
containing different oxides and in diverse molar percentages. The glass frits were provided by GTS 
Ltd (Sheffield, UK) along with apatite-wollastonite (AW), used as comparison material. 
In the first part of the work glass powders were characterised in terms of physico-chemical and 
biological properties. Subsequently, the glass powders were processed in form of dense bulk 
materials, and their sintering and mechanical behaviour was evaluated.  
On the basis of the biocompatibility data, assessed using rat osteoblasts, three formulations were 
selected for further characterisation. In vitro bioactivity testing using simulated body fluid showed 
that after 7 days of incubation the three materials, and NCL7 in particular, showed the formation 
of globular shape apatite precursor precipitates, indicating the bioactive behaviour of these glasses.  
In the last part of the study, 3D porous structures were manufactured via a binder jetting, powder-
based 3D printing technology. The sintered 3D printed parts exhibited architecture and mechanical 
property values similar to those of AW. In addition, the in vitro biocompatibility indicated a 
biological positive response with a cell viability comparable to AW after 7 days.  
The research overall has processed and characterised a range of novel bioceramic formulations, 
and demonstrated the potential and effectiveness of the 3DP strategy to manufacture highly 
reproducible ceramic-based structures.  
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Chapter 1. Introduction 
Annually, more than two million bone graft procedures are performed worldwide to repair bone 
defects in orthopaedics, neurosurgery and dentistry (Van Lieshout et al., 2011). In 2013, the global 
market for joint reconstruction and replacement was worth nearly €11.8 billion. In Europe the 
market has been estimated to increase from €3.4 billion in 2013 up to €4 billion by 2018 (Joint 
Reconstruction and Replacement: Materials, Technologies, and Global Markets, 2014). 
Among the human tissues, bone has been considered one of the most transplanted, second only to 
blood (Giannoudis et al., 2005). In addition to other important properties, bone possesses the 
intrinsic capacity of self-healing in response to injury (Dimitriou et al., 2011). Hence, most of small 
skeletal fractures heal spontaneously without the need of further treatments. However, in complex 
clinical conditions (such as skeletal reconstruction of large load-bearing bone defects resulting 
from trauma, infection, tumour resection and skeletal abnormalities), or cases in which the 
regenerative process is compromised (like avascular necrosis, atrophic non-unions and 
osteoporosis), the tissue cannot heal on its own, and therefore additional reconstructive surgical 
interventions are required (Logeart-Avramoglou et al., 2005). 
Since the first reported use of a calcium sulphate to fill bone defects in 1892 (Dressmann, 1892), 
material-based strategies have seen remarkable progress, emerging as a promising alternative to 
the more common autologous tissue-based approach (Salgado et al., 2004).  
Particularly, in 1969 Prof. L. Hench proposed the first glass intended for bone tissue repair, later 
commercially known as Bioglass® (Hench, 1991; Hench, 1998b). Hench’s studies represented the 
fundamentals to launch the field of bioactive glasses, a class of biomaterials highly and still widely 
investigated (Jones, 2013).  
The most important feature of bioglasses is their ability to form a strong bond with soft as well as 
hard host tissue, and to induce cell response resulting in osteoinductive behaviour (Hench et al., 
1971; Xynos et al., 2000b). More specifically, it has been demonstrated that when a bioglass is put 
in contact with biological fluids, a layer of carbonated hydroxyapatite (HCA) develops on its 
surface promoting material-tissue bonding (Gerhardt and Boccaccini, 2010; Chen et al., 2012). In 
addition to the beneficial property to bond to bone, bioactive glasses degrade over time, releasing 
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soluble ions that promote cell proliferation, differentiation and activate gene expression (Xynos et 
al., 2000a; Xynos et al., 2001; Kanczler and Oreffo, 2008; Hoppe et al., 2011) 
After Bioglass® introduction, many new formulations in the silicate, phosphate and borate-based 
system have been designed to meet a set of requirements that are both crucial and necessary for 
optimised tissue-engineered substitutes (scaffolds). The purpose was to improve specific 
properties, such as controlled degradation rate, biocompatibility and most importantly mechanical 
strength (Kokubo et al., 2003; Rahaman et al., 2011; Will et al., 2012; Kaur et al., 2013). However, 
the possibility to extend the range of bioactive glasses applications, particularly for load-bearing 
bone defects, is still an open challenge.  
In addition to material properties, design characteristics of bone-like substitutes are decisive 
aspects in bone tissue repair field (Hollister et al., 2002). An accurate control on both microscopic 
and macroscopic level is thus necessary during the scaffold fabrication process (Henkel et al., 
2013). In this direction, the advances in material processing using additive manufacturing (AM) 
technologies are offering a promising opportunity to generate “smart”, custom-made, and 
ultimately patient-specific devices for bone tissue repair applications (Melchels et al., 2012; Yoo, 
2014; Mota et al., 2015). Furthermore, along with the possibility of tailoring the device geometry 
according to patient needs, AM enables the fabrication of 3D implants with differences in spatial 
distribution of porosities, pore sizes, mechanical and chemical properties over the large scale 
(Henkel et al., 2013). Additionally, this approach overcame the limitations of conventional 
techniques, and most importantly offered great benefit to the healthcare sector (Bose et al., 2013; 
Arafat et al., 2014; Giannitelli et al., 2014). 
Indirect powder-based 3D printing is a versatile technology (Bose et al., 2013), developed in the 
early 1990s at MIT (Cambridge, MA), and is based on jetting of a binder solution onto a powder 
bed, following a layer by layer procedure (Sachs et al., 1992). The advantages of this method, in 
the field of bone tissue repair, derive from the flexibility in material usage and the possibility of 
printing objects with defined geometry, controlled and interconnected structure without the use of 
any toxic solvent (Utela et al., 2010; Butscher et al., 2011; Bose et al., 2013). After the success of 
its application for the fabrication of bioceramics scaffolds (Lee et al., 2005; Leukers et al., 2005; 
Irsen et al., 2006a; Utela et al., 2006b; Vorndran et al., 2008; Butscher et al., 2012; Cox et al., 
2015), the use of 3D printing technology for the production of bone-like substitutes is likely to 
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increase in the coming years, primarily focusing on the development of medical implants that can 
be customised according to patient and clinical needs. 
1.1  Aim and objectives of the work 
Beyond the current state of the art and within the European RESTORATION (Resorbable Ceramic 
Biocomposites for Orthopaedic and Maxillofacial Applications) project (EU FP7 280575), this 
work focused on the processing and characterisation of eight novel silicate, phosphate and borate 
glass formulations (coded as NCLx, where x=1 to 8), containing different oxides and in diverse 
molar percentages, as potential biomaterials to support the repair and regeneration of load bearing 
bone defects. 
To achieve the aim, the following specific objectives were developed: 
 OB1: development of a series of novel glass compositions (later termed bioceramics) 
containing specific doping agents; 
 OB2: evaluation of the physico-chemical and biological properties of the glass powders; 
 OB3: evaluation of the physico-chemical, mechanical and in vitro bioactive properties of 
dense sintered bioceramic pellets; 
 OB4: optimisation of the methodology for the fabrication of three dimensional (3D) porous 
glass-derived substitutes; 
 OB5: evaluation of the physico-chemical, mechanical and biological properties of the 
previously fabricated 3D porous sintered substitutes. 
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1.2  Thesis structure 
In order to achieve the research objectives, the overall thesis is divided into nine chapters.  
The current Chapter 1 provides an introduction to the work, highlighting the aim and the resulting 
objectives, and illustrates how the overall manuscript is organised. 
Chapter 2 starts with a brief overview about bone biology, covering human bone tissue function, 
composition, structure and mechanical properties; and it concludes with an insight on bone 
development, modelling and remodelling processes.  
Chapter 3 presents the current state of the art on bone tissue repair and regeneration. It begins with 
an introduction on the existing clinical approaches, followed by the recent progress on biomaterials 
used for bone tissue substitution. Specifically, it focuses on the use of bioactive glasses and the 
possibility to modify their compositions by adding specific and functional doping agents. 
Furthermore, a relevant literature review on 3D porous structures fabrication methodology is 
presented, along with an in-depth description of additive manufacturing technologies, in order to 
frame the scope of the work. 
According to the emerging clinical need of developing new biomaterials with tailored physico-
chemical and mechanical features, Chapter 4 reports the rationale for the design and development 
of eight novel bioceramic formulations for bone tissue repair and regeneration, along with their 
structure and molar composition.  
Chapter 5 deals with the methodology adopted for the novel glasses production, processing (in 
form of glass powders, bioceramic pellets and 3D porous scaffolds via 3DP technology), and 
characterisation of their physico-chemical, biological and mechanical properties. 
In Chapter 6 are reported the main achievements resulting from the experimental work, carried 
out on the processing and characterisation of the as-synthesised glass powders and dense 
bioceramic pellets. Chapter 7 instead presents the results deriving from the processing and 
characterisation of 3D printed bioceramic substitutes. 
In Chapter 8 a general discussion about the key findings resulting from the experimental work is 
presented; and finally, the overall project conclusions with the limitations and potential future 
developments are outlined in Chapter 9. 
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Chapter 2. Human bone tissue 
2.1  Function and composition of human bone 
Bone is a highly complex living tissue, characterised by its stiffness (typically in the range 0.1-
20GPa) and fracture toughness (typically between 0.1-12MPa·m1/2) (Fu et al., 2011), repair and 
regeneration ability that provides internal support for all higher vertebrates (Marks Jr and Popoff, 
1988). Its basic functions include: i) mechanical support for muscular activity, ii) physical 
protection of organs and soft tissue, and iii) significant flexibility without compromising the 
mechanical strength. Together with its protective functions, bone tissue serves as a reservoir for 
inorganic ions and a source of calcium necessary during the remodelling process which each bone 
continuously undergoes during life (Marks Jr and Popoff, 1988; Marks Jr and Odgren, 2002; 
Clarke, 2008).  
Most biological tissues are frequently defined in terms of both structural and material properties 
(Pal, 2014). Bone is a composite material based on 50 to 70% minerals (inorganic phase), 20 to 
40% organic matrix, 5 to 10% water content, and < 3% lipids (Clarke, 2008). The bone extracellular 
matrix (ECM) is composed of collagenous and non-collagenous proteins. Type I collagen is the 
main constituent of bone organic phase (accounting for approximately 90%) along with smaller 
amounts of type III, V, XI and XIII collagen. The remaining 10% of the ECM proteins weight is 
composed of glycoproteins, proteoglycans and growth factors including bone morphogenetic 
proteins (BMP), alkaline phosphatase (ALP), osteopontin, bone sialoprotein, osteocalcin, 
cytokines and adhesion molecules, which contribute the matrix mineralisation process, bone cell 
proliferation and bone cell activities (Velleman, 2000; Sommerfeldt and Rubin, 2001; Clarke, 
2008; Gentili and Cancedda, 2009). 
Regarding the mineral content, this is mainly made by hydroxyapatite [(Ca10(PO4)6(OH)2)] (85%) 
with traces of calcium carbonate (10%), calcium fluoride (2-3%) and magnesium fluoride (2-3%) 
(Polo-Corrales et al., 2014). Hydroxyapatite (HA) crystals, characterised by a plate shape, are the 
smallest known biological crystals (30-50nm in length, 20-25nm wide, and 2-5nm thick) (Zipkin, 
1970; Boskey, 2007; Palmer et al., 2008). Unlike geological HA [(Ca5(PO4)3(OH)2)] with a Ca/P 
molar ratio equal to 1.67, Ca/P values in bone and dentin were found between 1.37 and 1.87 (Hing, 
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2004). This variation happens because bone is used by the human body as reservoir, maintaining 
magnesium, calcium and phosphate ions homeostasis (Palmer et al., 2008).  
 
From a material science prospective, the organic and inorganic bone components work together to 
confer to bone its exclusive anisotropy characteristics. The amount of mineral content is correlated 
to bone strength and stiffness degree, while the organic phase provides bone its flexibility. 
Specifically, the collagen content gives the bone the ability to support tense loads instead the bone 
mineral constituents give it the ability to support compressive loads (Rho et al., 1998; Tranquilli 
Leali et al., 2009).  
Regarding the cellular makeup of bone, it consists of four different types of cells: osteoblasts (bone-
forming), osteocytes (bone development), bone lining cells (bone protection), and osteoclasts 
(bone-resorbing). A first difference among bone cells is based on their origin: osteoblasts, 
osteocytes and bone lining cells originate from mesenchymal stem cells (MSCs), also known as 
osteoprogenitor cells, whereas osteoclasts originate from hemopoietic stem cells. MSCs are 
multipotent cells that arise from the mesenchyme during tissue development (Marion and Mao, 
2006). Concerning the location, osteoblasts, osteoclasts and bone lining cells are located along the 
bone surface whereas osteocytes are in the internal part of the bone (Figure 2.1) (Buckwalter et al., 
1996). 
 
Figure 2.1: Osteoblasts, osteoclasts, osteocytes and bone lining cells: origins and locations (Marks Jr 
and Odgren, 2002). 
Osteoblasts are mononucleated cells and originate from pluripotent mesenchymal stem cells of the 
bone marrow stroma (Owen, 1988; Pittenger et al., 1999). They are functionally responsible for 
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ECM production and the regulation of the mineralisation process (Clarke, 2008; Neve et al., 2011). 
During osteogenesis (the process of formation of new bone), osteoblasts secrete an amorphous 
matrix called osteoid predominantly consisting of type I collagen along with many non-collagenous 
proteins of the bone matrix, such as bone sialoprotein, osteocalcin and osteopontin (Aubin and 
Triffitt, 2002; Boskey, 2007; Heino and Hentunen, 2008).  
Eventually, osteoblasts can become relatively inactive and form bone lining cells. Due to their 
inactivity these cells have fewer cytoplasmic organelles than osteoblasts, even though it has been 
hypothesised that bone lining cells can be osteoblast precursors (Franz-Odendaal et al., 2006). In 
terms of morphology they are thin and elongated and cover most of bone surface in an adult 
skeleton (Buckwalter et al., 1996; Marks Jr and Odgren, 2002). 
In calcified cartilage and woven bone, mineralisation is initiated by the matrix vesicles that grow 
from the plasma membrane of osteoblasts to create an environment for the concentration of calcium 
and phosphate ions. In lamellar bone, the process is vesicle independent and seems to be started by 
collagen molecule components (Landis et al., 1993). In both cases, collagen serves as template for 
initiation and propagation of mineralisation process. The mineral deposition makes the matrix 
impermeable. Osteoblasts surrounded by the bone matrix progress to their ultimate differentiation 
stage, the osteocytes. It has been estimated that osteocytes make up more than 90% of the bone 
cells in an adult skeleton bone. These cells are located within a space or lacuna and have long 
cytoplasmic process through canaliculi in the matrix to contact processes of adjacent cells. 
Osteocytes have the ability to communicate metabolically and electrically through gap junctions 
(Sheng et al., 2014), which consist of arrays of intercellular channels made of integral membrane 
proteins called connexions (Sosinsky and Nicholson, 2005). The cellular network can sense the 
mechanical deformation that takes place in bone and contributes to bone formation and resorption 
process (Kimmel, 1993). Responsible for the bone resorption process are another class of cells, the 
osteoclasts. They derive from hematopoietic stem cells and the differentiation process requires cell-
cell interactions via either osteoblast or osteoblast precursor cells (Figure 2.2) (Aubin and Triffitt, 
2002; Karaplis, 2002; Heino and Hentunen, 2008). 
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Figure 2.2: Schematic representation of osteoblasts and osteoclasts pathway to bone formation (Kini 
and Nandeesh, 2012). 
A summary of bone cells location, origin and morphology can be found in Table 2.1.  
Table 2.1: Bone cells type, location, origin and morphology. 
Cell type Location Origin Morphology 
Osteoblasts bone surface 
mesenchymal stem 
cells 
cuboidal cells 
Osteoclasts bone surface 
hemopoietic stem 
cells 
giant and 
multinucleated cells 
Lining cells bone surface 
mesenchymal stem 
cells 
thin and elongated 
cells 
Osteocytes inner part of the bone 
mesenchymal stem 
cells 
star-shaped cells 
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2.2  Bone structure and mechanical properties 
At the microscopic level, human bone is characterised by two different types: woven and lamellar 
bone. Woven bone is considered primary and immature with a disoriented arrangement of collagen 
fibres that turn into lamellar bone during adolescence. Lamellar bone is a highly organised structure 
with collagen bundles oriented in the same direction (Hollinger et al., 2004; Ossification, 2004). 
Macroscopically bone can be divided into trabecular (also known as spongy or cancellous) bone, 
which forms the porous inner core, and cortical (also called compact) bone, which forms a dense 
outer shell (Figure 2.3(a)). Their proportions usually differ at various locations in the skeleton, but 
generally cortical bone accounts for 80% of the weight of the human skeleton and cancellous bone 
for the remaining 20% (Rho et al., 1998). Considering a bone cross-section, the end of long bones 
(i.e. tibia or femur) has a hard outer surface of dense compact bone and a porous internal structure, 
whereas flat bones (skull, ilium and rib cage) have two thin layers of cortical bone with a variable 
volume of cancellous bone embedded between them.  
As it was previously stated, cortical bone is highly dense and consists of a hierarchical structure, 
going from the solid material (> 3mm), to the osteons (10–500μm) firstly (Figure 2.3(b)), then to 
lamellae (3–20μm), and finally to the collagen-mineral composite (60–600nm) (Figure 2.3(c)) 
(Lovell, 1990). The osteon, containing blood vessels and nerves in the centre, forms a cylindrical 
structure of about 200-250μm in diameter giving strength to cortical bone. The single lamella 
consists of collagen fibrils (1μm) and they are arranged concentrically around the central Haversian 
canal. The thick and dense arrangement of the structure allows cortical bone to have a much higher 
resistance to torsional and bending forces. In contrast, cancellous bone is highly porous, consisting 
of a honeycomb-like network of branching bars, plates and rods, called trabeculae, interspersed in 
the bone marrow compartment (Figure 2.3(a)).  
The high surface area provided by the porous trabeculae permits the diffusion of nutrients and 
circulation of growth factors. It has also been demonstrated that cancellous bone is metabolically 
more active and is quicker in adapting to changes in mechanical loading and unloading than cortical 
bone (Buckwalter et al., 1996; Rho et al., 1998).  
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Figure 2.3: Hierarchical structure of bone, from macrostructure to sub-nanostructure (Nalla et al., 
2006).  
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In addition, although the elemental composition and the materials are the same for both types of 
bone (Downey and Siegel, 2006), the microstructure produced by cortical bone is characterised by 
regular, cylindrically shaped lamellae. On the contrary, the microstructure of cancellous bone is 
composed by irregular, sinuous convolutions of lamellae, which allows cancellous bone to have 
greater resilience and better absorption of loads (Rho et al., 1998). 
As result of the hierarchically organised architecture and the diverse orientation of bone 
components, the mechanical properties of bone tissue at each anatomical level are different, 
varying according to the loading direction. For these reasons, bone is considered an anisotropic and 
heterogeneous material. 
In particular, for cortical bone the mechanical properties depend mainly on the porosity (5-10%), 
the mineralisation level and organisation of the solid matrix. For the cancellous bone the 
mechanical properties are characterised by a wider range, as reported in Table 2.2, and they vary 
considerably around the periphery, along the length and by a factor of 2-5 from bone to bone 
(Downey and Siegel, 2006).  
The structure-mechanical stresses relationship has been studied since 1982 in terms of Wolff’s law, 
which states that bone and in particular long bones undergo adaptive changes during their growth 
in response to external mechanical stimuli (Goodship, 1987; Clarke, 2008). Furthermore, 
considering the heterogeneity of bone structure and the different mechanical functions, several 
studies (Goldstein, 1987; Kokubo et al., 2003; Currey et al., 2007; Gerhardt and Boccaccini, 2010; 
Fu et al., 2011) have reported that mechanical properties for both cortical and trabecular bone 
should be stated in a range of rather single values, as indicated in the Table 2.2.  
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Table 2.2: Mechanical properties of human cortical and trabecular bone. 
 Compressive 
strength (MPa) 
Flexural 
strength 
(MPa) 
Tensile 
strength 
(MPa) 
Young’s 
Modulus 
(GPa) 
Fracture 
toughness 
(MPa m1/2) 
Porosity 
(%) 
Reference 
cortical 
bone 
130-200 135-193 50-151 7-25 2-12 5-10 
(Evans, 1961; Reilly et 
al., 1974; Hench, 1991; 
Hall, 1992; Rho et al., 
1995; Hernandez et al., 
2001) 
trabecular 
bone 
2-12 10-20 1-5 0.1-5 0.1-0.8 50-90 
(Martin; Reilly et al., 
1974; Goldstein, 1987; 
Hench, 1991; Hall, 
1992; Thompson and 
Hcnch, 1998; Hernandez 
et al., 2001; Currey et 
al., 2007) 
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2.3  Bone development, modelling and remodelling 
As it was previously stated, bone plays a key role in a series of fundamental processes for the 
human body, i.e. growth factor and cytokine depository, acid-base equilibrium and detoxification. 
Additionally, given the capability of adapting its mass and morphology to functional needs, the 
ability of being a mineral reservoir and the capacity of self-repairing, bone tissue has been 
described as the ultimate “smart” material (Sommerfeldt and Rubin, 2001).  
The formation of normal healthy bone takes approximately 4 to 6 months, and occurs by two 
developmental pathways: intramembranous ossification and endochondral ossification (Marks Jr 
and Odgren, 2002). Differentiation and proliferation of mesenchymal stem cells into osteoblasts 
occur during both processes (Heino and Hentunen, 2008). The first one describes the direct 
transformation of mesenchymal stem cells into osteoblasts and it is responsible for the formation 
of craniofacial bone, skull and parts of the clavicle and mandible. Endochondral ossification 
(Greek: endon, “within” and chondros, “cartilage”) arises mainly in long bones involving cartilage 
tissue as a precursor. In this complex and multistep process, mesenchymal progenitor cells 
condense and differentiate into chondrocytes, which are responsible for depositing cartilaginous 
structures that serve as template for developing bones (Karaplis, 2002). 
During life, human bone continually grows in both longitudinal and radial directions, modelling as 
well as remodelling, through the collaborative action of osteoblasts, osteocytes, and osteoclasts 
together with growth factors (Clarke, 2008; Seeman, 2009). Modelling is the process through which 
bone changes its shapes subsequently to physiologic or mechanical stimuli and it occurs at a low 
rate throughout life (Roberts et al., 2004). During this process, bone resorption and formation are 
two uncoupled pathways and they happen on distinct surfaces (Clarke, 2008). In contrast 
remodelling, which is more frequent than modelling in adults (Kobayashi et al., 2003), is the 
process in which bone resorption precedes bone formation, occurring along specific sites on the 
same bone surface, in particular at the interface with the hematopoietic bone marrow (Goodship, 
1987; Seeman, 2009). This mechanism guarantees tissue turnover while maintaining bone strength 
and mineral homeostasis in mature skeleton (Hadjidakis and Androulakis, 2006). During the 
remodelling process old bone is continuously removed and replaced with new bone to prevent 
microdamage accumulation (Turner, 1998). Furthermore, it is a lifelong process and its frequency 
varies according to the demands of the body (Kini and Nandeesh, 2012). Bone remodelling starts 
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with the differentiation of osteoclast precursors into mature multinucleated osteoclasts that are 
attracted at the remodelling site and then activated for the resorption phase. This stage is followed 
by a brief reversal phase during which the osteoblasts proliferate and differentiate into mature 
osteoblasts to repair the resorption defects caused by osteoclasts. Afterwards, during the much 
slower formation phase, some of the osteoblasts are incorporated into the bone matrix as bone-
lining cells or osteocytes. Figure 2.4 summarises the four sequential phases of the overall process: 
activation, resorption, reversal and formation (Rucci, 2008).  
 
Figure 2.4:Schematic representation of bone remodelling process (Services., 2004). 
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Chapter 3. State of the art in bone repair and regeneration 
3.1  Clinical need for bone repair and regeneration 
Thanks to the intrinsic regenerative capacity of bone (Einhorn, 1998; Dawson et al., 2014), 
particularly in young people, the majority of bone fractures heal well without scar formation and 
with no need of further intervention (Gruber et al., 2006; Dimitriou et al., 2011; Dimitriou et al., 
2012; Oryan et al., 2015). However, in patients with defects two and half times bigger than the 
bone radius (commonly called critical size bone defects) (Schroeder and Mosheiff, 2011), and 
which are caused by trauma, bone tumour resections (Cancedda et al., 2007) or severe non-union 
fractures (permanent failure of healing following a broken bone), osteoporosis and avascular 
necrosis, bone regeneration is necessary in a quantity that goes beyond the normal potential for 
self-repair (Bosch et al., 1998; Horner et al., 2010; Dimitriou et al., 2011).  
The incidence of bone diseases such as arthritis, osteoporosis, tumours, trauma and their related 
symptoms is growing worldwide, and it has been estimated to double by 2020 (Amini et al., 2012) 
due to a variety of causes, such as the life expectancy increase and the growing needs of baby-
boomers. Furthermore, with the increase of the older UK population, of which 23% will be 65 and 
over by 2035 (Figure 3.1), the obesity rates, and a lifestyle characterised by poor physical activity 
(Office for National Statistics, 2012), bone tissue replacement and regeneration have become a 
major clinical demand. 
 
Figure 3.1: Percentage of older people in the UK over the all population:1985, 2010 and 2035 (Office 
for National Statistics, 2012).  
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Bone is one of the most common transplanted tissues, the second only after blood (Liu et al., 2013; 
Oryan et al., 2014). According to a new report from research and consulting firm GlobalData, the 
global bone grafts and substitutes (BGS) market value will increase progressively over the coming 
years, going from almost $2.1 billion in 2013 to approximately $2.7 billion by 2020, at a Compound 
Annual Growth Rate (CAGR) of 3.8%. 
Traditional treatments for large bone defects are based on transplant of a) autologous bone (from 
the same patient), b) allogeneic bone (from a human cadaver), and c) xenogeneic bone (from an 
animal) (Petite et al., 2000; Rose and Oreffo, 2002). Based on the use of autologous tissue, 
autograft procedures are considered the ‘gold-standard’ in bone grafting, showing osteogenic, 
osteoinductive (the process by which osteogenesis is induced) and osteoconductive (the process by 
which bone growth is permitted on a material’s surface) properties with the best clinical outcomes 
(Albrektsson and Johansson, 2001; De Long et al., 2007; Brydone et al., 2010). Nevertheless, their 
use in medical practice is limited due to their short supply and to the high percentage of donor site 
morbidity (Younger and Chapman, 1989). The use of allografts or xenografts could be an 
alternative for their high availability and low cost. However, these approaches present also risks, 
like infection transmission and adverse host immune response, resulting in poor outcomes (Galea 
et al., 1998; Burg et al., 2000; Mankin et al., 2005; Khan et al., 2008). The limitations of current 
treatments together with the impact on healthcare system costs encouraged interest in alternative 
therapeutic solutions (De Long et al., 2007; Oryan et al., 2014).  
From a biological perspective, cells, growth factors, extracellular matrix along with cell-matrix 
interactions are crucial for the in vivo process of bone repair (Kanczler and Oreffo, 2008). However, 
when a critical size bone defect develops, the cells cannot migrate from one side to the other, 
requiring for this purpose a solid support (commonly known as scaffold) on which they can anchor 
and build new bone (Schroeder and Mosheiff, 2011). Scaffolds, cells, and signalling molecules are 
defined as basic pillars of bone tissue engineering (BTE) (Amini et al., 2012). The term “tissue 
engineering” was introduced in the late 1980s (Nerem, 2006), although effective awareness of the 
concept started a decade later with the publication of a paper by Langer and Vacanti (Langer and 
Vacanti, 1993). They stated what is now recognised as the definition of TE: “an interdisciplinary 
field that applies the principles of engineering and the life sciences toward the development of 
biological substitutes that restore, maintain, or improve tissue functions or a whole organ” (Vacanti 
and Vacanti, 2013).   
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3.2  3D porous substitutes for bone restoration  
3D porous constructs act as biological and mechanical support, which once implanted into the bone 
defect should induce and direct the growth of new tissue and restore its function (Dvir et al., 2011).  
Due to the complex internal and external structure, but also composition of human bone tissue, 
scaffolds for bone tissue repair and regeneration are governed by many interdependent and also 
conflicting essential prerequisites (Chen et al., 2008). Currently, as many scaffold-based 
approaches are still experimental, there are no specific design criteria that define the properties of 
the so-called “ideal scaffold” for bone repair (Fu et al., 2011). In 2004 Hutmacher stated: “It could 
be argued that there is no ‘ideal scaffold’ design per se, instead each tissue requires a specific 
matrix design with defined material properties” (Hutmacher et al., 2004). The choice of appropriate 
materials, which is of crucial importance for scaffold-based solutions, will be investigated later in 
this chapter. 
Besides chemistry and material selection, it is also widely stated that a scaffold intended for 
orthopaedic applications, should mimic the morphology, structure and function of bone tissue 
(Hutmacher, 2000; Hollister et al., 2002; Salgado et al., 2004), enhancing cell adhesion, 
proliferation and differentiation (Hutmacher, 2001; Stevens, 2008). According to the recent 
literature, a set of desirable requirements for tissue engineered scaffolds is summarised in the Table 
3.1. 
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Table 3.1: Desirable requirements for the design of bone tissue engineered scaffolds. 
Requirement Function 
Biocompatibility Ability to perform its function without exhibiting any immune response 
in the host tissue (Hutmacher, 2000; Hutmacher, 2001) 
Biodegradability 
Tailoring rate of degradation according to the growth rate of the host tissue 
(Reis and Román, 2004) 
Mechanical properties 
The mechanical strength of the scaffold, which is given by the intrinsic 
properties of the biomaterial together with the porous architecture itself, 
should match the strength of natural bone even during the degradation and 
remodelling processes (Yang et al., 2001; Wagoner Johnson and 
Herschler, 2011) 
Porosity and pore size 
The scaffold should have an interconnected porous structure that can 
allow fluid flow, cell migration, bone ingrowth and vascularization (Liu 
et al., 2013). Pore dimensions in the range of 200 to 350 μm have been 
found to be ideal for bone tissue in-growth (Bose et al., 2012); if the pores 
are too small, pore occlusion by cell migration can happen (Salgado et al., 
2004). Furthermore, while macroporosity (pore size > 50 μm) plays an 
important role for osteogenic outcomes, an adequate microporosity (pore 
size <10μm) is essential in order to allow capillary ingrowth. Porosity and 
interconnectivity together are also essential for an accurate diffusion of 
nutrients and for the removal of metabolic waste (Karageorgiou and 
Kaplan, 2005). Additionally, the degree of porosity influences the scaffold 
mechanical stability, therefore its value should be in the range of strength 
and stiffness of the host tissue (Hutmacher, 2000; Karageorgiou and 
Kaplan, 2005; Loh and Choong, 2013). 
Surface properties 
Appropriate surface chemistry is required to promote cell attachment, 
differentiation and proliferation activities (Hsin and Yiwei, 2011; Mitra et 
al., 2013) 
Osteoinductivity 
The scaffold should be able to induce new bone formation (osteogenesis) 
through molecular signalling and the recruitment of osteoprogenitor cells 
(Albrektsson and Johansson, 2001). 
Osteoconductivity 
Scaffold composition should let bone cells to adhere, proliferate and form 
extracellular matrix on its surface and into the pores (Albrektsson and 
Johansson, 2001). 
Processing 
The fabrication process should not affect the material properties and 
subsequent clinical use of the scaffold (Leong et al., 2003). 
Commercialisation  
The processing conditions should be suitable for scaffold 
commercialisation at reasonable costs (Thavornyutikarn et al., 2014). 
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3.3  Biomaterials for bone tissue repair  
Several materials with different compositions and microstructures have been adopted or 
synthesised, and subsequently processed as 3D constructs for bone tissue repair and regeneration 
(Bose et al., 2012). 
The extracellular matrix of bone is a composite of biological materials, mainly based on ceramics 
(i.e. hydroxyapatite), biological polymers (i.e. collagen matrix) and water. Therefore, synthetic 
and/or naturally occurring ceramics, polymers and their composites are the materials mainly 
investigated for the fabrication of bone-like substitutes (Rezwan et al., 2006; Raucci et al., 2012). 
The next paragraphs will provide a review of the current state of art on biomaterials for bone repair, 
where basic and advanced characteristics will be discussed, focusing primarily on bioceramic class 
materials.  
 Natural and synthetic polymers 
Biological polymers, such as hyaluronic acid, collagen, fibrin and chitosan have seen an increasing 
use as promising candidates for bone repair applications (Griffith, 2000; Hutmacher, 2000; Seal et 
al., 2001; Dalton et al., 2009). They are usually biocompatible and enzymatically biodegradable 
materials. The main advantage from their use is the support of cell attachment, proliferation, and 
differentiation through the use of biofunctional molecules (Narayan, 2009). Furthermore, they have 
the potential to interact biologically with the host tissue, and have low immunogenic properties 
(Salgado et al., 2004). However, depending upon the application, the rate of the previously 
mentioned enzymatic degradation may not be easily controlled. Therefore, it may be difficult to 
determine the lifespan of natural polymers in vivo.  
Flexibility in processing, the ability to tailor their chemistry and their biodegradation rate are 
additional advantages of synthetic polymers (Planell et al., 2009; Bose et al., 2012). The most 
common biodegradable synthetic polymers used for 3D structures are: saturated poly-α-hydroxy 
esters, including poly(lactic acid) (PLA) and their forms (L-PLA (PLLA), D-PLA (PDLA), and 
mixture of D,L-PLA (PDLLA)), poly(glycolic acid) (PGA) as well as poly(lactic-co glycolide) 
(PLGA) copolymers (Mano et al., 2004; Gentile et al., 2014).  
The degradation products of certain polymers (PLA, PGA) are usually removed by the natural 
physiological pathways. However, they may create a local acidic environment with the consequent 
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adverse host tissue response (Chen et al., 2012). Additionally, the adoption of polymeric materials, 
mainly natural polymers, for bone repair and regeneration is challenging, especially for their 
limited abilities in achieving strong bonding with bone, and in some circumstances unsuitable 
mechanical properties.  
In particular, for the regeneration of load-bearing bones, these polymers exhibit low elastic moduli 
(Griffith, 2000; Seal et al., 2001), and are prone to a deformation mechanism known as creep 
(Lichte et al., 2011). Hence, to overcome the above mentioned drawbacks, proposed strategies are: 
to i) reinforce polymers with other materials (i.e. bioceramics or metals) and use them as 
composites (section 3.3.2) or ii) to use ceramics themselves as unique component (section 3.3.3). 
 Composites 
Composites materials are those that combine two or more different materials in order to obtain 
better resultant outcomes, mimicking the composite structure of natural bone tissue (Davis and 
Leach, 2008). To improve specific properties such as fracture toughness, bioactivity and 
biocompatibility, at least two phases are combined together: the matrix and the dispersed phase 
(Wang, 2003). The matrix has the main function of filling the volume and transfer the stress to the 
dispersed phase, instead this last one, which is harder and stiffer, is responsible for enhancing one 
or more properties of the final composite (Dorozhkin, 2011).  
Composite materials generally can be particle-reinforced, fibre reinforced and structural 
composites. Specifically for bone tissue repair, composite materials are commonly made of 
polymers that are used as a matrix, and then are combined with a ceramic phase (inorganic 
component) in order to obtain biomaterials with improved mechanical and bioactive properties 
(Dhandayuthapani et al., 2011) and enhanced degradation profiles (Gloria et al., 2010). Example 
of composite structures developed for load bearing segmental bone defects are reported in the Table 
3.2. 
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Table 3.2: In vivo pre-clinical studies of load-bearing bone defects using composite scaffolds (adapted 
from (Pilia et al., 2013)). 
Ceramic phase Polymeric phase Defect area and size 
Length of the 
study 
Reference 
TTCP and DCPA PLGA 
Wistar rat femur (2.3 
mm) 
2 weeks 
(Lickorish 
et al., 
2007) 
BCaP Collagen  
New Zeland white 
rabbit femur (20 
mm) 
18 weeks 
(Jegoux et 
al., 2008) 
TCP PCL 
CGH/Rnu rat femur 
(8 mm) 
3 weeks 
(Rai et al., 
2010) 
β-TCP PGA 
Sprague-Dawley rat 
femur (3 mm) 
12 weeks 
(Cao and 
Kuboyama, 
2010) 
HA HT-PPFhm Rabbit femur (4 mm) 48 weeks 
(Jayabalan 
et al., 
2010) 
Bioglass 
Collagen-
phosphatidylserine 
Sprague-Dawley rat 
femur (3.5 mm) 
6 weeks 
(Xu et al., 
2011) 
 Bioceramics 
Referring to the definition of Hench, “bioceramics are those ceramics used for the repair and 
reconstruction of diseased or damaged parts of the musculoskeletal system” (Hench, 1991). More 
recently the definition of bioceramics have been extended to “a large class of specially designed 
ceramics for the repair and reconstruction of diseased or damaged parts of the body” (Baino et al., 
2015). 
Bioceramics, such as hydroxyapatite, calcium phosphates and bioactive glasses are the most 
investigated biomaterials for orthopaedic and maxillofacial applications, as demonstrated by the 
considerable amount of literature that has been published in this specific field (Figure 3.2).  
The growing interest in the use of these materials is due to their versatile properties, which can be 
tailored according to their composition, and their ability to form a direct physical bond to bone via 
the formation of an apatite layer on the surface of the implant (Hench, 1998c; Ducheyne and Qiu, 
1999; Kokubo et al., 2003).  
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Figure 3.2: Literature published between 1990 and 2015 in the area of bioceramics (Source: Scopus). 
Generally, the term bioceramic is used to cover a broad class of biomaterials, specifically: bioactive 
glasses such as Bioglass®, glass-ceramics such as AW, and ceramics such as synthetic HA (Hench, 
1999). Traditionally, bioceramics have been used very successfully within the human body for a 
wide range of applications as shown in Figure 3.3. Specifically, orthopaedics and dentistry are the 
favourite areas. Classic applications involve bone fillers and dental implants in form of dense or 
porous substitute, injectable cement pastes and prosthesis surface coating (Hench, 1991; Hench, 
1998a; Hench, 1998b). 
Currently, this class of biomaterials are proposed for a broader range of clinical applications that 
goes beyond bone tissue engineering field (i.e. otoryngological implants and keratoprostheses). 
Miguez-Pacheco et al., reviewed the use of bioactive glasses for soft tissue repair, finding eight 
different novel applications, from cardiac tissue and nerve regeneration to laryngeal and lung tissue 
repair (Miguez-Pacheco et al., 2015). Ocular surgery is another clinical field where bioceramics 
are playing an important role (Baino and Vitale-Brovarone, 2015). 
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Figure 3.3: Clinical use of bioceramic materials (Hench and Wilson, 1993). 
 
According to their biological behaviour and the interaction with the host tissue, bioceramics may 
be effectively bioinert (alumina, zirconia), bioactive (Bioglass® and AW), and bioresorbable 
(TCP) (Hench, 1998b; Baino et al., 2015). 
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For the purpose of medical devices, the term bioinert refers to a material that, once implanted in 
the host tissue, induces a minimal level of adverse response in the surrounding physiological 
environment (Best et al., 2008). 
In a general sense a bioactive material has been defined as a material able to induce a specific 
biological activity (Williams, 2009). In 1990, Kokubo described the capacity of a material to 
develop an HA-like layer on its surface, when immersed in a simulated body fluid (SBF) solution, 
as indication of its bioactivity (Kokubo et al., 1990). More precisely, for the case of bone tissue, a 
bioactive material is a material that, when in a biological environment, forms a carbonated 
hydroxyapatite surface layer, leading to a strong bone-tissue bonding and eventually promoting the 
natural bone regeneration (Kokubo and Takadama, 2006; Erol-Taygun et al., 2013). 
Bioresorbable materials degrade over time and are intended to be replaced by the natural host tissue 
(Stevens, 2008). The optimal material should adapt its degradation kinetic to the living tissue 
formation process, which usually is slower, and then be resorbed (Chen et al., 2012). This aspect 
sometimes is a challenge during the design process, although recent works have shown the 
possibility to tailor the degradation rate of bioceramics by manipulating their formulation, making 
them an emerging research field within the medical device industry (Huang et al., 2006; Yao et al., 
2007; Fu et al., 2010a). 
  Calcium phosphates 
Due to the similarity with the mineral component of human bone, calcium phosphate ceramics have 
been extensively used as biomaterials for the repair and regeneration of bone tissue for the last 30 
years (Barrère et al., 2006).  
There are different forms of CaP ceramics available in nature, the most commonly investigated in 
the field of BTE are: HA, β-tricalcium phosphate (β-TCP) and biphasic calcium phosphate (BCP) 
(Best et al., 2008; Dorozhkin, 2010; Samavedi et al., 2013). A detailed list of CaP compounds, 
their abbreviations, the chemical formula, and Ca/P molar ratio are reported in Table 3.3. 
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Table 3.3: CaP-compounds with corresponding abbreviation, chemical formula and Ca/P molar ratio 
(re-adapted from (Dorozhkin, 2010)). 
Compound Abbreviation Chemical formula Ca/P ratio 
Monocalcium phosphate 
monohydrate 
MCPM Ca(H2PO4)2·H2O 0.5 
Monocalcium phosphate 
anhydrous 
MCPA or MCP Ca(H2PO4)2 0.5 
Dicalcium phosphate 
dihydrate 
DCPD CaHPO4·2H2O 1.0 
Dicalcium phosphate 
anhydrous 
DCPA or DCP CaHPO4 1.0 
Octacalcium phosphate OCP Ca8(HPO4)2(PO4)4·5H2O 1.33 
α-Tricalcium phosphate α-TCP α-Ca3(PO4)2 1.5 
β-Tricalcium phosphate β-TCP β-Ca3(PO4)2 1.5 
Amorphous calcium 
phosphates 
ACP 
CaxHy(PO4)z·nH2O,  
n = 3 − 4.5 
1.2 – 2.2  
Calcium-deficient 
hydroxyapatite 
CDHA 
Ca10−x(HPO4)x(PO4)6−x(OH)2−x  
(0 < x < 1) 
1.5 – 1.67 
Hydroxyapatite HA or HAp Ca10(PO4)6(OH)2 1.67 
Fluorapatite FA or FAp Ca10(PO4)6F2 1.67 
Oxyapatite OA or OAp Ca10(PO4)6O 1.67 
Tetracalcium phosphate TTCP Ca4(PO4)2O 2 
 
HA is the most widely used CaP because it shares chemical similarities to inorganic component of 
bone tissue (Yoshikawa and Myoui, 2005). Although it is not highly soluble, it supports nucleating 
sites for the precipitation of apatite crystals in culture medium (Bohner and Lemaitre, 2009).  
TCP is a biodegradable bioceramic with a Ca/P molar ratio of 1.5. It exists in two different phases, 
which are α and β. Both phases are less stable than HA and therefore more soluble in aqueous 
environments. Despite their similarities in chemical composition, α-TCP is more soluble than β-
TCP, but from a clinical perspective β-TCP is considered to be osteoconductive and osteoinductive, 
and hence more widely used in bone regeneration than α-TCP (Barrère et al., 2006; Samavedi et 
al., 2013). As previously stated, depending on the situation, it might be necessary for an implant to 
    
26 
  
resorb slowly before being replaced by the host tissue. For this reason, a combination of HA and 
TCP has been investigated, in which the higher TCP/HA ratio leads to a higher dissolution rate 
(Best et al., 2008; Dorozhkin, 2010). CaP ceramics represent a class of tuneable biomaterials with 
exclusive properties, they are used in different areas of the human skeleton (e.g. treatment of bone 
defects, maxillofacial applications, spinal fusion and bone augmentation). However, how calcium 
phosphate properties help osteoinductivity/osteoconductivity are still unanswered questions 
(Samavedi et al., 2013), and for this reason they are a class of materials still actively being 
researched (Jarcho, 1981; Matsumine et al., 2004; Saikia et al., 2008; Sun and Yang, 2015; Wang 
et al., 2015).  
  Apatite – wollastonite  
In the early 1970s Hench was developing the Bioglass® composition at University of Florida. 
Around the same time in Japan Kokubo et al. were the first to develop a new bioceramic material, 
known as apatite-wollastonite (AW) glass-ceramic (Kokubo et al., 1982; Magallanes-Perdomo et 
al., 2011). AW is a formulation composed by small apatite particles and reinforced by wollastonite 
crystalline phases in a glassy matrix (Best et al., 2008). The nominal composition (wt%) comprises 
MgO (4.6%), CaO (44.7%), SiO2 (34%), P2O5 (16.2%) and CaF2 (0.5%) (Kokubo, 2008). 
This bioceramic possesses the highest mechanical properties in comparison to other bioactive 
glasses and glass-ceramics, because of wollastonite and apatite crystals’ presence. Furthermore, its 
exceptional ability to form strong chemical bonds with bone tissue has been widely demonstrated 
(Kokubo and Takadama, 2006; Kokubo, 2008; Park and Ozturk, 2013).  
AW has been adopted for a broad range of medical applications, either in a powder form as bone 
filler, as porous structures or as a bulk material (Kokubo, 1999; Kokubo et al., 2003) and showed 
excellent biocompatibility in vitro and in vivo (Ohsawa et al., 2004; Dyson et al., 2007; Lee et al., 
2015). 
With regard to the mechanical properties of this material, Table 3.4 demonstrates that dense AW 
has considerably higher compressive as well as bending strength than human cortical bone. 
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Table 3.4: Mechanical properties of natural bone and AW glass-ceramic (Kokubo, 2008). 
 Natural bone AW glass-ceramic 
Bending strength (MPa) 30-190 200-220 
Compressive strength (MPa) 90-230 1000 
Elastic modulus (GPa) 3.8-17 120 
 
 Bioactive glasses 
Over the last four decades bioactive glasses for orthopaedic and maxillofacial applications have 
attracted the interest of many researchers, playing an important role for bone tissue repair and 
regeneration, thanks to their outstanding osteoconductive and osteoinductive properties, as well as 
bioactivity and customable degradation rate (Hench, 1999; Rahaman et al., 2011; Jones, 2013).  
Bioactive glasses represent the subset of biomaterials designed mainly for hard and soft bone tissue 
repair and regeneration (Rahaman et al., 2011; Jones and Clare, 2012; Jones, 2013). So far different 
methods have been adopted to process them, predominantly as 3D porous structures, and several 
new strategies have been proposed to manipulate their compositions, and the parameters that affect 
their performance in biomedical applications (i.e. chemistry, microstructure, thermal behaviour, 
fabrication method, porosity, mechanical properties) (Lee et al., 2013; Bretcanu et al., 2014; 
Rahaman et al., 2014; Brauer, 2015; Miguez-Pacheco et al., 2015). 
As far as the glass production method is concerned, bioactive glasses are generally prepared via 
sol-gel or melting-quenching process. The sol-gel route consists in the formation of a gel from a 
solution containing the compositional precursors. Through a reaction at room temperature, 
nanoparticles are assembled together to obtain a wet inorganic network, forming a gel, which is 
subsequently dried and heated to form a glass (Hench and West, 1990). In the melt-derived route, 
which is the production method selected for this study, the precursors are homogenised, and then 
melted in a platinum crucible at high temperatures typically in the range 1200 - 1500 ºC. 
Afterwards, the molten glass is poured into moulds in order to obtain solid blocks or is quenched 
in cold water or oil to obtain glass “frits”, ready to be further processed (O'Donnell, 2012). If the 
cooling process is sufficiently quick, no crystallisation will occur and the result will be an 
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amorphous structure, known as glass; otherwise a glass-ceramic, with a combination of a 
crystalline phase and a residual glassy phase will form (Figure 3.4) (Tilley, 2013). 
 
Figure 3.4: Structure of: a) crystalline silica and b) amorphous silica (Vogel, 2013). 
Whether the resulting material will be a glass or a glass-ceramic, three different components are 
generally associated to their structure:  
i) the network formers, which are the basic and stand-alone pillars of the structure, and include 
silicon dioxide (SiO2), phosphorous pentaoxide (P2O5) and boron trioxide (B2O3). These oxides 
represent the building unit of silicate, phosphate and borate-based glasses respectively; 
ii) the network modifiers, which are usually oxides of alkali or alkaline-earth metals that break-up 
the glass network, and modify the glass structure, as the name suggest, (i.e. sodium, calcium and 
strontium); 
iii) the intermediate oxides, which can help the glass formers or modifiers during the process (i.e. 
aluminium and iron), but they do not form glasses by themselves (Vogel, 2013).  
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  Silicate-based glasses 
Silicate-based glasses are by far the most common and most widely investigated bioactive glasses 
for orthopaedic applications. They are based on the 3D glass-forming SiO2 network in which Si is 
fourfold coordinate to O, as shown in Figure 3.5 (Rahaman et al., 2011).  
 
Figure 3.5: Schematic representation of silica tethraedron (Jones and Clare, 2012). 
Furthermore, these materials present an open structure that allows the arrangement of alkali and 
alkali-earth cations (Na+, K+, Ca2+, etc.), which cause the breaking of the Si–O–Si bonds and the 
formation of non-bridging oxygen groups as network modifiers (Scholze, 2012).  
The concentration of non-bridging groups is one of the crucial stage during the bioactive process, 
since, as described by Hench, they are responsible of the dissolution of silica and the consequent 
formation of silanol groups at the glass surface, which are considered the nucleation centres of the 
apatite formation (Kokubo, 1990; Hench and Wilson, 1993). At this stage a silica-rich layer (~ 1-
2µm thickness) is formed on the surface of the glass, followed by the nucleation of an amorphous 
calcium phosphate (ACP) layer, which incorporates (OH)ˉ and (CO3)
2ˉ from the solution and finally 
crystallise as an HCA layer (Hench, 1991).  
The most widely investigated bioglass for biomedical applications, with a composition in the Na2O-
CaO-SiO2-P2O5 system, belongs to the silicate-based glass group. It was synthesised by Hench et 
al. in the 1970s, designated as bioglass 45S5, and it is now commercially known as Bioglass® 
(Hench, 1998b). 
Bioglass® has been extensively studied because of its ability of forming an HCA layer on the glass 
surface (known as bioactivity) when in contact with body fluids, through the mechanism that will 
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be detailed described in paragraph 3.3.5. The bioactive behaviour of Bioglass® is accomplished by: 
i) the low amount of SiO2 (less than 60mol%), if compared to more chemically stable silicate 
glasses; 
ii) the high content of NaO2 and CaO; 
and iii) the high CaO/P2O5 ratio (wt%) (Hench, 1998b).  
The development of this glass revolutionised the definition of biomaterial, moving the perspective 
from inert to a material that, interacting with the human body, is capable to elicit a specific 
biological response (Hench et al., 1971). Additionally, the osteoconductive as well as the 
osteoinductive behaviour of 45S5 bioglass has long been established, as it does not only support 
the regeneration at bone-implant interface, but also far away from that region (Kaur et al., 2013).  
Furthermore, 45S5 bioglass® has been used in clinical practice since 1985 in the form of particulate 
for dental applications (Perioglas®, Novabone, USA), and afterwards as dense material or in form 
of granules for bone defect filling (Baino and Vitale-Brovarone, 2011). 
However, although Bioglass® was demonstrated to be an excellent material, considered for long 
time the gold standard for bone tissue regeneration, it suffers from several drawbacks. Specifically, 
the difficulties are related to the material processing in form of 3D porous scaffolds, due to the 
limited ability of this glass in sintering. This aspect arises because 45S5 bioglass® tends to 
crystallise above 1000 ºC, leading to poor densification of the structure with the consequent weaker 
and less interconnected structure, accompanied by the formation of micro-cracks and poor 
mechanical strength (Gerhardt and Boccaccini, 2010). Furthermore, the 45S5® glass devitrifies 
during the sintering process, which has the effect of reducing the rate of HA precipitation. (Brink, 
1997; Chen et al., 2006; Yao et al., 2007). Additionally, other weaknesses in the use of Bioglass® 
include: its slow degradation kinetic with the consequent difficulties to match the formation rate of 
new tissue, and the abrupt pH variations of the biological microenvironment, due to the increase in 
the concentration of ions such as Na+ and Ca2+, especially in the short term when the degradation 
is faster (Huang et al., 2006; Rahaman et al., 2011; Fu et al., 2012).  
Two decades after Bioglass® discovery, a new silicate-based glass was developed to overcome its 
processing limitations. The new composition, termed 13-93 glass, is based on the 45S5 Bioglass® 
composition, but has higher silica content (53wt%) and K2O and MgO as additional network 
modifiers (see Table 3.5 for the detailed composition). This glass showed an enhanced viscous 
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flow behaviour, less tendency to crystallize, and in the form of porous scaffold it exhibited porosity 
content and mechanical properties comparable to those of cancellous bone (Brink, 1997; Fu et al., 
2007).  
The bioactive behaviour of the 13-93 glass was demonstrated by the formation of an HA layer on 
the surface of 13-93-derived scaffold surface, in less than 7 days of immersion in SBF, indicating 
its potential of bonding to bone (Fu et al., 2007). Furthermore, in vivo studies demonstrated the 
ability of the 13-93 formulation in supporting tissue ingrowth (Fu et al., 2010b). As XRD 
investigations confirmed, this glass remained amorphous even after the sintering treatment (Fu et 
al., 2007). Table 3.5 reports the composition of some silicate bioactive glasses mainly investigated 
in the literature. 
Table 3.5: Composition of various silicate glasses developed over the years (Silver et al., 2001; 
Rahaman et al., 2011; Jones, 2013). 
Composition (wt%) 45S5 13-93 58S 70S30C 77S 13-93B1 
SiO2 45 53 58.2 71.4 80 34.4 
K2O 0 12 0 0 0 11.7 
Na2O 24.5 6 0 0 0 5.8 
MgO 0 5 0 0 0 4.9 
P2O5 6 4 9.2 0 4 3.8 
B2O3 0 0 0 0 0 19.9 
CaO 24.5 20 32.6 28.6 16 19.5 
 
Worldwide many researchers have used the SiO2-Na2O-CaO-P2O5 system and particularly its 
ancestor (the 45S5 bioactive glass), as template materials to develop new silica-based formulations 
(Krishnan and Lakshmi, 2013). Nevertheless, the possibility to tailor the glass properties, altering 
the main formulation by using different oxides, is currently an open challenge for the design of 
more complex compositional systems (Jones, 2013).  
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  Borate-based glasses 
Recent studies have shown the possibility to control the degradation rate of bioactive glasses by 
tailoring their composition (Deliormanli, 2013). Specifically, by partially or totally replacing the 
SiO2 in 45S5 and 13-93 with B2O3, the glass degradation rate can cover a wider range, and in this 
way the bone regeneration can be easily attained (Huang et al., 2006; Yao et al., 2007). In 1990 
Brink et al. proposed the first borosilicate glass for biomedical applications, in which various 
proportions of B2O3 were used (Brink, 1997). Borate-based glasses are very reactive materials with 
low chemical durability; hence, they degrade faster and convert more completely to HA than 
silicate-based, such as 45S5 and 13-93 glass (Huang et al., 2006).  
In a study conducted by Huang et al., the gradual replacement of SiO2 with B2O3 in the parental 
glass resulted in a substantial increase of HA conversion in diluted phosphate solutions. 
Furthermore, unlike silicate glasses, borate-based materials form an HCA layer directly on the 
surface of the underlying unreacted glass, without the formation of a borate-rich layer as 
intermediate stage (schematically shown in Figure 3.6) (Huang et al., 2006). 
 
Figure 3.6: Schematic representation of the conversion mechanisms of a borate (3B) and 45S5 silicate 
(0B) glass to HA in a diluted phosphate solution (Huang et al., 2006). 
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According to the amount of silica replaced, the bioactive process and thus the conversion rate to 
HA of the resulting B2O3 composition can be controlled within a wide range (from hours to months) 
(Baino and Vitale-Brovarone, 2011). Moreover, from a material processing perspective, some 
borate-containing glasses exhibited a more controllable sintering behaviour than Bioglass®, 
becoming very promising candidates for scaffold production (Liang et al., 2008).  
The first borate-based scaffolds were produced in 2005 by soft pressing of the glass powders 
(Rahaman et al., 2005). More recently Fu et al. used the polymer foam replication method to 
successfully produce 13-93B2 (22mol% CaO, 6mol% Na2O, 8mol% MgO, 8mol% K2O, 18mol% 
SiO2, 36mol% B2O3, and 2mol%P2O5) 3D porous borate-derived scaffolds, which showed a 
microstructure and mechanical properties similar to trabecular bone (see Figure 3.7) (Fu et al., 
2009). However, Liu et al. demonstrated that the degradation process significantly influenced the 
mechanical properties of 13-93B2 scaffolds. In fact, after 15 days of immersion in phosphate 
solution, the scaffold mechanical strength decreased from 6.2 to 2.8MPa (Liu et al., 2009; Xin et 
al., 2010).  
B2O3-based compositions support cell proliferation in vitro and enhance tissue formation in vivo. 
However, the leaching out phenomena of certain level of boron (> 0.65mM) from the glass 
exhibited a toxic effect during static in vitro cell culture (Fu et al., 2009). This cytotoxic effect was 
not observed in vivo, where borate bioactive glasses regenerated tissue as effectively as silicate-
based glasses (Jung et al., 2013), and they also produced a level of boron in the blood much lower 
than the toxic threshold (Liu et al., 2010). The main reason of this different behaviour was ascribed 
to the fact that during the in vivo study, being a fully dynamic system, the fluids were continuously 
replaced and the pH values were closer to the environment (Jones and Clare, 2012). 
Conclusively, i) the easier processing route, with respect to silicate-derived scaffolds, ii) the 
possibility to tailor their degradation according to tissue regeneration rate, iii) the more controllable 
conversion rate to HA, and iv) the microarchitecture similarity to human trabecular bone make 
B2O3-based glasses promising materials for clinical applications as bone substitutes. Additionally, 
the potential of borate-based compositions has been exploited as carriers for the release of 
elemental ions essential for bone repair and regeneration (Liang et al., 2008; Xiao et al., 2009; Liu 
et al., 2010; Hoppe et al., 2011). Currently, the main issue related to the use of borate-based glasses 
is the toxicity of boron released in solution. Brown et al. performed an in vitro study in static 
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conditions and found that boron concentration higher than 2.5mM produced a significant inhibition 
of MC3T3 cell proliferation (more than 50%) (Brown et al., 2009). Furthermore, it has been 
reported that boron content >250-350mg (per kg of mass) caused adverse toxic disorders during in 
vivo trials on rabbit models (Nielsen). A partial answer to the potential negative effect of boron 
release has been found in the dilution of phosphorous pentoxide to contain the toxicity of the 
medium (Huang et al., 2006; Ning et al., 2007; Yao et al., 2007; Jung et al., 2013).  
 
Figure 3.7: SEM micrograph showing (a) human trabecular bone, and (b) 13-93B2 glass scaffold 
prepared using a polymer foam replication technique (Fu et al., 2009). 
 
  Phosphate-based glasses  
The growing need of designing new biomaterials capable to resorb once they have attained their 
function, and with no adverse effects for the human body, led to the development of a novel class 
of bioactive glasses (Knowles, 2003). As the name suggests, phosphate glasses are based on the 
P2O5 as glass former, and the [PO4] tetrahedron, for which a phosphorous atom is surrounded by 
four oxygen atoms (Figure 3.8 (a)), and that represents the basic unit in their structure. The 
asymmetric nature of the [PO4] unit is considered to be the reason of the low durability of these 
glasses. Furthermore, in the P-O-P bond (Figure 3.8 (b)), three of the four oxygen atoms are free, 
conferring them more flexibility in the orientation of the tetrahedral (Kaur et al., 2013). Hence, the 
higher number of free oxygen atoms in phosphate glasses, with respect to silicate glasses, offers a 
wider range of possible bond formation (Hoppe, 1996).  
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Figure 3.8: Schematic representation of: a) phosphate tethraedron and b) P-O-P bond. 
P2O5-containing glasses in the CaO–Na2O–P2O5 system have been demonstrated to have distinctive 
dissolution properties in aqueous-based fluids, which can be tailored and predicted by adding 
appropriate oxides into the main composition (Abou Neel et al., 2009b). Besides, depending on 
their composition, their solubility can vary from hours to weeks, and in general it rises by increasing 
the P2O5 content (Abou Neel et al., 2009b; Jones and Clare, 2012). Furthermore, the use of CaO 
and Na2O as network modifiers makes the composition of phosphate-based glasses very similar to 
the mineral phase of bone, conferring them additional clinical potential as synthetic bone grafts 
(Knowles, 2003). In addition, this class of bioactive glasses have been considered very smart 
materials, since they can be synthesised and doped with specific ions such as zinc, strontium, 
copper or fluoride, which are elements able to induce a precise biological response and enhance 
their biocompatibility (Baino and Vitale-Brovarone, 2011; Kaur et al., 2013).  
Phosphate bioactive glasses have been used for different biomedical applications, going from soft 
to hard bone tissue, in form of bulk or powders, and in combination with polymers (Navarro et al., 
2004; Leonardi et al., 2010; Novajra et al., 2011; Bretcanu et al., 2014; Sun and Yang, 2015; 
Tarafder et al., 2015), as fibres for nerve repair (Jeans et al., 2007), and also as antimicrobial 
delivery devices (Abou Neel et al., 2005; Neel et al., 2005; Valappil et al., 2007). At present only 
few phosphate-based compositions have been used to produce 3D porous scaffolds for bone repair 
and regeneration, in comparison to the most common silica-containing glasses. 
In 2004, Navarro et al. processed phosphate glass powders by H2O2 foaming method, and the result 
was a 3D scaffold with a microstructure very similar to trabecular bone (Navarro et al., 2004). 
Later on, Abou Neel and her research group produced strontium-doped phosphate based glasses 
using different amount of SrO (from 0 to 5mol%). The substitution of Na2O with SrO in the original 
composition affected considerably the properties of the glass, increasing its density, transition 
temperature and degradation rate (Abou Neel et al., 2009a). Additionally, another research group, 
b) a) 
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affiliated at Politecnico di Torino (Turin, Italy), exploited phosphate glasses properties for bone 
tissue applications. They developed a new bioactive glass (GC-ICEL2) and processed it as 
phosphate-derived scaffolds (see Figure 3.9) (Vitale-Brovarone et al., 2009). GC-ICEL2 scaffolds 
enhanced the proliferation and differentiation of bone marrow stromal cells, and they were found 
to be bioactive and bioresorbable after soaking in different media, exhibiting an architecture similar 
to trabecular bone (Vitale-Brovarone et al., 2009; Vitale-Brovarone et al., 2011; Bretcanu et al., 
2014). More recently, the same research group produced bone-like scaffolds by co-sintering silicate 
and phosphate-based glasses. The resulting 3D structures revealed to be a promising strategy to 
customise osteoinductivity, dissolution rate and bioactive properties (Novajra et al., 2015). 
 
Figure 3.9: GC-ICEL2 scaffold produced by foam replication method  (Vitale-Brovarone et al., 2009). 
 Selection of trace ions 
Over the last four decades, a significant amount of research work has been carried out on bioactive 
glasses as promising materials for producing scaffolds intended for bone repair and regeneration 
(Hench, 1999; Jones et al., 2006; Rahaman et al., 2011; Jones, 2013; Brauer, 2015). Figure 3.10 
describes the biological response to ionic dissolution products of bioactive glasses through a 
schematic overview, according to the evidences reported in the literature (Hoppe et al., 2011).  
The main potential of this class of bioceramics is the possibility of customising their properties by 
doping the main composition with network modifiers and/or intermediate oxides (Murphy et al., 
2009; Fu et al., 2010a; Fu et al., 2010c; Murphy et al., 2010; Pan et al., 2010; Hoppe et al., 2011; 
Baino et al., 2013; Kaur et al., 2013). To this extent, it has been demonstrated that slight changes 
in the glass formulation can substantially affect the material behaviour, particularly the physico-
chemical and mechanical properties, dissolution rate, bioactivity and bioresorbability (Franks et 
al., 2000; Huang et al., 2006; Fu et al., 2010a; Murphy et al., 2010; Sharma et al., 2012; Wu et al., 
2013). 
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Figure 3.10: Biological response to ionic dissolution products from bioactive glass surface (Hoppe et 
al., 2011). 
Furthermore, several studies investigated how the release of specific ions from the glass network 
(i.e. Cu, Zn, Fe, Cr, Sr, Al, Ag, and Mg) can promote cell proliferation and differentiation, activate 
gene expression, and in some cases exhibit antibacterial properties (Bellantone et al., 2002; Branda 
et al., 2002; Singh et al., 2009). Additionally, Table 3.6 reports some of the most important 
elements that are vital constituents of human body, and at the present also considered potential 
glass network modifiers, with their main function on bone tissue metabolism, regeneration and 
mineralisation (Murphy et al., 2009; Murphy et al., 2010; Hoppe et al., 2011). 
Trace ions like V, Mo, Bi Al, Cr, Y, and La have been recently used as dopants, since they are 
known to be involved in the bone metabolism, and also because they play a physiological role in 
angiogenesis, growth and mineralisation of bone tissue (Demling, 2009; Chellan and Sadler, 2015).  
At present, an extensive literature have been published describing the ion incorporation as network 
modifiers, and their effect on SiO2, P2O5, and B2O3-based glass compositions (Murphy et al., 2009; 
Fu et al., 2010a; Fu et al., 2010c; Murphy et al., 2010; Pan et al., 2010; Hoppe et al., 2011). Most 
of the existing studies have investigated the effect of doped bioglasses on the bioactive properties 
    
38 
  
and HA formation (Li et al., 1992; Branda et al., 2002; Rahaman et al., 2005; Yao et al., 2005; 
Zhang et al., 2009; Zhao et al., 2010; Oudadesse et al., 2011; Deliormanli, 2013; Zhang et al., 
2013; Macon et al., 2015). Furthermore, the influence of network modifiers on the mechanical 
properties and biocompatibility have been also widely examined (Eslami et al., 2010; Balagna et 
al., 2011; Novajra et al., 2011; Zheng et al., 2012; Tarafder et al., 2015). Additionally, Mourino et 
al., considered the use of metallic ions as therapeutic agents and the need to design strategies for 
controlling their release (Mourino et al., 2012).  
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Table 3.6: Role of elemental ions on bone repair and regeneration. 
ELEMENT ROLE REFERENCE 
Magnesium (Mg) 
It plays a key role in bone metabolism, 
mineralisation of calcified tissues, directly 
stimulating osteoblast proliferation; it is an also 
active component of several enzymes. 
(Tsuboi et al., 1994; 
Rude et al., 2003) 
Copper (Cu) 
Essential for hematologic and neurologic systems, 
helps in iron absorption, important in maintaining 
bone matrix and bone density, and plays a significant 
role in angiogenesis. 
(Finney et al., 2009; 
Josko, 2011; 
Hordyjewska et al., 
2014) 
Cobalt (Co) 
It stimulates angiogenesis via regulation of the 
hypoxia-inducible factor 1 (HIF-1). 
(Chachami et al., 
2004; Wan et al., 
2008) 
Zinc (Zn) 
Essential in cellular metabolism and cofactor in 
metabolism of vitamins, DNA synthesis and cell 
division, as well as tissue repair and wound healing 
process. 
(Demling, 2009; 
Josko, 2011) 
Manganese (Mn) 
It activates several important enzyme systems and it 
is involved in the synthesis of proteoglycans in 
cartilage. 
(Soetan et al., 2010) 
Strontium (Sr) 
It plays stimulatory effect on bone formation. 
Helpful in calcification of bones and teeth, bone 
healing, bone resorption. 
(Marie et al., 2001; 
Marie, 2010) 
Silver (Ag) It shows antibacterial and antimicrobial properties. 
(Chellan and Sadler, 
2015) 
Fluorine (F) 
It prevents dental caries and increases bone 
mechanical properties. 
(Soetan et al., 2010; 
Chellan and Sadler, 
2015) 
Silicon (Si) 
Essential in bone mineralisation, component of 
connective tissues, stimulates collagen I formation 
and osteoblast differentiation; it is also associated 
with the formation and calcification of hard tissue 
(Carlisle, 1970; 
Reffitt et al., 2003; 
Nielsen and Poellot, 
2004) 
Calcium (Ca) 
Constituent of bones and teeth, favours osteoblast 
proliferation, differentiation and ECM 
mineralisation. 
(Heaney, 2008; 
Soetan et al., 2010) 
Phosphorus (P) 
Essential for calcium phosphate deposition and 
extracellular matrix mineralisation. 
(Boskey, 2003; 
Boskey, 2007; Soetan 
et al., 2010) 
Iron (Fe) 
It enhances bone metabolism, particularly osteoblast 
proliferation, differentiation, and calcification. 
(Beard, 2001; Gaston 
and Simpson, 2007; 
Yamasaki and 
Hagiwara, 2009) 
Boron (B) 
It helps in bone formation and stimulates RNA 
synthesis in fibroblast cells. 
(Dzondo-Gadet et al.; 
Uysal et al., 2009) 
Selenium (Se) 
Essential nutrient for the body, protects the organism 
from harmful free radicals. 
(Lee, 2010) 
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In 1994, Vrouwenvelder et al. showed how modifying the basic 45S5 glass network with small 
substitutions or additions of certain ions like iron, titanium, fluorine or boron affected the bioactive 
behaviour of the resulting formulations. Specifically, the incorporation of CoO, ZnO, and MgO 
delayed the HA formation, while the use of titanium increased proliferation and osteoblast 
expression. Furthermore, the addition of boron, iron and fluorine lowered the osteoblast activity 
with respect to the un-doped formulation (Vrouwenvelder et al., 1994). Singh et al. doped 
borosilicate glasses with specific amounts of iron (5, 10 and 15wt%), and evaluated the bioactive 
properties by immersion in SBF solution. After 36 days of soaking, only the compositions with a 
percentage of iron between 10 and 15% showed the formation of an apatite layer (Singh and 
Bahadur, 1999). Later on, the same research group investigated the structural and bioactive effects 
of Al, Cr, Y and La on calcium borosilicate glasses. In particular, Y2O3 and Cr2O3 containing 
glasses formed an HA layer after 25 days of immersion in SBF, whereas no signs of apatite crystals 
were detected for Al2O3 and La2O3 doped glasses, which instead exhibited higher dissolution rate, 
proving that modifying the glass composition, the durability and bioactive properties were affected 
(Singh et al., 2009).  
Bioactive glasses doped using ZnO have also been widely investigated. Oudadesse et al. studied 
the effect of Zn on the bioactive and cytotoxic behaviour of a silicate-based glass. According to the 
obtained results, the Zn-doped glass slowed down the Ca and P ionic release in SBF, and thus the 
chemical reactivity. However, the release of Zn2+ did not influence directly the cell viability, which 
was more affected by particle size and release rate (Oudadesse et al., 2011). Another study has 
shown that the incorporation of Zn (5mol%) in a sol-gel based bioglass produced a positive effect 
on cell attachment and pH balance in SBF solution. Furthermore, in the same work, it has 
demonstrated that Zn addition increased ALP activity and osteoblast proliferation (Balamurugan 
et al., 2007).  
Recently, trace elements of SiO2 and ZnO in conjunction with a 3D printed technology were used 
to produce 3D porous β-TCP scaffolds. The use of silica and zinc oxide improved β-TCP 
osteoinductivity by modulating collagen I and osteocalcin production. Furthermore, it was found 
that neovascularization increased up to three times in the doped material with respect to the pure 
β-TCP, used as control. Overall, this research findings indicated the addition of SiO2 and ZnO as a 
possible alternative to introduce osteoinductive properties to CaPs, avoiding the use of biological 
or pharmacological agents (Fielding and Bose, 2013). 
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Vitale-Brovarone research group investigated the effects of different ion-doped bioactive glasses. 
Specifically, they demonstrated how the addition of different amounts (0, 2.5 and 5mol%) of TiO2 
to a phosphate-based glass showed reduced solubility and improved in vitro biocompatibility 
(Novajra et al., 2011). Furthermore, they evaluated the biocompatibility and antibacterial response 
of a silver-doped bioactive glass in the system SiO2-CaO-CaF2-Na2O-K2O-P2O5-MgO. The 
produced Ag-containing scaffolds were able to inhibit bacteria adhesion and proliferation, however 
they showed a negative effect on osteoblast cell-like viability, making necessary the optimisation 
of Ag content (Balagna et al., 2011). Moreover, the same research group investigated the in vitro 
behaviour of SiO2-CaO-Na2O-K2O-P2O5-MgO glass introducing two different amounts of 
manganese oxide (0.25 and 0.5mol%). The presence of Mn for both compositions seemed to delay 
the bioactive process with respect to the parental glass. However, no cytotoxic effect was found, 
and interestingly the addition of Mn promoted osteoblast proliferation and ALP expression (Miola 
et al., 2014).  
As stated above, a broad range of biomedical applications based on the release of therapeutic ions 
integrated in an organic matrix have been proposed (Hum and Boccaccini, 2012; Vallet et al., 2012; 
Cordero-Arias et al., 2015; Stähli et al., 2015). Metallic ions such as Cu2+, Sr2+ and Co2+ are being 
considered cost-effective and safer alternatives for enhancing the biological impact of bioglasses, 
if compared to growth factors and gene therapies. Furthermore, they can be easily processed, are 
stable at high temperatures and have a tuneable release kinetic (Mourino et al., 2012).  
At present, there is a large volume of published studies on the ability of copper to stimulate 
angiogenesis and proliferation of endothelial cells during in vitro culture (Hu, 1998; Finney et al., 
2009; Gerard et al., 2010; Wu et al., 2013). Furthermore, the use of copper, as network modifier, 
has also shown an osteogenic effect in enhancing the differentiation of MSCs into osteoblast cells 
(Rodriguez et al., 2002; Wu et al., 2013).  
Different inorganic matrixes, including silicate (Wu et al., 2013; Stähli et al., 2015), borate (Erol 
et al., 2012; Wang et al., 2014; Zhao et al., 2015) and phosphate glasses (Neel et al., 2005; Stahli 
et al., 2013) have been used in order to incorporate Cu ions, whose effects on bone tissue repair 
and regeneration were examined. In 2013, 45S5 glass scaffold were produced via foam replication 
method and doped using different CuO percentages (0.1, 1 and 2.5wt%). In vitro experiments in 
SBF solution were performed on the Cu-containing samples, which revealed high bioreactivity as 
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confirmed by the fast formation of HCA layer on their surface. Furthermore, the possibility to tailor 
the Cu degradation of the novel designed Cu-doped bioglasses, according to the culture conditions, 
make them promising candidate materials for regenerative medicine and mainly for bone tissue 
healing (Hoppe et al., 2013). 
Later on, Wang et al. evaluated the ionic release effects of Cu-doped (0 – 3wt%) borate-based 
glasses in vitro and in vivo. The nucleation of HA tested in SBF solution decreased slowly with the 
increase of Cu in the glass, whereas the Cu ions leaching in solution increased with the increase of 
copper amount. These findings were promising in predicting that borate-based scaffolds could act 
as carrier systems for the controlled release of Cu ions (Wang et al., 2014). 
Furthermore, the Cu-derived scaffolds showed no detrimental effects on human MSCs viability, 
and they further enhanced ALP activity by increasing culture time and Cu content. Most 
interestingly, Wang et al. found that after in vivo implant in rat calvarial defects, the scaffolds with 
the highest Cu content (3wt%) exhibited superior ability to stimulate bone regeneration and 
angiogenesis with respect to the undoped borate scaffolds used as control (Wang et al., 2014). 
Strontium-containing bioactive glasses are another class of doped bioglasses that have been broadly 
considered in the literature (Marie et al., 2001; Meunier et al., 2002; Pan et al., 2010; Zhao et al., 
2010; Vickers, 2013). Particularly, strontium has been shown to have a beneficial effect when 
treating osteoporosis-affected patients, as it has the ability to stimulate new bone deposition in 
osteoblasts and to inhibit osteoclasts and thus bone resorption (Bonnelye et al., 2008). Gentleman 
et al. proved that Sr-doped silicate glasses enhanced bone cell activity. In particular, replacing the 
amount of calcium in the system SiO2-P2O5-Na2O-CaO with strontium (up to 100%), the osteoblast 
activity was improved and the osteoclast differentiation inhibited (Gentleman et al., 2010). 
Hesaraki et al. using a Sr-containing bioactive glass concluded that strontium addition enhanced 
ALP activity and increased proliferation of rat calvaria osteoblast cells (Hesaraki et al., 2010). 
Recently, Sr-doped AW scaffolds have been produced using different mol% of SrO. The 
formulation having 6.2mol% of strontium showed better performance in terms of bioactivity and 
osteogenic differentiation of human mesenchymal stem cells (MSCs) (Vickers, 2013).  
Lately, the adoption of cobalt-doped bioactive glasses for bone tissue applications have been 
considered as well. Melt-derived 13-93 glass compositions were prepared by Hoppe et al. using 
1wt% and 5wt% of CoO. The Co-containing bioactive scaffolds were tested in SBF solution; 
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interestingly, the kinetic of CaP layer formation was similar for both the doped compositions. 
However, for the samples with higher amount of Co an amorphous CaP layer was formed on the 
top of their surface after 7 days in immersion, whereas a mixed Ca-P-Si rich layer with HCA 
characteristics, and similarly to the un-doped 13-93 glass, was detected on the samples with less 
Co content. Furthermore, according to the degradation test results, the Co concentration after 21 
days was within a therapeutic range (~2ppm), making them a potential platform for controlled Co 
release (Hoppe et al., 2014). In the same year Vyas et al. tested the bioactive properties of Co-
doped silicate glasses, where the original SiO2 content (45wt%) was partially replaced with cobalt 
(0.5, 1, 1.5 and 2wt% respectively). It was concluded, partially conversely with Hoppe et al. 
findings (Hoppe et al., 2014), that the increasing of cobalt amount positively affected the bioactive 
behaviour of the glass (Vyas et al., 2015). 
Additionally, cobalt ions have been known to induce hypoxia conditions and thus stimulate 
angiogenesis via regulation of the hypoxia-inducible factor 1 (HIF-1), whose role has been 
identified crucial for angiogenesis and skeleton regeneration (Chachami et al., 2004; Emans et al., 
2007; Wan et al., 2008). Moving from these consideration, Hoppe et al. used the same Co-
containing glasses, analysed in their previous study (Hoppe et al., 2014), to evaluate the 
biocompatibility of cobalt-derived glass particulates and 3D porous scaffolds in culture with 
osteoblast-like cells and human dermal micro endothelial cells. The formulation with 1 wt % of 
CoO exhibited better in vitro biocompatibility with respect to 5 wt % CoO-containing glass, which 
showed a cytotoxic effect during in vitro culture; in addition, the glass doped with less cobalt 
content slightly enhanced mitochondria activity.  
Similar outcomes were obtained using human endothelial cells, leading to conclude that 1 wt % 
Co-containing glass can be considered a promising candidate as hypoxia mimicking material in the 
field of bone tissue applications; instead, the increase in cobalt amount showed a negative effect 
on physiological fluids, assuming that it may outreach the acceptable threshold (Hoppe et al., 
2015).  
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 In vitro bioactivity of bioceramics 
Bioactivity and bone bonding mechanisms have been widely investigated. As previously 
mentioned, bioactivity is the ability of a material to bond to the host tissue through the formation 
of an HA-like layer (Kokubo and Takadama, 2006). According to the literature, bioceramics were 
the first class of materials to display bioactive behaviour (Hench, 1998b). Specifically, the concept 
was introduced by Hench at the beginning of 70’s, when he described the bonding process of 45S5 
bioglass to bone as a process based on the formation of a carbonated hydroxyapatite (HCA) layer 
on the surface of the material in contact with the host tissue (Hench, 1991).  
The sequence of reaction events involved during the bond formation between bone and a bioactive 
glass, initially proposed by Hench and subsequently modified by Gerhardt and Boccaccini (Hench, 
1998b; Gerhardt and Boccaccini, 2010), is reported in the Figure 3.11 below. 
 
Figure 3.11: Sequence of reactions on the surface of a bioactive glass implant (from (Gerhardt and 
Boccaccini, 2010)). 
Later on, Kokubo discovered that also AW glass-ceramic showed bioactive behaviour, bonding to 
bone in vivo (Kokubo, 1990), and in 1991 he stated that “the essential requirement for an artificial 
material to bond to living bone is the formation of bone-like apatite on its surface when implanted 
in the living body, and that this in vivo apatite formation can be reproduced in a simulated body 
fluid” (Navarro et al., 2008). This was the origin of in vitro bioactivity tests.  
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The solution proposed by Kokubo was an a-cellular fluid with an ionic concentration almost equal 
to human blood plasma (Table 3.7). Since Kokubo protocol development, the in vitro apatite 
formation on the surface of a material, when immersed in SBF, has been considered a useful 
method of assessing potential in vivo bioactivity of a new material (Kokubo et al., 1990; Kokubo 
and Takadama, 2006). 
Table 3.7: Ion concentrations (mM) of human blood plasma and SBF solution (Kokubo and 
Takadama, 2006). 
 Na+ K+ Mg2+ Ca2+ Cl- HCO3– HPO42– SO42– 
Human blood plasma 142.0 5.0 1.5 2.5 103.0 27.0 1.0 0.5 
SBF 142.0 5.0 1.5 2.5 148.8 4.2 1.0 0 
 
Although a large number of studies for the bioactivity evaluation are based on the protocol 
proposed by Kokubo (Wu and Xiao, 2009), the strength of this test method for the assessment of 
bone-bonding ability has not been scientifically demonstrated. Furthermore, numerous 
modifications of both ion concentration as well as test method conditions have been suggested to 
investigate the bioactive behaviour of new implants (Salinas and Vallet-Regi, 2013): 
i) the refresh of the solution at set time points; 
ii) the renewal of the solution through a dynamic system; 
iii) the use of a different buffer and the reaching of a physiological carbonate ions concentration; 
iv) the modification of SBF solution by adding plasma proteins such as albumin. 
More recently, a new unified method for the assessment of the apatite-forming ability of bioactive 
glasses has been proposed. The aim of the study was to provide a valid protocol, in particular for 
bioactive glass samples with high surface area, and to verify its reproducibility over a wide number 
of research groups. Based on the modification of the ISO standard 23317:2012, which fixes the 
surface area to solution volume ratio when comparing samples, and is performed in static 
conditions, the new proposed method uses fixed mass per solution volume ratio and agitated 
solution. Furthermore, the method involved 10 laboratories of 8 different countries and it was 
validated through a round robin test (Macon et al., 2015).   
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3.4  Scaffold fabrication technologies 
As described in paragraph 3.2, in bone tissue engineering 3D porous scaffolds are essential pillars 
to guide tissue growth and regeneration. Hence, after the selection of an adequate bone matrix-like 
biomaterial, which depends on the biological and mechanical properties of the anatomic site that 
needs to be replaced, another important aspect of TE approach is the selection of an appropriate 
processing technology to fulfil the scaffold requirements. 
Polymer foam replication is the most widely exploited technique to produce bioactive glass and 
glass-ceramic scaffolds (Renghini et al., 2009; Fu et al., 2010a; Baino et al., 2013). In addition to 
this method, a variety of different technologies have been developed through the years to produce 
3D porous glass and glass-ceramic scaffolds, including sol-gel (Bielby et al., 2002; Sepulveda et 
al., 2002; Jones and Hench, 2003a; Rainer et al., 2008; Correia et al., 2015), organic phase burning-
out (Brovarone et al., 2006; Fu et al., 2007; Vitale-Brovarone et al., 2008), thermally induced phase 
separation (TIPS) (Yin et al., 2003; Fabbri et al., 2010), and freeze casting (Zhang et al., 2005; 
Deville et al., 2006b; Song et al., 2006; Mozafari and Moztarzadeh, 2014). An overview of these 
so-called conventional techniques together with their main advantages and disadvantages is 
reported in Table 3.8 (Rezwan et al., 2006; Baino and Vitale-Brovarone, 2011; Fu et al., 2011; 
Rahaman et al., 2011; Jones, 2013; Lu et al., 2013; Gao et al., 2014). All the above mentioned 
methods bring to scaffolds with different morphologies, structures and properties. 
Specifically, polymer burning-out was the technique used to produce the first example of 
bioceramic scaffold for bone regeneration (Bellucci et al., 2011). In this case, the ceramic powder 
is mixed with an organic pore former (porogen) that is subsequently removed during a thermal 
treatment necessary to consolidate the inorganic phase. Generally, the scaffold produced with this 
method are characterised by low porosity and limited interconnectivity (Brovarone et al., 2006). 
Foam replication method was introduced for the first time in 2006 by Chen et al. (Chen et al., 
2006), and it has been widely investigated since then. It is a relatively inexpensive processing 
technique, based on the use of a polymeric sponge, which is impregnated in a bioceramic-based 
slurry. Afterwards, during a heat treatment, the polymeric template is burned out and the ceramic 
phase is sintered. This technique leads to the production of scaffolds with controllable pore size, 
high porosity (> 80%) and better interconnectivity than polymer burning-out method (Bretcanu et 
al., 2008; Vitale-Brovarone et al., 2011). However, the greater porosity is associated to high 
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brittleness and low mechanical properties, which represent the main drawbacks of this technique. 
For this reason, Bellucci et al. considered the development of alternative strategies highly 
necessary. Specifically, whereas in the original method the exceeding slurry was removed by 
squeezing the sample, and the green bodies (un-sintered specimens) were left to dry before the 
sintering process, in the new protocol the samples were kept entirely loaded of slurry, which was 
previously mixed with PE particles and that led to an increased and more controlled final porosity 
(Bellucci et al., 2011). 
Sol-gel phase separation, TIPS and freeze casting also belong to the class of conventional 
techniques for scaffold production. 
Sol–gel scaffold fabrication is a versatile method based on the preparation of a sol-gel glass of 
desired composition, and consequent foaming of the sol by the addition of a surfactant, followed 
by condensation and gelation reactions. The obtained foamed solutions are then cast into moulds, 
and after a drying process, they are sintered to produce consolidated structures (Jones et al., 2004; 
Rainer et al., 2008). Through this technique it is possible to obtain glass or glass-ceramics in 
different forms, including hierarchical porous architectures, ultra-fine or spherical-shaped 
powders, ceramic fibres, thin-film coatings and microporous inorganic membranes (Raucci et al., 
2010; Chen, 2011). The peculiarity of this method is related to the nanopores (2–50nm) resulting 
from the sol-gel process and the interconnected macropores (10–500μm) deriving from the foaming 
process. However, because of the resulting nanopores, which lead to a higher surface area, the 
scaffolds undergo a fast degradation process (Sepulveda et al., 2002; Fu et al., 2011). Furthermore, 
the sol-gel-derived scaffolds have low strength, therefore they are not suitable for load-bearing 
applications (Jones et al., 2006). 
The phase separation route involves the use of a polymer that is dissolved in an organic solvent. 
Once a homogeneous polymer-based solution is formed, glass or glass-ceramic powders are added 
and a mixture is obtained. To induce phase separation, the polymer solution is cooled rapidly, and 
a porous structure is produced after evaporation of the solvent via sublimation and following 
stabilisation (Boccaccini and Maquet, 2003). The large number of variables on which the 
methodology is based (including polymer and solvent selection, concentration of polymer, and 
phase separation temperature) allows tailoring of the properties of the final porous structures 
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(Molladavoodi et al., 2013). However, the possibility of solvent residue and the sensitivity of the 
method to slight changes in the parameters, limit the use of this technique (Cao et al., 2006).  
Regarding the freeze casting method, this is based on the rapid freezing of a colloidal suspension, 
using an organic solvent (i.e. water, camphene or camphene mixture), and the casting of the 
solution in a non-porous mould. After sublimation of the solvent and a drying process, the 3D 
constructs are sintered to consolidate their structures (Deville, 2008). The main advantage of this 
method lies in the preparation process, which is easy and does not require expensive equipment 
(Sofie and Dogan, 2001; Thavornyutikarn et al., 2014). Furthermore, this technique allows to 
control the directionality of the porosity by the solidification conditions yielding porous ceramics 
with a specific macro-porosity (Deville et al., 2006a; Deville et al., 2006b; Fu et al., 2010b). 
However, as for the TIPS technique, also for this method the solvent residue present in the structure 
can be harmful to biological tissues (Sachlos et al., 2003; Zhu and Chen, 2013). 
Despite the fact that conventional fabrication methods have been widely used over the last three 
decades to produce promising scaffolds for medical applications (Morsi et al., 2008), most of the 
scaffold requirements (i.e. pore geometry, pore size, shape and interconnectivity) cannot be fully 
controlled with many of them. Moreover, depending on the fabrication method used, the 3D 
scaffold also lacks of the mechanical strength necessary to withstand stress and forces of the living 
tissues (i.e. sol-gel method) (Jones et al., 2006). In addition, some of these processing techniques 
use organic solvents, and the presence of their toxic residues can cause severe inflammatory 
response (i.e. TIPS and freeze casting). Furthermore, most of these methods are manual, resulting 
in poor reproducibility over the large scale and inconsistent outcomes (Leong et al., 2003; Sachlos 
et al., 2003; Zhu and Chen, 2013).  
Based on these observations scaffold fabrication for bone repair and regeneration remains a 
research challenge. Therefore, the emerging need for novel 3D constructs with tailored physico-
chemical and mechanical features has led to the development of new manufacturing technologies 
(Utela et al., 2008; Melchels et al., 2012; Thavornyutikarn et al., 2014; Mota et al., 2015). The aim 
of next section is to describe and review the state of the art of additive manufacturing (AM) 
techniques, for the design and fabrication of scaffolds for bone tissue repair. 
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Table 3.8: Conventional techniques for the production of bone tissue substitutes. 
METHOD DESCRIPTION ADVANTAGES DISADVANTAGES 
Organic 
phase 
burning-out 
A blend is obtained by 
mixing glass particles and 
organic phase, after they 
are thermally treated to 
remove the organic phase 
and sinter the glass. 
- No organic solvents 
 
- Residual of porogens 
- Low porosity (<60%) 
and limited 
interconnectivity 
Foam 
replication 
Impregnation of a 
polymeric sponge 
template in a glass-based 
slurry followed by a 
thermal treatment to 
remove the organic phase 
and sinter the glass. 
- No organic solvents 
- Control of porosity 
and pore size 
- Possibility of an 
inhomogeneous coating of 
the foam 
- Low mechanical strength 
(2-20MPa) 
Sol-gel 
A solution of metal 
alkoxides leads to the 
formation of the sol 
phase, made by solid 
particles that then will 
condense in gel-like 
materials. After a drying 
process the so obtained 
material is treated at high 
temperature. 
- Hierarchical pore 
structure 
- Interconnected 
macropores 
- Nanoporous texture 
 
- Many variables affect 
the final morphology ( i.e. 
glass particles, surfactant, 
gelation time) 
- Low mechanical strength 
(0.3-2.3MPa) 
Thermally 
induced phase 
separation 
(TIPS) 
A polymer mixed 
with/without glass 
particles, is dissolved in a 
solvent and a liquid-liquid 
or solid-liquid phase 
separation is obtained by 
lowering the temperature. 
The solvent is removed by 
sublimation to give a 
porous structure. 
- Incorporation of 
biologically active 
molecules 
- High porosity 
- Slight changes in the 
parameters (i.e. type of 
polymer, glass particles, 
and solvent used) affect 
the morphology of the 
scaffold 
- Possibility of solvent 
residues 
Freeze casting 
The method involves the 
rapid freezing of 
colloidally-stable 
suspension of particles in 
a nonporous mold. The 
frozen solvent is removed 
by sublimation to avoid 
cracking prior to 
sintering. 
- Oriented 
microstructure 
- High mechanical 
strength in the 
direction of orientation 
- Small pore size (10–
40μm) 
- Possibility of solvent 
residues 
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 Overview of additive manufacturing techniques 
The use of AM, or also called solid free form fabrication (SFF), rapid prototyping (RP) or more 
recently 3D printing processes, to produce custom-made devices with well-designed architecture, 
has become a fast-developing research field in the last few years (Thavornyutikarn et al., 2014; 
Mota et al., 2015). The concept of AM was introduced for the first time by Chuck Hull in 1986 via 
his patented stereolithography (SLA) process (Hull, 1986). Since its launch, many applications 
advanced from the outstanding and time-saving capabilities of its production method (Arafat et al., 
2014; Giannitelli et al., 2014; Yoo, 2014). According to ASTM F2792, AM is defined as “the 
process of joining materials to make objects from three-dimensional model data usually layer upon 
layer” (F2792, 2012). Conversely to the conventional fabrication methods that remove material 
from a bulk, using AM techniques 3D objects are built through a layer-by-layer approach via the 
processing of solid filament, liquid or powder stock materials (Hutmacher et al., 2004; Bartolo et 
al., 2009). AM provides exclusive methods to produce accurate (macro-architecture as well as 
microstructure) and consistent (mechanical properties, porosity and interconnectivity) bone-like 
substitutes matching patient’s defects (Sun et al., 2004). The above mentioned advances have led 
to a growing interest in the development of novel scaffolds with a tailored architecture and 
customable properties as well as enhanced in vitro behaviour. Leong et al. (2003) reported the 
common steps of AM techniques in a flowchart (Figure 3.12). 
 
Figure 3.12: Common process steps for all AM techniques-based approach (re-printed by (Leong et al., 
2003)).  
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In summary, medical images of the anatomic site are acquired by computer tomography (CT) or 
magnetic resonance imaging (MRI). The 2D image data are then treated by computer-aided design 
(CAD) software, and afterward the obtained 3D model is converted into a standard tessellation 
language (STL) file. Subsequently the .stl file is sliced into layers and loaded in the AM machine. 
According to the fabrication process, the 3D build parts can need further finishing and cleaning 
work. At present, different AM techniques have been widely explored for TE scaffold fabrication, 
although none of those proposed has been acknowledged as a gold standard approach. The four 
techniques represented in the Figure 3.13 have been recognised as the most commonly used 
strategies for the production of TE substitutes (Melchels et al., 2012), namely they are: 
a) Stereolitography, b) Selective laser sintering, c) Fused deposition modelling and d) Powder-
based three dimensional printing. 
 
Figure 3.13: The four most common and commercially available AM techniques that are used for 
tissue engineering scaffold fabrication (adapted from (Mota et al., 2015)).  
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  Stereolithography 
Stereolithography (SLA) is the oldest AM technology (Hull, 1986). The process, as schematically 
described in Figure 3.13, uses ultraviolet (UV) light or laser to polymerise layer-by-layer a 
photosensitive polymer. Once one layer is completed, the construction platform is vertically 
lowered to a given distance and a new uniform layer of resin is placed on the top of the previous 
solidified one. The process is repeated until the 3D object is completed. Further actions include the 
removal of non-polymerised resin and the post-curing of the printed 3D part under UV light 
(Thavornyutikarn et al., 2014; Mota et al., 2015). This approach has been applied to fabricate 3D 
scaffolds from polymers, bioceramics and composite materials (Chu et al., 2002; Cooke et al., 
2003; Melchels et al., 2009; Arcaute et al., 2010). SLA technology can also be used to produce 
hydrogel/polymer scaffolds in combination with cells for soft tissue engineered applications. The 
success of cell encapsulation is determined by several elements, such as UV light intensity, 
exposure time and free radical formation (Lu et al., 2006; Park et al., 2011). However, considerable 
shortcomings (for example the shrinkage of the structure during the production process, the 
necessity of a support and the presence of a toxic resin) limit the use of this technique. 
  Select laser sintering 
Select laser sintering (SLS) process is based on the use of a high intensity laser beam such as CO2 
that selectively sinters regions of powder-based material placed in a powder bed until the formation 
of a powder layer. After the generation of the first layer, the powder bed is vertically lowered by 
one layer thickness and the new layer of powder is spread mechanically by a roller on the top of 
the previous one. In this technology the non-sintered powder serves as support for the build-up of 
the next layers. The process is iteratively repeated until the 3D structure is finalised 
(Thavornyutikarn et al., 2014; Mota et al., 2015). TE constructs based on polymers, ceramics and 
metals have been produced using the SLS technique. In 2005 Ciardelli et al. developed a select 
laser sintered scaffold of PCL and a polysaccharide (starch, gellan and dextran), finding a 
promising and easy method to improve PCL biocompatibility (Ciardelli et al., 2005). Usually, TE 
scaffolds produced via SLS technique show low mechanical properties, however Goodridge et al. 
(2007), using a SLS method, fabricated an apatite-mullite glass-ceramic with good surface finish 
and mechanical properties (flexural strength around 16 MPa) in the range of cancellous bone 
(Goodridge et al., 2007). Very recently, Lee et al. used SLS to produce 3D porous AW scaffolds. 
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MSC-seeded and unseeded AW scaffolds were tested in vivo using MF1 nude mice. Osteoid 
formation and tissue in-growth were observed after 4 weeks and without the need for osteogenic 
pre induction, demonstrating that SLS custom-designed scaffolds enhance in vivo biocompatibility 
and osteoconductive capacity of AW glass ceramics (Lee et al., 2015). Furthermore, the use of SLS 
technology has been extended to polymer/ceramic composites; however, despite the advantages of 
this method, the performance of 3D porous constructs depends on the combination of the above 
described process parameters (Thavornyutikarn et al., 2014).  
  Fused deposition modelling 
Fused deposition modelling (FDM) was developed and commercialised by Stratasys Inc. in 1992. 
It is based on the melting and extrusion of material (usually a thermoplastic polymer) onto a 
platform. The filament of material is provided by two rotating rollers to a mobile nozzle, which 
moves in x and y direction, as shown in the Figure 3.13. Through an orifice in the extruder head 
the material can be deposited on a platform. After fabrication of the first layer and when the 
material is solidified, the platform moves downwards in z-direction and the process is repeated 
layer-by-layer until the 3D object is completed (Thavornyutikarn et al., 2014; Mota et al., 2015).  
Although a variety of material can be used to produce FDM scaffolds, polymer or composite-based 
scaffolds are the most investigated. A PCL-HA composite was the first scaffold produced using 
the FDM technique by Hutmacher et al. (Hutmacher, 2000). Later on, different scaffolds were 
printed using PCL, and in 2009, PCL scaffolds fabricated via FDM were approved by FDA for 
craniofacial applications (Low et al., 2009). In addition, in 2010 PCL and PCL-TCP bi-layered 
constructs were investigated for the repair and regeneration of osteochondral defects (Ho et al., 
2010).  
The use of FDM technique allows the manufacture of interconnected porous scaffolds with an 
extremely reproducible architecture, with no need of solvents, and at a quite low maintenance costs 
(Kalita et al., 2003). However, the major limitations of this strategy are: i) the use of materials in 
the form of filament with specific diameters, and ii) the effect that the high operating temperatures 
(sometimes up to 280ºC) can have on the raw material properties (Sung‐Hoon et al., 2002; 
Thavornyutikarn et al., 2014; Carneiro et al., 2015). 
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  Powder-based three-dimensional printing 
Three-dimensional printing (3DP) is an ink-jet printing technology, developed at MIT (Cambridge, 
MA) in 1989 (Sachs et al., 1992). It is used to produce complex 3D solid objects by jetting a liquid-
based binder onto a bed of loose powder. 3DP technology has been largely used to create 3D tissue 
substitutes from a wide range of materials (Bose et al., 2013).  
Although the first published study using this technique was about the use of a mixture of PLGA 
and NaCl (Kim et al., 1998), bioceramics such as HA, bioactive glasses, TCP, but also polymers 
and hydrogels have been then processed using 3DP technology (Leukers et al., 2005; Seitz et al., 
2005; Butscher et al., 2011). Among the different AM methodology, 3DP has been considered a 
versatile technique, which became popular for the production of scaffolds for bone tissue 
engineering applications (Bose et al., 2013).  
For the manufacture of medical devices the main advantages of this technology derive from the 
possibility to fabricate 3D custom substitutes with defined design, controlled and interconnected 
porosity, with a wide range of materials, and also without the contamination problems related to 
the use of toxic solvents (Leukers et al., 2005; Detsch et al., 2011; Bose et al., 2013). However, 
process parameter optimisation, appropriate binder selection, and removal of the loose powder after 
printing are important features that need to be considered for the final success of the printed parts 
(Butscher et al., 2012). All these parameters will be analysed in major detail in the next section 
(3.4.2).  
The key parameters together with advantages and disadvantages of the AM techniques mostly used 
for TE scaffold fabrication are summarised in the Table 3.9. Indirect 3DP was adopted in this 
research project as a method to process bioceramic powders to create 3D structures, and it is 
described in greater detail in the next paragraph (3.4.2.1). 
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Table 3.9: The four most commonly used AM technologies for the production of bone tissue substitutes 
with their advantages (+) and disadvantages (-). 
TECHNIQUE PARAMETERS 
ADVANTAGES (+)/ 
DISADVANTAGES (-) 
REFERENCE 
SLA 
Layer thickness: 25-100 
µm 
Resolution: 14-150 µm 
+ High accuracy and good surface finish; 
possibility of cell encapsulation; 
- support structure needed; 
photopolymer needed; possible use of 
toxic resins; possible shrinkage during 
polymerisation. 
(Melchels et al., 
2009; Melchels et 
al., 2010; 
Butscher et al., 
2011; Mota et al., 
2015) 
SLS 
Layer thickness: 75-150 
µm 
Resolution: 50-1000 µm 
+ No support structure needed; solvent 
free; fast process; 
- heat transfer generated by the laser; 
difficulties to remove trapped powder; 
poor surface finish. 
(Dalton et al., 
2009; Swift and 
Booker, 2013; 
Thavornyutikarn 
et al., 2014; Mota 
et al., 2015) 
FDM 
Layer thickness: 50-750 
µm 
Resolution: 100-500 µm 
+ No support structure needed; no 
material trapped; solvent free; 
- high temperature needed; mechanical 
anisotropy; thermoplastic polymers 
needed; filament preparation necessary. 
(Zein et al., 2002; 
Kalita et al., 
2003; Leong et 
al., 2003; Swift 
and Booker, 
2013; 
Thavornyutikarn 
et al., 2014) 
3DP 
Layer thickness: 50-150 
µm 
Resolution: 50-300 µm 
+ Wide material range; no support 
structure needed; cost-effective; fast 
process (10 min for 20 scaffolds); 
solvent free; 
- poor surface finish; low green body 
strength to handle the samples; 
depowdering process necessary; powder 
can be trapped in the pores. 
(Utela et al., 
2008; Butscher et 
al., 2011; 
Melchels et al., 
2012; Bose et al., 
2013; Mota et al., 
2015) 
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 Indirect powder-based 3DP for bone repair applications 
3DP is a powder-based methodology, whose working stages are schematically represented in 
Figure 3.14. During the process a liquid binder (usually a water-based solution) is jetted, using an 
ink-jet print-head, onto a powder bed of loose material. The particles are then bonded together and 
the first 3D layer is produced.  
After the printing of this first layer, the powder bed is lowered in the z-direction and a new layer 
of loose powder is spread on the top of the previous one in the x-y plane. As in the case of SLS, 
also in this process the powder bed acts as a physical support for the printed part. Following a layer-
by-layer approach, each step is repeated until the predesigned object is concluded. The 3D printed 
part, technically called a green body or unfinished part, needs then the removal of the loose powder 
and depending on the material (i.e. HA, TCP or AW)(Seitz et al., 2005; Santos et al., 2012; Alharbi, 
2015) the consolidation of the structure by thermal treatment (Butscher et al., 2011).  
It is important to note that before starting the process, and after the material selection, thorough 
optimisation of the printing parameters, e.g. layer thickness, powder packing density, powder 
wettability, powder flowability as well as binder drop volume, is necessary to obtain a good 
outcome (Bose et al., 2013). For any new powder-based material the optimisation process may 
require long time; this can be considered one of the major shortcomings of 3DP technique.  
Once the material has been chosen, the preparation of the powder (in terms of particle size and 
distribution) is a crucial step for the quality of the final 3D printed part, as it will affect the 
sinterability, pore dimension, surface area and surface finish (Cima and Cima, 1996; Sachs, 2000). 
The powder formulation is the first stage of the 3DP process, followed by the selection of the binder 
and possible additives (Utela et al., 2008). 
There are different ways of binding the powder; among these the most commonly used are organic 
(i.e. polyvinyl) or inorganic (i.e. colloidal silica) liquids and in-bed adhesives (i.e. maltodextrin 
(MD) or sucrose) (Cima et al., 1995; Bredt and Anderson, 1999; Feenstra, 2005; Suwanprateeb 
and Chumnanklang, 2006). Liquid binders are the most versatile methods as they work with almost 
any material (Bredt et al., 2003). However, in the case of organic binders, they can dry in the 
printhead, causing the obstruction of the nozzle (Greil, 2000). The use of an in-bed binder is an 
alternative method: a powder-based component is added to the starting formulation and it binds the 
particles after interaction with a sprayed liquid (Irsen et al., 2006a). Even though, it is a time 
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consuming process, as it requires the further step of mixing two materials any time a new powder 
is processed, it reaches higher green body strengths if compared to liquid binders (Utela et al., 
2010). 
  
Figure 3.14: 3D printing iterative phases. (1) The process starts with the spreading of a first thin layer 
of powder in the built area (2) and the formation of a supportive powder bed. (3) The ink-jet print-head 
sprays droplets of a liquid binder on the powder bed and hence the powder particles start to bond one to 
each other, until all the layers of the predesigned CAD file is printed. (4) The roller places the second 
layer of powder onto the built area and the process is repeated until the 3D structure is completed and 
the extra powder is removed. 
Additives are generally added to the raw material to influence the post-processing behaviour and 
the resulting properties of the sintered parts (Bose et al., 2002). Particularly, a ceramic powder can 
be mixed together with polymeric grains, with the same or different particle sizes (Utela et al., 
2010). The addition of polymeric material, which will burn out during the heat treatment, will 
produce a ceramic structure with a degree of porosity and a level of interconnectivity that depends 
on the percentage as well as grain dimensions of the porogen (Seitz et al., 2005; Vorndran et al., 
2008).  
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Regarding the printing parameters, the layer thickness, which depends partially on the material 
particle size, should be a compromise value to avoid i) binder penetration and over spreading (in 
the case of very thin layers), and ii) high saturation and difficulties for the powders to bond with 
possibility of displacement (in the case of too thick layers) (Tarafder et al., 2013). The powder 
packing density is the density of powder that the roller spreads in the powder bed. If the resulting 
layer is not homogenous, specimen resolution and shape of the geometry can be compromised 
(Gibson et al., 2014). The flowability of the powder plays a crucial role during the spreading phase, 
as it defines the spreading capability of the material (Schulze, 1995), but also during the 
depowdering process, which will be clarified later on in this paragraph (Butscher et al., 2011). As 
the final resolution is usually at least twice the dimension of the powder particle size (Vacanti et 
al., 2001), using fine powder is convenient to achieve high resolutions. However, dry and fine 
particles tend to agglomerate causing poor flowability, hence, a compromise between flowability 
and resolution is necessary (Butscher et al., 2011). 
Furthermore, another important aspect for the printing accuracy is the powder wettability. This 
parameter is generally related to surface energy and chemistry of the particles (Spori et al., 2008). 
In particular, low wettability generates brittle binder-powder composites, resulting in low green 
body strength, whereas high wettability causes widespread of binder limiting the printing resolution 
(Hogekamp and Pohl, 2004; Butscher et al., 2012). The green strength is another essential 
requirement of printed objects. It defines the mechanical properties immediately after the printing 
process and before the sintering treatment. An appropriate green strength is important to maintain 
handle ability, and to meet the final mechanical properties of the 3D printed part, since it influences 
the strength after the sintering treatment (Cox et al., 2015). The depowdering process, which can 
be either manual or mechanical, is the last step of the printing procedure, and it is carried out to 
remove the loose powder from the printed specimens (Butscher et al., 2011).  
Subsequently, a heat treatment needs to be performed on the green bodies to burn out the binder 
and any additives used, and consolidate the structure. Sintering is the most important post-
processing step, which provides an increased mechanical strength to the 3D printed object. Every 
material has specific sintering temperature, usually defined as the temperature where the maximal 
densification rate is being reached (Palmour et al., 2013), although many factors such as grain size, 
specimen dimensions, heating rate, phase transformations, liquid phase formation and porosity can 
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affect the sintering properties of a material and its densification behaviour (Muralithran and 
Ramesh, 2000; Dorozhkin, 2010).  
Additionally, during the sintering process the composition (i.e. phase changes), mechanical and 
structural properties of a material are also influenced (Butscher et al., 2011). In most cases, heat 
treatment allows a structure to retain its shape, even though the process can cause a significant 
degree of sample shrinkage (Dorozhkin, 2010). This phenomenon can be compensated by scaling 
the initial CAD model according to a pre-determined correction factor (Shanjani et al., 2010). 
Figure 3.15 shows the particles distribution before and during the sintering treatment and the 
resulting shrinkage behaviour.  
 
Figure 3.15: Schematic representation of the sintering mechanism: a) particles free flowing, b) neck 
formations and c) voids shrinkage (reprinted by (Dorozhkin, 2010)). 
  3D printed ceramic-based scaffolds 
The use of 3DP technology has been widely documented for BTE applications, mainly processing 
bioactive ceramics, such as tricalcium phosphates, bioactive glasses and HA (Leukers et al., 2005; 
Seitz et al., 2005; Tarafder et al., 2013; Cox et al., 2015).  
In recent years, several composite materials have been investigated for 3DP scaffold production 
using the combination of different ceramics or ceramics and polymers (Gbureck et al., 2007; 
Khalyfa et al., 2007; Will et al., 2008). In 2005 Seitz et al. stated the applicability of 3DP 
methodology for the fabrication of a porous HA scaffold with internal channels between 450 and 
570µm (Seitz et al., 2005). 
In 2010, Warnke et al. evaluated the biocompatibility of HA 3D printed scaffold and their ability 
to promote and support human osteoblast proliferation. Interestingly, their results found the 
superior biocompatibility of HA scaffold compared to the commercial available Geistlich BioOss®, 
a bone substitute material derived from the mineral portion of bovine bone. (Warnke et al., 2010).  
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Later on, Tarafder et al. developed a 3D printed and microwave sintered β-TCP, with a high degree 
of interconnectivity along the structure (Figure 3.16) (Tarafder et al., 2013). In another study, 
conducted in 2015 by Tarafder et al., the properties of β-TCP scaffolds were improved, doping the 
main composition with SrO and MgO. A significant increase in mechanical strength was achieved 
as well as higher osteoid, bone and haversian canal formation, which are essential conditions for 
early wound healing and mineralisation in vivo (Tarafder et al., 2015).  
 
Figure 3.16: 3D printed TCP scaffolds sintered at 1250 °C using a microwave furnace and the resulting 
surface morphology (inset) (Tarafder et al., 2013). 
In addition to in vitro experiments, Habibovic et al. demonstrated how 3D printed brushite 
(dicalcium phosphate dihydrate) and monetite (dicalcium phosphate anhydrous) cements, with a 
controlled open porosity, enhance in vivo osteoconduction (Habibovic et al., 2008).  
More recently, Inzana et al. fabricated a 3D printed collagen-calcium phosphate composite via 
inkjet printing, and afterwards they assessed the healing performance using a critically sized murine 
femoral defect. After 9 weeks of implant the bone substitutes confirmed their osteoconductive 
properties (Inzana et al., 2014). Furthermore, according to in vivo studies, 3D printed ceramic 
scaffolds hold great potential for bone tissue repair, showing invaluable biocompatibility and 
osteoconductivity (Habibovic et al., 2008; Will et al., 2008; Inzana et al., 2014). 
In Table 3.10 is reported a summary of mechanical and biological properties of the most 
investigated 3D printed ceramic-based substitutes intended for bone tissue applications.  
In conclusion, despite the disadvantages of powder-based 3DP mentioned in this paragraph, and 
also described in Table 3.10, the broad range of biomaterials and the variety of designs that are 
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achievable with this technology makes it a promising and versatile approach for custom medical 
device production. 
Table 3.10: Mechanical and biological properties of some ceramic-based 3D printed scaffolds. 
Material 
Sintering 
condition 
Mechanical 
properties  
Biological properties Reference 
HA 1250ºC/2h 
compressive strength: 
21.2±2.2 MPa (dense 
part) 
Cells were seeded on the scaffolds 
and cultivated under static and 
dynamic setups. This last method 
showed better results with a deep cell 
proliferation into the HA structure. 
(Leukers et al., 
2005; Seitz et 
al., 2005) 
HA 1250ºC/2h 
compressive strength: 
21.2±2.2 MPa (dense 
part) 
Cell viability tests showed superior 
biocompatibility of HA scaffolds to 
BioOss® 
(Seitz et al., 
2005; Warnke 
et al., 2010) 
β-TCP 1400°C 
compressive strength:  
8.66± 0.11 MPa 
 (% porosity 
46.07±8.52) 
In vitro cytotoxic assays showed a 
good cell–scaffold interaction, thus 
revealing the scaffolds' 
biocompatibility 
(Santos et al., 
2012) 
β-TCP/ 
Bioglass 
1000°C 
bending strength: 
14.9 ± 3.6 MPa 
– 
(Bergmann et 
al., 2010) 
HA/AW 1300°C/3h 
bending strength: 
35.22±6.56 MPa 
(% porosity 
30.00±1.50) 
In vitro tests showed that osteoblast 
cells attach and attain normal 
morphology on the surface of the 3D 
printed scaffolds. 
(Suwanprateeb 
et al., 2009) 
Brushite - 
bending strength: 
5.2 MPa 
In vivo implantation of both brushite 
and monetite scaffolds showed their 
osteoinductive potential. 
(Habibovic et 
al., 2008; 
Klammert et 
al., 2010) 
Monetite 134°C/2h 
bending strength: 
3.9MPa 
TTCP/ β-
TCP 
1200°C/6h 
1400°C/6h 
compressive strength: 
1.3±0.1MPa 
3.9±0.1MPa 
MC3T3-E1-cells grew on the 
scaffolds as adherent cell showing the 
increase in ALP activity over the 3 
weeks in culture. (Khalyfa et al., 
2007) 
TTCP/ 
CaSO4 
1000°C/6h 
compressive strength: 
0.1±0.01MPa 
- 
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Chapter 4. Novel material design 
4.1  Development and rationale of novel bioglass formulations 
Bioactive glasses are one of the last glass subgroups that have been explored, revealing as 
promising materials for the production of 3D structures for bone tissue repair (Hench, 1999; Jones, 
2013; Krishnan and Lakshmi, 2013).  
However, since their discovery in 1969 by Hench, there are still several criticisms related to the 
clinical use of this class of biomaterials (Hench and Jones, 2015). Firstly, whether or not glass 
dissolution products have a positive effect on adult stem cells is still an open debate; secondly, they 
have often resulted inadequate when used in load-bearing bone defects, due to their low tensile 
strength and fracture toughness. Ultimately, there are no large-scale porous bioactive glasses on 
the market, thus their commercial success is limited (Rahaman et al., 2011; Hench and Jones, 
2015).  
Based on the current state of the art, eight novel silicate, phosphate and borate glass formulations 
(coded as NCLx, where x=1,…,8), containing different oxides and in diverse molar percentages, 
were initially proposed for this research. Specifically, ions such as Ca, Na, K and Mg were 
incorporated in all the glass compositions as they are essential elements for all living organisms, 
and they stimulate the cellular and sub-cellular processes of bone formation (Bracci et al., 2009).  
Furthermore, trace ions like Sr, Cu, Co or Zn are recognised for their anabolic effects in bone 
metabolism (Nielsen, 1990; Saltman and Strause, 1993; Meunier et al., 2002; Pan et al., 2010). 
Ag2O was selected since it is known to provide antibacterial effects if used as doping agent (Luo 
et al., 2010; Balagna et al., 2011). Sr, which can accumulate in bone due to its chemical similarity 
to Ca, has been widely investigated for its therapeutic potential in bone metabolism, and also for 
its property of reducing the incidence of fractures in osteoporotic patients (Gentleman et al., 2010; 
Wu et al., 2011; Tarafder et al., 2015). Cu and/or Zn ions were incorporated for the importance of 
these elements in maintaining the bone matrix and bone density (Cousins, 1998); additionally, Cu 
helps collagen formation and plays an important role during angiogenesis, and Zn shows anti-
inflammatory effects (Hu, 1998; Rodriguez et al., 2002; Lai and Yamaguchi, 2005; Lang et al., 
2007; Finney et al., 2009; Gerard et al., 2010; Wu et al., 2013). CaF2 has been considered a 
promising network modifier since it has been demonstrated that F-doped bioactive glasses enhance 
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the formation of fluorapatite, which is chemically more stable than biological HA (Brauer et al., 
2010). Finally, Al and Fe were selected in order to increase the mechanical strength of the glasses 
(Hoppe et al., 2011; Sharma et al., 2012).  
The molar compositions, along with the rationale and innovative characteristics of the novel 
materials with respect to previously developed glass formulations, are reported in Table 4.1.  
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Table 4.1: Molar composition and rationale of the novel glass formulations. 
CODE COMPOSITION (mol%) RATIONALE REFERENCE 
NCL1 
40SiO2 - 5P2O5 - 8Na2O - 
10CaO - 8K2O - 5MgO - 
5MnO2 - 5ZnO - 10SrO - 1CuO 
- 1Bi2O3 - 1TeO2 - 1V2O5 
Aim: to develop a material with osteogenic properties, mainly determined by 
the presence of a high amount of silica. 
Network former: SiO2. 
Selected dopants 
Ca and P: main components of biological apatite; 
Na, K and Mg: essential elements for all living organisms, which stimulate the 
cellular and sub-cellular processes of bone formation;  
(Zn + Mn + Cu): enhance the osteointegration of the material;  
SrO reduce the incidence of fractures in osteoporotic patients; 
V: beneficial effects during the normal development and metabolism of the 
skeleton; 
(Te + Bi): improve the sinterability of the material. 
(Yamaguchi, 1998; 
Silver et al., 2001; 
Xynos et al., 2001; 
Zreiqat et al., 2002; 
Dietrich et al., 2009; 
Gentleman et al., 
2010; Wu et al., 
2011; Sansone et al., 
2013; Tarafder et al., 
2015) 
NCL2 
45SiO2 - 5P2O5 - 2B2O3 - 
4Na2O - 15CaO - 3K2O - 8MgO 
- 2MnO2 - 5Al2O3 - 2CaF2 - 
5Fe2O3 - 1Li2O - 1MoO3 - 
1SeO2 - 1Cr2O3 
Aim: intended to develop a load-bearing material with osteogenic properties 
and tailored degradation rate. 
Network former: SiO2. 
Selected dopants 
P2O5, B2O3, MgO, and MnO2: regulate the degradation process of the glass; 
B2O3, CaO, CaF2, Na2O and P2O5: help the acellular bioactivity; 
Ca and P: as for composition NCL1; 
Na, K: as for composition NCL1;  
Al, Fe and F: increase the mechanical properties; 
Se: improve the healing process; 
Li, Mo, Cr:  known as trace elements in the human body. 
(Abou Neel et al., 
2005; Demling, 
2009; Hoppe et al., 
2011; Chen et al., 
2012; Sharma et al., 
2012; Whitney and 
Rolfes, 2013) 
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CODE COMPOSITION (mol%) RATIONALE REFERENCE 
NCL3 
25SiO2 - 2P2O5 - 35B2O3 - 
6Na2O - 7CaO - 5K2O - 5MgO 
- 2Al2O3 - 3TiO2 - 5Fe2O3 - 
1Li2O - 1BaO – 1CoO - 1V2O5 
- 1Cr2O3  
Aim: to develop a material with improved degradation rate and appropriate level 
of bioactivity as well as mechanical properties. 
Network former: B2O3. 
Selected dopants 
Si: essential for metabolic process, bone tissue formation and calcification 
Ca and P: as for composition NCL1; 
Na, K and Mg: as for composition NCL1;  
V: beneficial effects during the normal development and metabolism of the 
skeleton; 
Co: influences the thermal stability, sinterability and microstructure 
(Al + Fe + Li + Ti): responsible for the material strength; 
Ba and Cr: known as trace elements in the human body. 
(Carlisle, 1970; 
Carlisle, 1981; 
Singh and Bahadur, 
1999; Singh and 
Srinivasan, 2010; 
Hoppe et al., 2011; 
Vyas et al., 2015) 
NCL4 
20SiO2 - 5P2O5 - 40B2O3 - 
5Na2O - 5CaO - 5K2O - 5MgO 
- 5ZnO - 5SrO - 2CaF2 - 1CuO 
- 1MoO3 - 1SeO2  
Aim: to develop a material with tailored degradation rate and osteogenic effects. 
Network former: B2O3. 
Selected dopants 
Si: as for composition NCL3; 
Ca and P: as for composition NCL1; 
Na, K and Mg: as for composition NCL1;  
Zn: plays anti-inflammatory role and helps bone formation; 
Sr: as for composition NCL1; 
CaO, CaF2, Na2O and P2O5: help the acellular bioactivity; 
Cu, Mo and Se: known as trace elements in the human body. 
(Yamaguchi, 1998; 
Marion et al., 2005; 
Lang et al., 2007; 
Bonnelye et al., 
2008; Liang et al., 
2008; Fu et al., 
2010c; Gentleman 
et al., 2010; Pan et 
al., 2010; Hoppe et 
al., 2011) 
  
    
66 
  
CODE COMPOSITION (mol%) RATIONALE REFERENCE 
NCL5 
45P2O5 - 7Na2O - 10CaO - 
6K2O - 10MgO - 5ZnO - 
5MnO2 - 10SrO - 1TiO2 
1Sb2O3 
Aim: to develop a resorbable glass with controlled degradation rate. 
Network former: P2O5. 
Selected dopants 
Ca: involved in bone metabolism, enhances osteoblast proliferation, 
differentiation and ECM mineralisation; 
Na, K and Mg: essential elements for all living organisms, which 
stimulate the cellular and sub-cellular processes of bone formation; 
(MgO, TiO2, MnO2 and SrO): regulate the degradation rate of the 
glass  
Zn: as for composition NCL4; 
Sr: as for composition NCL1.  
(Yamaguchi, 1998; 
Maeno et al., 2005; 
Barrère et al., 2006; Lang 
et al., 2007; Bonnelye et 
al., 2008; Abou Neel et 
al., 2009a; Gentleman et 
al., 2010; Leonardi et al., 
2010; Hoppe et al., 2011; 
Novajra et al., 2011; 
Vitale-Brovarone et al., 
2011; Lakhkar et al., 
2013) 
NCL6 
8SiO2 - 50P2O5 - 10B2O3 - 
8Na2O - 10CaO - 3K2O - 
10MgO - 2MnO2 - 2CaF2 - 
1CuO - 1CoO - 1Cr2O3 
Aim: to develop a resorbable glass with controlled degradation rate, 
and improved mechanical strength. 
Network former: P2O5. 
Selected dopants 
Si: as for composition NCL3; 
B: stimulates bone formation; also, B2O3 helps the bioresorbability of 
the glass; 
Ca: as for composition NCL5; 
Na, K and Mg: as for composition NCL5; 
(Mg + F): improve the microhardness of the glass; 
(Cu + Co +Cr): enhance the sintering ability. 
(Saranti et al., 2006; Sun 
et al., 2010; Hoppe et al., 
2011; Mourino et al., 
2012) 
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CODE COMPOSITION (mol%) RATIONALE REFERENCE 
NCL7 
50SiO2 - 5P2O5 - 15Na2O - 
15CaO - 2K2O - 3MgO - 5AgO 
- 2TiO2 - 2Fe2O3 - 1CuO  
Aim: intended to develop a material with antibacterial properties, mainly 
determined by the presence of silver oxide, and a good level of 
bioactivity. 
Network former: SiO2. 
Selected dopants 
Ca and P: main component of biological apatite; 
Na, K and Mg: essential elements for all living organisms, which 
stimulate the cellular and sub-cellular processes of bone formation;  
Ag: exhibits inhibitory effects on bacteria growth; 
Ti, Fe and Cu: enhance osteoblast proliferation and activity; 
(Ti + Fe): increase the mechanical properties of the material. 
(Vrouwenvelder et al., 
1994; Valappil et al., 
2007; Luo et al., 2010; 
Balagna et al., 2011; 
Hoppe et al., 2011) 
NCL8 
45SiO2 - 5P2O5 - 2B2O3 - 
10Na2O - 15CaO - 5K2O - 
5MgO - 5MnO2 - 1ZnO - 
1Fe2O3 - 1SrO - 2.5CaF2 - 
0.5CuO - 0.5CoO - 0.5MoO3 - 
0.5SeO2 - 0.5Cr2O3 
Aim: intended to develop a material with osteogenic properties and 
tailored degradation rate for non-load bearing applications. 
Network former: SiO2. 
Selected dopants 
P2O5, B2O3, MgO, and MnO2: as for composition NCL2; 
B2O3, CaO, CaF2, Na2O and P2O5: as for composition NCL2; 
Na, K, Mg: as for composition NCL1 
Zn, Sr, Cu, Co, Mo, Se and Cr:  known as trace elements in the human 
body. 
(Murphy et al., 2010; 
Hoppe et al., 2011; 
Chen et al., 2012; 
Whitney and Rolfes, 
2013) 
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Chapter 5. Experimental methods 
5.1  Research approach 
In order to obtain gradual confirmation of the feasibility of the main aim of this study, the overall 
research project was developed through three sequential stages: 
i) glass powders preparation and characterisation; 
ii) bioceramic pellets preparation and characterisation (dense materials);  
iii) 3D printed bioceramic structures preparation and characterisation (porous materials). 
An overview of the experimental work carried out during each phase is reported in Table 5.1. 
Starting with the production of the new glasses (described in paragraph 5.2), this chapter deals with 
the material processing (reported in paragraph 5.3), and the characterisation methods performed 
during each stage (presented in paragraph 5.4). 
5.2  Material production 
The novel glasses were produced and supplied by Glass Technology Service (GTS) Ltd (Sheffield, 
UK) along with AW that will be used as comparison material. Briefly, the individual components 
(reported in Table 4.1) of each formulation were weighed out and then mixed together to obtain a 
uniform blend ready to be processed. Subsequently, the glass mixtures were melted in platinum 
crucibles for times and temperatures, which varied according to the composition. 
. 
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Table 5.1: Overview of the experimental work performed on: glass powders, bioceramic pellets and 3D printed bioceramic structures. 
MATERIAL EXPERIMENTAL WORK COMMENTS CHAPTER 
Glass powders 
Crystallinity (XRD) 
Morphological characterisation (SEM) 
Thermal properties (HSM) 
pH variation in dH2O 
Ionic release (ICP-OES) 
In vitro cytotoxicity assessment  
During the first stage of the work the 
processing and characterisation of all the 
novel glass formulations were performed. 
6 
Bioceramic pellets  
Sintering condition optimisation 
Morphological characterisation (SEM) 
Shrinkage evaluation  
Crystallinity (XRD) 
Mechanical properties assessment 
In the second stage the processing to 
bioceramic pellets and the subsequent 
characterisation of the sintered dense 
structures was carried out. 
6 
Bioceramic pellets  In vitro bioactivity tests (SBF) 
On the basis of the physico-chemical, 
mechanical and biological characterisation 
results, only three formulations were 
selected for bioactivity tests. 
6 
3D printed bioceramic 
scaffolds 
Sintering condition optimisation 
Morphological characterisation (SEM) 
Shrinkage evaluation  
Porosity and micro-architecture (microCT) 
evaluation  
Mechanical properties assessment 
In vitro cytotoxicity assessment 
In vitro antibacterial tests 
In the last part of the work, the three 
formulations previously selected were 
processed to porous 3D printed scaffolds 
(via a powder-based 3DP technology), and 
subsequently characterised. 
7 
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5.3  Material processing  
 Glass powders  
Glass frits of all the materials were ground in a one-bowl zirconia ball milling machine (Planetary 
Mono Mill Pulverisette 6, Fritsch GmbH, Germany) using a rotational speed of 400rpm for 30 min 
(10 min each repetition). The obtained powders were then sieved using a mechanical sieve shaker 
(Impact Test Equipment Ltd, UK) to have a final particle size about 20μm and below 53µm 
(Boccaccini et al., 2007).  
 Bioceramic pellets 
Dense bioceramic pellets were processed from fine glass powders, previously sieved as described 
in section 5.3.1. Firstly the raw material (0.35±0.01g) was carefully mixed together with 
isopropanol solution (Sigma-Aldrich, UK) in the proportion 3:1 (w/w), until the particles bound 
together and a paste-like texture was formed. Then it was left to dry for about 40s at room 
temperature. Afterwards, the mixture was placed into a 10mm cylindrical die and cold pressed 
using an automatic hydraulic press (Specac-Atlas™ 8T, Specac Ltd., UK) for 2 minutes under a 
load of 1 tonne (Figure 5.1). 
 
Figure 5.1: Specac Atlas 8T automatic hydraulic press (http://www.specac.com/). 
Subsequently, the pressed pellets, also called green bodies, were treated through a sintering process 
to consolidate their structure. As reported in chapter 2, the sintering temperature is usually defined 
as the temperature where the maximal densification rate is being reached (Palmour et al., 2013). 
Hence, the pressed green bodies were placed in a furnace (Carbolite 1200 CWF, Carbolite GmbH, 
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Germany) and heat treated according to the results derived from the hot stage microscopy analysis 
that will be described in section 5.4.2. 
 Indirect 3D printed bioceramic substitutes 
Figure 5.2 schematically represents the three different phases of the entire 3D printing fabrication 
process: i) pre-processing, ii) processing and iii) post-processing, which are described in detail in 
the following paragraphs.  
 
Figure 5.2: Flow chart describing the three stages of the 3D printed scaffold fabrication: pre-
processing (yellow), processing (blue) and post-processing (green).  
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  Powder blend preparation 
Once received from GTS Ltd., the starting materials were processed to glass powders according to 
the procedure reported in the paragraph 5.3.1. As the particle size affects the printing results as 
well as the properties of the final parts (Sachs et al., 1992; Bredt et al., 2003; Utela et al., 2008; 
Bergmann et al., 2010; Butscher et al., 2012; Farzadi et al., 2015), for this study the range of 
particle diameters was chosen between 0 and 53µm.  
Subsequently, each powder formulation was mixed together with MD (Oneon, Bristol, UK) in the 
same range of particle size. Before the printing process, to achieve a homogeneous mixture, the 
two base materials (70wt.% of glass powders and 30wt.% of MD) were blended for 1h using a 
roller mixer (Stuart, SRT6) (Figure 5.3). 
 
Figure 5.3: Powder blend preparation using a roller mixer. 
MD was used as an in-bed and solid binder to improve the printing behaviour of the powder, and 
to react with the jetted liquid binder, enhancing the adhesion between the glass particles but also 
leading to a porous final structure. 
The liquid binder (zb®60), which consists of a water-based solution, was purchased from EMCO 
Education Ltd, UK.  
  Design of 3D structures 
Two different geometries were drawn using Autodesk Inventor® (Autodesk, USA): a cylindrically 
shape with height of 2.25mm and 10.35in diameter, and a bar shape with height 5mm, width 6mm 
and length 40mm, as reported in Figure 5.4.  
The CAD files were then saved in .stl format, and processed by the ZCorp 310 software, prior to 
printing.  
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Figure 5.4: CAD design of the 3DP: a) cylindrical and b) bar shape structures. 
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  Indirect powder-based 3D printing: the process 
A commercial ZPrinter® 310 Plus 3D printer (Z Corporation, USA), illustrated with all its main 
components in Figure 5.5, was used to print all the samples of this research study. Before starting 
the process, the blended powder was poured into the build area and pressed to get a firm layer. 
Once a flat and compact surface was obtained, the feed piston was moved up to the same level as 
the build piston.  
 
Figure 5.5: Commercial ZPrinter® 310 Plus 3D printer (Z Corporation, USA) and its main components 
(www.zcorp.com). 
The printing parameters were adjustable through the Z310 Plus software (graphic interface is 
shown in Figure 5.6). They were selected on the basis of the optimisation process developed and 
described by Alharbi (Alharbi, 2015), and maintained the same for all the powder blends (see Table 
5.2). 
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Figure 5.6: Graphic interface of ZPrint 7.10 software. 
Table 5.2: Powder blend settings for ZPrinter® 310 Plus 3D printer. 
Layer thickness (mm) Saturation level Binder/volume ratio Bleed compensation 
0.1 
Shell Core Shell Core X Y Z 
100% 100% 0.21 0.10 Off Off Off 
After the printing process was completed, which usually took approximately 10min to print 20 
cylindrical scaffolds and 12min to print 10 bars (see CAD model in Figure 5.4), the green parts 
were left to dry overnight before being removed from the build area. Once taken out, any loose 
powder still present on the specimens was cleaned out using an air blower. The green bodies, with 
a relatively weak and delicate structure were thermally post-processed through a sintering 
treatment, using the same equipment described in section 5.3.2. A number of different heat 
treatments, according to the results derived from the hot stage microscopy (section 5.4.2), were 
evaluated to burn out the organic binder from the green bodies and to sinter the glass powders, 
obtaining mechanically competent porous structures.   
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5.4  Characterisation methods 
Various techniques were applied to characterise firstly the glass powders, then the bioceramic 
pellets and finally the 3D printed structures. These include: hot stage microscopy (HSM) to 
evaluate the sintering parameters, scanning electron microscopy (SEM) to assess particles and 
structure morphology, and X-ray diffraction (XRD) to investigate the crystalline composition. 
Tests in simulated body fluid (SBF) were also performed to assess the bioactive behaviour of the 
new materials. Furthermore, pH variation analysis as well as ionic release in different liquid 
solutions and at specific time points were measured. Additionally, the mechanical and biological 
properties in different conditions were evaluated. Details of these techniques and their experimental 
settings are given in the following sections. 
 X-ray diffraction analysis 
To investigate the presence of crystalline phases in the novel materials, XRD analysis was 
performed using a PANalytical X'Pert Pro MPD, powered by a Philips PW3040/60 X-ray generator 
fitted with an X'Celerator detector. Diffraction data was acquired by exposing powder samples to 
Cu-Kα X-ray radiation, which has a characteristic wavelength (λ) of 1.5418Å. X-rays were 
generated from a Cu anode supplied with 40kV and a current of 40mA. 
The data were collected over a 2θ range between 5-80º 2θ, with a step size equal to 0.0334º, a 
counting time per step of 200 seconds using the scanning X’Celerator detector. Fixed anti-scatter 
and divergence slits of 1o were used together with a beam mask of 10mm. All scans were carried 
out in ‘continuous’ mode. 
Phase identification was carried out by means of the PANalytical X'Pert HighScore Plus© 
software, in conjunction with the ICDD Powder Diffraction File 2 Database (2004), ICDD Powder 
Diffraction File 4 - Minerals (2014) and the Crystallography Open Database (February 2013; 
www.crystallography.net). 
 Hot stage microscopy 
The sintering ability of the novel glass powders was determined by using hot stage microscopy 
(Misura®, Expert System Solutions, Italy). This technique allowed the quantification of the 
sintering interval by measuring the variation of the sample dimensions during the heating treatment 
(Bretcanu et al., 2009).  
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The test was performed in air to approximate the conditions inside the furnace chamber during the 
heating process, which develops with a rate of 10°C/min up to 1200°C. The samples for HSM 
analysis were prepared by manually pressing the glass powders into a small cylindrical die 
(2x3mm) and placed on a 10x15x1 mm alumina support. During the process the specimens were 
observed by a video camera and images of the changing sample profile were acquired up to 1450ºC. 
Afterwards, the shrinkage–temperature curves were analysed and the shrinkage at different 
temperatures was calculated from the reduction of the sample dimensions, using the following 
formula: 
𝑠ℎ𝑟𝑖𝑛𝑘𝑎𝑔𝑒 (%) =
𝐴0 − 𝐴𝑇
𝐴0
𝑥100 
where 𝐴0 (𝑚𝑚
2) is the area of the sample at instant (𝑡 − 1) and 𝐴𝑇 (𝑚𝑚
2) is the area at instant 
𝑡. 
 Morphological and microstructural characterisation 
  Scanning electron microscopy 
To assess the glass particle morphology and the bioceramic pellet surface, microstructural 
observations were determined by scanning electron microscope, (Philips XL30 ESEM FEG, which 
is fitted with a Rontec Quantax system for the EDS analysis). Furthermore, morphological analysis 
were conducted before and after the sintering process of the specimens to determine if the heat 
treatment had any detrimental effect on bulk structure. The formation of neck struts and appropriate 
densification level were examined. 
Before the imaging acquisition, the specimens were sputtered with a thin layer of gold 
(approximately 10nm, sputter time 40s at 40mA), and afterward analysed. All the images were 
taken at an operation voltage of 20 kV, and working distance between 5 and 10mm. 
  X-ray microtomography 
Scaffold architecture and structural interconnectivity was also investigated by micro-computed 
tomography (micro-CT; XRadia/Zeiss VersaXRM-410). The scanner was set at a voltage between 
60 and 80kV and a current of 248A, and the samples were scanned with an isotropic voxel size of 
2.4μm by approximately 1600 slices covering the sample height. Afterward, the scanned 2D slices 
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were reconstructed to give 3D views of the entire structure using Avizo Fire software (Durham 
University, UK). 
  Analysis of the porosity 
The open porosity of the samples, which represent the percentage of pores that are penetrated by 
an immersion liquid or that are connected with the atmosphere, was measured according to the BS 
EN 623-2:1993 using Archimedes method with the following formula: 
𝑂𝑝𝑒𝑛 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦 (%) =
( 𝑚2 −  𝑚1)
( 𝑚2 −  𝑚3)
 𝑥 100 
Samples were weighed by means of a density determination kit in an analytical balance (Kern 
ABT220-5DM). The dry weight of the samples was recorded as 𝑚1. Then, they were immersed in 
distilled water to force the liquid to fill the pores of the samples until no bubbles emerged from the 
water baker and the submerged mass (𝑚3) was measured. Afterward, the specimens were taken 
out and re-weighed to calculate the wet mass (𝑚2) in air. 
Five specimens for each group were tested to calculate the average porosity. The results were 
expressed as mean ± standard error of the mean (SE). 
The total porosity, given by the sum of the close and open porosity, was measured according to the 
formula:  
𝑇𝑜𝑡𝑎𝑙 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦 (%) = 1 −  
𝑚𝑠
𝜌 𝑉𝑠
 𝑥 100 
where 𝑚𝑠 is the dry mass of the sample, 𝜌 is the density of the material and 𝑉𝑠 is the volume of the 
sample. Five specimens for each group were tested to calculate the average porosity. The results 
were expressed as mean ± standard error of the mean. 
The density of the material in turn was calculated through the pycnometer method (ISO 1183-
1:2004), using the formula reported below: 
𝜌 = 𝜌𝑙
 𝑚2
( 𝑚1 + 𝑚2 − 𝑚3)
  
where 𝜌𝑙 is the density of the liquid, 𝑚1is the mass of the liquid in the pycnometer filled completely 
with liquid, 𝑚2 is the mass of the sample material and 𝑚3 is the mass of the sample and liquid 
together in the pycnometer. The average of five specimens for each composition was considered. 
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 pH variation  
A pH meter (Mettler Toledo Ltd., UK) was used to measure the effect induced by the novel glass 
compositions on the pH variation. The meter was calibrated with standard solutions (at pH 4 and 
7) every time before use. Specifically, the pH values induced by raw glass powder, considered the 
most critical scenario, were measured daily up to 7 days to verify its confinement within a 
‘‘physiological range’’. Un-sintered glass powders with a concentration of 10 mg/ml were 
immersed in deionised water (Veolia Water Technologies, UK) and incubated under an atmosphere 
of 5% CO2 and 95% air at 37°C. Two different tests were performed: i) an extreme condition, 
without changing the solution, and ii) a more realistic one to simulate the physiological fluids 
exchange, refreshing the solution every 48h. 
 Ion leaching evaluation  
In order to evaluate the ionic release potential of each composition, raw glass powders were 
immersed in deionised water (Veolia Water Technologies, UK) at a concentration of 10 mg/ml and 
stored in static condition at 37ºC. After each storage period, the specimens were removed via 
filtration, and filtrates retained for ionic content analysis.  
The ion concentration was measured using an inductively coupled plasma optical emission 
spectrometer (ICP-OES) Specto-Ciros-Vision (Sheffield University, UK), which allows 
simultaneous multi-element analysis following the calibration of the instrument by introduction of 
standards of known concentrations of the elements of interest.  
 Shrinkage evaluation  
In most cases, heating treatments cause the shrinkage of ceramic samples. Specifically, the 
structure retains its shape producing a significant degree of reduction of its dimensions. Hence, 
dimensional changes of the sintered specimens were carefully evaluated. The following formula 
was applied to calculate the volumetric shrinkage that occurred during the sintering treatment of 
bioceramic pellets and 3D printed structures: 
𝑉𝑜𝑙𝑢𝑚𝑒𝑡𝑟𝑖𝑐 𝑠ℎ𝑟𝑖𝑛𝑘𝑎𝑔𝑒 (%) =
𝑉1 − 𝑉2
𝑉1
𝑥100 
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where 𝑉1(𝑚𝑚
3) is the volume of the sample before sintering and 𝑉2(𝑚𝑚
3) is the volume of the 
sample after sintering. To measure the dimensions of the specimens a digital caliper (accuracy of 
±0.02mm) was used (Mitutoyo Ltd, UK).  
 Mechanical characterisation 
  Compressive test 
The mechanical properties of the sintered pellets were measured using a Tinius Olsen, universal 
testing machine (Figure 5.7). In this study, cylindrical samples were prepared with diameters of 
about 8.5±0.5 mm and a thickness of about 2.5±0.3mm.  
Five pellets for each composition were evaluated at room temperature and in dry conditions, 
according to previous work (Prakasam et al., 2015). For all the experimental tests, the machine was 
equipped with a 25 kN load cell and the cross-head speed was set at 1mm/min. Since the specimens 
were too hard, they did not reach the failure point, hence the stress (σc) after the 20% of the initial 
deformation (εc) was calculated rather than the compressive strength of the dense pellets. The 
compressive modulus (𝐸𝑐) was determined as the slope of the initial linear part of the stress-strain 
curve (C773, 1988). All the results were expressed as mean ± SE. 
  
Figure 5.7: Compressive test performed using a Tinius Olsen universal testing machine; inset shows 
the specimen before the test.  
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  Three-point bending test 
Regarding the mechanical properties of the 3D printed structures, flexural strength and flexural 
modulus were determined by a three-point bending test, using an INSTRON 5567 testing machine 
(Figure 5.8). 
 
Figure 5.8: Three-point bending test determined by an INSTRON 5567 universal testing machine. 
The conditions of the test were performed according to the ASTM C1161 – 13 standard. Beam 
shaped specimens with dimensions of 40x4x3mm were produced; the cross-head speed of the 
machine was set at 1mm/min, and the support span length at 20mm. A load cell of 1kN was used, 
and five replicates were tested (Figure 5.9). 
 
Figure 5.9: Schematic representation of the three-point bending test conditions. 
The flexural strength (𝜎𝑓) was calculated according to the following equation:  
𝜎𝑓 =
3𝑃𝐿
2𝑏𝑑2
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where P represents the applied load (N), L (mm) is the support span length, b (mm) is the sample 
width and d is the depth (mm). The flexural modulus (𝐸𝑓) was calculated according to the 
following equation: 
𝐸𝑓 =
𝐿3𝑚
4𝑏𝑑3
 
where L (mm) represents the support span length, m (N/mm) is the gradient (i.e. slope) of the initial 
linear part of the load deflection, b (mm) is the sample width, and d (mm) is the sample depth. All 
the results were expressed as mean ± SE. 
 In vitro bioactivity evaluation  
In order to assess the bioactive potential of the novel materials, raw glass powders were processed 
as sintered pellets (following the procedure described in section 5.3.2) and then soaked in 10 ml of 
a simulated body fluid (SBF) solution prepared according to Kokubo’s protocol (Kokubo and 
Takadama, 2006).  
The specimens were incubated at constant temperature (37°C) for various time points (1, 3, 7, 14 
and 28 days), refreshing the solution every 2 days. At the end of each time interval the specimens 
were removed from SBF, then abundantly rinsed with deionised water (Veolia Water Technologies, 
UK) and dried at room temperature. The pH of the solutions was measured using the equipment 
reported in paragraph 5.4.4 and the ion leaching was evaluated according to the procedure 
described in paragraph 5.4.5. Furthermore, the structural characteristics and chemical composition 
of the upper surface of the samples were investigated by SEM/EDS (experimental set-up described 
in section 5.4.3.1). Moreover, the sample solubility was quantitatively assessed by measuring the 
weight loss of the immersed pellets after 1, 3, 7, 14 and 28 days of soaking, using an analytical 
balance (Kern ABT220-5DM), according to the following formula 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑙𝑜𝑠𝑠 (%) =  
𝑀𝑏𝑖 − 𝑀𝑎𝑓
𝑀𝑏𝑖
𝑥100  
where 𝑀𝑏𝑖 is the mass of the sample before the immersion and 𝑀𝑎𝑓 is the mass of the sample after 
the immersion.  
Additionally, to quantitatively evaluate the composition of the precipitates, X-ray photoelectron 
spectroscopy (XPS) was performed using Theta Probe (Thermo Scientific, East Grinstead, UK), 
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with a micro-focused AlKa X-ray source (1486.6eV), operated with a 400µm spot size (100W 
power). Survey spectra were collected at a pass energy of 200eV, with the spectrometer operated 
in standard (not angle-resolved) lens mode. The results were expressed as the average of three 
points of each sample surface. 
 Biological characterisation 
The in vitro cytotoxicity of the novel glass formulations was evaluated via metabolic activity using 
the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) colorimetric assay 
according to ISO 10993-5 (Standard, 2009), firstly on the glass powders and afterward on the 3D 
printed scaffolds. 
  Cell culture 
Rat calvaria osteoblast (OB) cells at early passages (Figure 5.10), provided by Institute of Cellular 
Medicine (Medical School, Newcastle University, UK), were cultured in T75 flasks at 37°C in a 
humidified incubator with 5% CO2, using Dulbecco’s Modified Eagle Medium (D-MEM, Gibco®) 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 1% glutamine 
(Gibco®). When 70-80% confluent, the flasks were washed twice with 5mL of phosphate buffered 
solution (PBS, Lonza) and afterward trypsinised using 1.5mL of trypsin-EDTA (Gibco®) and 
incubated for 5 minutes at 37°C, 5% CO2. The detachment of the cells from the flasks was 
monitored using light microscopy. When the cells were detached, 8.5mL of fresh D-MEM was 
added to neutralise the trypsin. The cell suspension was placed in a tube and centrifuged for 5min 
at 1200rpm. The supernatant was carefully removed and the cell pellet was re-suspended in an 
appropriate amount of media for cell counting using a haemocytometer.  
 
Figure 5.10: Morphology of rat osteoblast cells.  
100 µm
    
84 
  
  Glass powder cytotoxicity 
Cells were seeded at a density of 1x104cells/well in 96-well plates and incubated at 37°C for 24 
hours. The glass powders were firstly sterilised using 100% ethanol solution, and then 
preconditioned for 24h in D-MEM at three different concentrations (0.1, 1 and 10mg/ml), in order 
to stabilise the pH variation due to the ionic exchange process between the powder surface and 
medium. The cells seeded on cell culture plate (0 mg/ml) were used as controls. Each condition 
was set up in triplicate. After 24 hours of incubation for the cells, two different experiments were 
performed: 
i) direct method, according to which the pre-conditioned DMEM solutions with the glass powders 
were directly added to each well without filtering, diluting or buffering; 
ii) indirect method, in which case after 24h of immersion in DMEM, the pre-conditioned glass 
powders were filtrated using a 0.22µm microbiological filter. The filtrated solutions were then 
added to each well for indirect cytotoxicity testing. 
The plates were then incubated for other 24h and the cytotoxic effect was measured exposing each 
well to MTT solubilisation. The MTT (Sigma–Aldrich, UK) substrate was prepared in a D-MEM 
solution at a final concentration of 0.5mg/ml. After each time point, 100 µl of MTT solution was 
added to each well and incubated at 37°C for another 4 h. MTT was taken up only by active cells 
and reduced in their mitochondria to insoluble purple formazan granules. The medium was then 
removed and 100µl of dimethyl sulfoxide (DMSO) was added to dissolve the precipitated 
formazan. The absorbance of the solution was evaluated spectrophotometrically at a wavelength of 
570nm, and acquired using a Sunrise microplate reader (Tecan Group Ltd., Switzerland).  
The absorbance values from three replicates were averaged and statistically analysed using two–
way analysis of variance (ANOVA) followed by Bonferroni post hoc analysis. P-values < 0.05 (*) 
were considered statistically significant, whereas P-values < 0.001 (**) were considered very 
significant. 
 In vitro evaluation of 3D printed scaffolds 
For the in vitro biological characterisation, bioceramic 3D printed scaffolds (8mm diameter and 
2mm height) were firstly sterilised in autoclave (10 min at 121°C), and then, similarly to the glass 
powders, they were preconditioned for 24h in D-MEM. After the preconditioning time, rat OB cells 
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were seeded at a density of 50x105cells/ml onto the top surface of the scaffolds placed in a 24-well 
plate. Once the cells were seeded, they were left undisturbed in an incubator at 37 °C for 1 h to 
allow their attachment. Then, an additional 1ml of culture medium was added to each well in order 
to provide the right amount of nutrients to the cells. Fresh medium was replaced every 2 days. 
The MTT solution was prepared according to the experimental procedure described in section 
5.4.9.2. After 1, 3 and 7 days of culture, 1 ml of MTT solution was added to each well and incubated 
at 37°C for another 4 h. The medium was then removed and 500µl of DMSO was added to dissolve 
the precipitated formazan. Each time point of the assay was carried out in triplicate for both direct 
and indirect methods and six samples were tested for each of the two methods. The cells seeded on 
the polystyrene standard culture microplate were used as a conventional 2-D control. Also in this 
case, the absorbance of the solution was evaluated spectrophotometrically at a wavelength of 
570nm, and acquired using the Sunrise microplate reader (Tecan Group Ltd., Switzerland).  
The results were reported as the averaged absorbance levels of six replicates. A two–way analysis 
of variance (ANOVA) followed by Bonferroni post hoc analysis was performed to determine the 
statistical significance of the differences in the absorbance values. P-values < 0.05(*) were 
considered statistically significant whereas P-values < 0.001(**) were considered very significant. 
Additionally, in order to evaluate the effect of the 3D printed scaffolds on the culture conditions, 
the pH of the medium as well as the resulting ionic release, determined by means of ICP-OES, 
were measured up to 7 days in culture.  
 Antibacterial tests  
The antibacterial potential of NCL7 formulation was assessed through the inhibition zone test (or 
also called agar diffusion test) ('Performance Standards for Antimicrobial Disk Susceptibility 
Tests; Approved Standard—Eleventh Edition ', 2012) in collaboration with the Dental School of 
Newcastle University (Oral Biology Dpt.), using Staphylococcus aureus provided by Cramlington 
Hospital (UK) from an infected joint. The test was performed on: i) glass powder solutions (particle 
size 0-53µm), prepared using deionised water (concentration 10mg/l), ii) sintered bioceramic 
pellets, and iii) sintered 3D printed porous bioceramic scaffolds. For this purpose, a Trypticase Soy 
Broth (TSB) was prepared dissolving S. aureus disk in 20ml of TSB, and incubated at 37°C in 
order to allow the bacterial colonies to growth. After 24 hours of incubation, 100µl of the 
suspension was spread on a pre-dried Trypticase Soy Agar (TSA) plate. Before performing the test, 
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all the samples were sterilised in autoclave (121°C for 10min). Afterwards, the following steps 
were performed: 
i) 10µl of glass powder solutions were added on the top of sterile paper discs, previously placed 
aseptically on the bottom half of the TSA plate (Figure 5.11(a)); 
ii) bioceramic pellets were aseptically placed on the top half of the TSA plate (Figure 5.11(a)); 
iii) 3D printed porous bioceramic scaffolds were aseptically placed on another TSA plate (Figure 
5.11(b)). 
Once the specimens were positioned, the TSA plates were incubated at 37°C. After 24 hours, the 
inhibition zones, if present, were observed as a halo around the samples where bacteria had not 
grown. 10µl Erythromycin solution (40mg/ml) was used as a positive control and AW as 
comparison material like for all the other experiments of this study. All tests were performed in 
triplicate. 
 
Figure 5.11: Staphylococcus aureus cultivation on TSA plates: (a) glass powders (bottom), bioceramic 
pellets (top) and (b) 3D porous scaffolds (top).  
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Chapter 6. Results: raw glass powders and bioceramic 
pellets preparation and characterisation 
In this chapter the results obtained from the experimental study conducted on the novel raw glass 
powders and on dense bioceramic pellets are presented. 
6.1  Glass production  
Once the individual components (reported in Table 4.1) of each formulation were mixed, they were 
melted in platinum crucibles for times and temperatures shown in Table 6.1. Afterwards, the glass 
melts were quenched in water, and glass frits (Figure 6.1) were obtained as last stage of the 
industrial process.  
Table 6.1: Production parameters for the new glass compositions. 
Glass code 
Melting 
temperature 
Melting 
time 
Casting 
temperature (ºC) 
Comments 
NCL1 1450º C 2 hours 1425 
Very fluid glass could be melted at 
lower fusion temperature 
NCL2 1450º C 2 hours 1425 
Very fluid glass could be melted at 
lower fusion temperature 
NCL3 
1450º C reduced to 
1400º C after 30 
min, then to 1350º C 
after a further 30 
min 
2 hours 1350 
Extremely fluid at 1450º C, melting 
reduced to 1350º C to cast, still fluid 
NCL4 
1450º C reduced to 
1300º C after 30 
min 
2 hours 1300 
Extremely fluid at 1450º C, melting 
reduced to 1300º C to cast, still very 
fluid. 
High level of evaporation noted and 
damage to crucible 
NCL5 1500º C 4 hours n/a 
Would not form a glass at this 
temperature 
NCL6 1450º C 2 hours 1425 
Very fluid glass could be melted at 
lower fusion temperature 
NCL7 1450º C 2 hours 1425 Fluid at 1450º C 
NCL8 1450º C 2 hours 1425 
Very fluid glass at 1450º C could be 
melted at lower fusion temperature 
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Figure 6.1: Representative image of the as-produced glass frits. 
As reported in Table 6.1, during the synthesis process the composition NCL5 could not form a 
glass at 1500ºC, which was the highest temperature reached by the furnace, so that the number of 
glass formulations was reduced to seven. 
6.2  Glass powder preparation 
The glass frits (Figure 6.2(a)), ground using a zirconia ball mill (Figure 6.2(b)), were sieved to 
obtain fine powder in the range 0-53µm as shown in Figure 6.2(c). 
 
Figure 6.2: a) glass frits, b) ground using a ball milling machine, and then c) sieved to obtain fine glass 
powder. 
 X-ray diffraction analysis 
The XRD patterns of the raw materials are reported in Figure 6.3. For NCL1, NCL2, NCL3, NCL4, 
and NCL8 the presence of a broad peak, common for glass samples, indicated the completely 
amorphous nature of these compositions. The amorphous peak was detected at 2θ values between 
25° and 30°, and confirmed that NCL1, NCL2, NCL3, NCL4 and NCL8 formulations were free 
from any detectable crystalline phase. 
Different patterns were detected for NCL6 formulation, which showed a glass-ceramic nature with 
a crystalline phase identified as calcium sodium phosphate (ICDD ref. code 01-074-1950). 
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Moreover, for the NCL7 composition a silver crystalline phase (ICDD ref. code 04-003-1425) was 
detected. Regarding the as-poured AW composition, the presence of hydroxylapatite phase (ICDD 
ref. code 01-080-6260) proved the glass-ceramic nature of this material, in agreement with the 
material investigation provided by GTS Ltd. Furthermore, a less intense β-wollastonite phase 
(ICDD ref. code 04-010-0710) was also observed in this composition. 
 
Figure 6.3: XRD patterns of as-synthesised glass powders (  hydroxylapatite,  β-wollastonite,  silver 
● calcium sodium phosphate). 
 Glass powders microstructure 
SEM analysis was performed in order to investigate the raw material microstructures. All the 
specimens were firstly gold-coated, and then analysed at an accelerating voltage of 20kV and 
working distance about 8.5mm. Figure 6.4(a-h) show the morphology of as-synthesised glass 
powders: where non-spherical and irregular shape particles can be observed. All the compositions 
were characterised by sharp edge particles. Furthermore, it can be seen that for all the glasses most 
of the particles were very fine, (ranging from 20µm to 53µm), with the presence also of grains 
smaller than 10µm, which tended to compact producing aggregates.   
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Figure 6.4: SEM analysis (magnification 1500x) showing the glass powders morphology: a) NLC1, b) 
NCL2, c) NCL3, d) NCL4, e) NCL6, f) NCL7, g) NCL8, and h) AW. 
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 Hot stage microscopy 
Table 6.2 and Table 6.3 summarise the morphological information and inferred thermal properties 
from the HSM. The experiments started at room temperature (TR) with heating rate of 10°C/min 
up to 1450ºC. All the specimens maintained their initial rectangular shape before the first shrinkage 
temperature (TFS), which varied between 550ºC and 1225ºC (see Figure 6.5(a-h)). For temperatures 
higher than the corresponding TFS, the samples started to shrink until the temperature of maximum 
shrinkage (TMS).  
The alterations of sample dimensions during the sintering process are reported in Figure 6.5(a-h). 
Figure 6.5(a-b, f-g) reveal also how the silicate-based specimens (NCL1, NCL2, NCL7 and NCL8), 
before reaching the melting status at complete melting temperature (TCM), started to expand up to 
their temperature of maximum volume (TMV). Furthermore, these silicate-based glasses showed a 
similar thermal profile, whereas the phosphate-based (NCL6) had a thermal curve (Figure 6.5(e)) 
more comparable to the borate-based glasses (NCL3 and NCL4) (Figure 6.5(c-d)).  
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Table 6.2: HSM results and resulting thermal parameters for NCL1, NCL2, NCL3 and NCL4. 
COMPOSITION TR  TFS TMS TMV TCM 
NCL1 
 
25ºC 
 
575ºC 
 
785ºC 
 
875ºC 
 
1025ºC 
NCL2 
 
25ºC 
 
600ºC 
 
730ºC 
 
1050ºC 
 
1175ºC 
NCL3 
 
25ºC 
 
555ºC 
 
625ºC 
---- 
 
760ºC 
NCL4 
 
25ºC 
 
550ºC 
 
650ºC 
---- 
 
782ºC 
    
93 
  
Table 6.3: HSM results and resulting thermal parameters for NCL6, NCL7, NCL8 and AW. 
COMPOSITION TR TFS TMS TMV TCM 
NCL6 
 
25ºC 
 
580ºC 
 
775ºC 
--- 
 
912ºC 
NCL7 
 
25ºC 
 
575ºC 
 
785ºC 
 
975ºC 
 
1025ºC 
NCL8 
 
25ºC 
 
500ºC 
 
730ºC 
 
875ºC 
 
1020ºC 
AW 
 
25ºC 
 
800ºC 
 
1225ºC 
--- 
 
1330ºC 
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Figure 6.5: Shrinkage profile derived from hot stage microscopy as function of temperature for: a) 
NCL1, b) NCL2, c)NCL3, d) NCL4, e) NCL6, f) NCL7, g) NCL8 and h) AW.  
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 pH variation 
The pH changes of the pre-sintered glasses, measured in deionised water at 37 ºC and for a 
concentration of 10mg/ml, are shown in Figure 6.6. The pH varied between 8.5 and 11.3 for both 
refreshed (Figure 6.6(a)) and non-refreshed solutions (Figure 6.6(b)). For the condition with 
refresh, the solution was changed every two days, whereas for the non-refreshed condition the 
solution remained the same for all the experiment durations, and it reached pH saturation values 
after 3 days. 
 
Figure 6.6: pH changes induced by the pre-sintered glass powder immersed in deionised water at 37 
°C: a) with refresh and b) without refreshing the solution.  
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 Ion leaching evaluation  
Figure 6.7 shows the results of ion release from NCL1 glass powders, soaked in deionised water 
up to 28 days, and quantified using an ICP-OES. Specifically: 
 the release of Si constantly increased up to 14 days, where it reached a plateau with 
135mg/l; 
 P, Mn, Zn, Bi and Cu concentrations all dropped significantly over the first 7 days, and 
showed similar kinetic profiles over the 28 days, whereas  
 Mg release dropped from 1.99 to 0.08 mg/l after 28 days in immersion; 
 K, Na, Te, and Va concentrations all rose steadily over the first 14 days; 
  Ca concentration increased during the first days of immersion, reaching a peak after 7 days 
with 22.5mg/l, whereas Sr release constantly rose until the end of the immersion time, 
varying beetwen 6.85mg/l and 25.9 mg/l. 
Regarding NCL2 composition (silicate-based glass with 45mol% of SiO2), according to the results 
reported in Figure 6.8, the following considerations can be taken: 
 similarly to NCL1 composition, Si concentration increased constantly during the 28 days 
of immersion, although in this case the maximum value reached was 85.9mg/l after the last 
time point; 
 P, Ca, Mg, Mn, Al and Fe all showed a decrease in the ion concentration levels in the initial 
stages, followed by a sudden growth after 14 days of soaking; 
 K, Na, B, Cr, Mo, Li and Se concentrations were characterised by a gradual increase during 
the overall period. 
Figure 6.9 and Figure 6.10 report the ionic release trends for NCL3 composition, which is a borate-
based glass (35mol% of B2O3). In this case: 
 the release of boron presented a constant increase reaching 590mg/l after 28 days in 
immersion, whereas Si and P concentrations showed no significant variations over the 
entire period; 
 Ca, Mg, K, Na (Figure 6.9), Li and Va (Figure 6.10) all showed an increment going from 1 
to 28 days of soaking; 
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 Mn displayed a decrease in the ion concentration levels in the initial stages, followed by a 
sudden growth after 14 days of soaking, whereas Al, Fe, Co, and Ti were characterised by 
a jagged kinetic profiles (Figure 6.10);  
 Cr and Ba release showed similar slightly curved profiles over the 28 days. 
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Figure 6.7: Ionic release concentrations deriving from NCL1 raw glass powders after 28 days of 
soaking in deionised water.  
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Figure 6.8: Ionic release concentrations deriving from NCL2 raw glass powders after 28 days of 
soaking in deionised water. 
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Figure 6.9: Ionic release concentrations deriving from NCL3 raw glass powders after 28 days of 
soaking in deionised water.   
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Figure 6.10: Ionic release concentrations deriving from NCL3 raw glass powders after 28 days of 
soaking in deionised water.  
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NCL4 is a borate-based glass with a higher content of boron (40mol% of B2O3) compared to NCL3 
composition (35mol% of B2O3). As reported in Figure 6.11: 
 boron concentration rose quickly over the first 14 days, reaching 800mg/l after 28 days; 
 phosphorous release profile was characterised by a progressive decrease during the 28 days; 
 silicon concentration showed a gradual increment during the initial 7 days, followed by a 
slow decrease; 
 Ca, Mg, K and Na release reached a plateau after 14 days;  
 Mo, Se and Sr all rose gradually up to 28 days; 
 Zn and Cu both displayed very low levels after 28 days of immersion. 
As NCL5 composition was not synthesised, NCL6 (50mol% of P2O5) was the only phosphate-
based glass out of the 8 initial proposed. According to the results reported in  
Figure 6.12 the following considerations can be taken:  
 phosphorous release profile had a continuous increase going from 52.7mg/l at day 1 to 
130mg/l at day 28; 
 the kinetic profiles of Si, K, Na, Co and B were quite comparable, and particularly they 
were characterised by a drop in their levels after 14 days; 
 Ca and Mn concentrations decreased gradually over the all interval; 
 Mg ionic release rose steadily over the 28 days, whereas Cr concentration was almost 
constant; 
 a zigzag profile arose from Cu release. 
In Figure 6.13 are reported the ionic release profiles for composition NCL7. This formulation is 
the silicate-based glass with the highest silicon content (50mol% of SiO2). For this glass: 
 the Si concentration increased very rapidly during the first 7 days and then almost steadly 
up to 28 days; 
 P, Ca, Mg and Cu concentrations slightly dropped over the first 7 days and afterward they 
restarted to rise; 
 Fe and Ti were subjected to a drop in their concentration levels already after the first 7 days 
in immersion, where small amount could be detected. A similar drop was showed by silver 
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release, which instead after 7 days and up to 28 days in immersion maintaiend values above 
zero. 
 K and Na concentrations were described by very similar profiles, which gradually increased 
over the 28 days of immersion. 
 
Figure 6.11: Ionic release concentrations deriving from NCL4 raw glass powders after 28 days of 
soaking in deionised water.  
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Figure 6.12: Ionic release concentrations deriving from NCL6 raw glass powders after 28 days of 
soaking in deionised water. 
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Figure 6.13: Ionic release concentrations deriving from NCL7 raw glass powders after 28 days of 
soaking in deionised water. 
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The last composition that will be presented is a silicate-based glass with the same silicon content 
of NCL2 (45mol% of SiO2). As shown in Figure 6.14 and Figure 6.15: 
 silicon was characterised by a gradual increase, reaching 167mg/l at day 28; 
 the release profiles of K, Na, B, Cr, Mo and Se, similarly to Si, steadily rose up to the end 
of the considered interval; 
 Mg, Mn, Zn, Fe, Cu and Co all dropped significantly over the first 7 days; 
 the level of Sr reached a peak at day 7 and then started to progressively decrease; 
 P and Ca profiles were characterised by a similar trend of NCL7 composition, with a 
significant drop after the first 7 days in immersion, followed by rapid increase up to 28 
days.  
As comparison, Figure 6.16 reports the ionic release profiles deriving from AW glass-ceramic. In 
this case:  
 silicon release reached a peak at day 14 with 85mg/l, and afterward started gradually to 
decrease arriving at 68.1mg/l at day 28; 
 P and Ca elements had quite comparable profiles, showing a minimum in the concentration 
values at day 7, followed by a gradual growth up to day 28; 
 the Mg ionic release varied over the period showing no clear trend. 
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Figure 6.14: Ionic release concentration deriving from NCL8 raw glass powder after 28 days of 
soaking in deionised water.  
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Figure 6.15: Ionic release concentration deriving from NCL8 raw glass powder after 28 days of 
soaking in deionised water.  
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Figure 6.16: Ionic release concentration deriving from AW raw glass powder after 28 days of soaking 
in deionised water. 
From the results obtained through the ICP analysis, it was possible to draw the following general 
considerations: 
 for NCL1 and NCL7 compositions, which are both silicate-based glasses, the release of 
silicon followed the same trend over the 28 days, characterised by a steadly increase over 
the first 14 days and then remained nearly constant; 
 NCL2 and NCL8 compositions showed a different silicon release profile with respect to 
NCL1 and NCL7 formulations. In the first case, most likely the presence of boron in the 
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glass matrix contributed to gradually rise up silicon release until the end of the considered 
interval. Furthermore, silicon and boron in these compositions displayed the same trend; 
 as network former, boron was released very quickly in comparison to silicon and 
phosphorous, and it displayed a progressive increase all over the interval either for NCL3 
and NCL4 compositions; 
 the presence of boron in the glass formulation, even as intermediate oxide, ehanched the 
release of other elements in the composition (i.e. vanadium and phosphorous from NCL3 
glass with respect to their release from NCL1 composition); 
 silicon release from borate-based glasses was more correlated to the amount of boron rather 
than its content in the glass matrix, as the results from NCL3 and NCL4 demonstrated; 
 as main network former, phosphorous in NCL6 composition was released more slowly than 
boron from NCL3 and NCL4 formulations. 
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 In vitro cytotoxicity 
In order to evaluate the cytotoxicity effect on rat osteoblast cells, all the novel powder-based 
biomaterials at different concentrations were tested through MTT assay, after one and seven days 
in culture. As described in paragraph 5.4.9.2, two different test conditions were assessed: 
i) the direct contact of the cells with the raw glass powders and 
ii) the indirect contact based on the filtering of the glass powders eluate. 
Figure 6.17 highlights the effect of NCL1 composition. According to the results reported in Figure 
6.17(a), for direct condition over the 7 days culture period, the cell viability was fairly constant for 
concentrations of 0.1 and 1mg/l of glass powder in media, but concentrations of 10mg/l of glass in 
media had a clear detrimental effect on viability.  
Regarding indirect condition (Figure 6.17(b)), no harmful outcomes were detected for 
concentration of 0.1 and 1mg/l of glass powder in media, whilst concentrations of 10mg/l of glass 
in media had a detrimental effect on cell viability after 7 days in culture; condition B, no harmful 
outcomes were detected up to 1 mg/l. However, the negative effect of NCL1 glass powders on cells 
mitochondrial activity arose significantly going from 1 to 10 mg/l in both tested conditions with 
absorbance values close to zero. 
 
Figure 6.17: Effect of NCL1 glass powders (measured in triplicate) on formazan formation after (a) 
direct and (b) indirect contact with rat osteoblast cells, evaluated through MTT assay after 1 day and 7 
days in culture. Error bars represent the standard error of the mean (p < 0.05(*) and p < 0.001(**)). 
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Regarding composition NCL2, whose effects on rat OB cells are reported in Figure 6.18, the 
following considerations can be taken: for the direct condition (Figure 6.18(a)) the cell viability 
was fairly constant for concentrations of 0.1 and 1mg/l of glass powder in media over the 7 days 
culture, but concentrations of 10mg/l of glass in media had a clear detrimental effect on viability. 
Overall, this formulation showed no detrimental influence on rat osteoblast mitochondrial activity 
by indirect contact (Figure 6.18(b)), either after 1 and 7 days in culture.  
 
Figure 6.18: Effect of NCL2 glass powders (measured in triplicate) on formazan formation after (a) 
direct and (b) indirect contact with rat osteoblast cells, evaluated through MTT assay after 1 day and 7 
days in culture. Error bars represent the standard error of the mean (p < 0.05(*) and p < 0.001(**)). 
Consequences of NCL3 composition on rat osteoblasts mitochondrial activity are displayed in 
Figure 6.19. Although for indirect condition the material did not show any significant negative 
effect on cells activity after 1 day in culture and at low concentrations (Figure 6.19(b)), for both 
conditions a significant detrimental behaviour was found at the highest concentration tested (10 
mg/l) with respect to the control (0 mg/l) after 7 days in culture.  
Figure 6.20 shows the MTT assay results for NCL4 formulation, which highlights a decrease in the 
cell mitochondrial activity after 7 days in culture, detected for both tested methods. No significant 
negative effects associated to the use of this glass powder were observed for the indirect method. 
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Figure 6.19: Effect of NCL3 glass powders (measured in triplicate) on formazan formation after (a) 
direct and (b) indirect contact with rat osteoblast cells, evaluated through MTT assay after 1 day and 7 
days in culture. Error bars represent the standard error of the mean (p < 0.05(*) and p < 0.001(**)). 
 
Figure 6.20: Effect of NCL4 glass powders (measured in triplicate) on formazan formation after (a) 
direct and (b) indirect contact with rat osteoblast cells, evaluated through MTT assay after 1 day and 7 
days in culture. Error bars represent the standard error of the mean (p < 0.05(*) and p < 0.001(**)). 
Concerning glass composition NCL6, as reported in Figure 6.21, no remarkable effects were 
showed after 1 day in culture for both test set-up, although for the direct method (Figure 6.22 (a)) 
the cell mitochondrial activity was approximately constant for concentrations of 0.1 and 1mg/l of 
glass powder in media over the 7 days culture period, but by increasing the concentrations up to 
10mg/l an evident cytotoxic effect on viability was observed with absorbance values very close to 
zero. For the indirect method (Figure 6.22 (b)), the cells mitochondrial activity decreased by 
increasing the amount of glass powders in media, after both 1 and 7 days in culture, showing a 
detrimental effect for rat OB mitochondrial activity.  
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Figure 6.21: Effect of NCL6 glass powders (measured in triplicate) on formazan formation after (a) 
direct and (b) indirect contact with rat osteoblast cells, evaluated through MTT assay after 1 day and 7 
days in culture. Error bars represent the standard error of the mean (p < 0.05(*) and p < 0.001(**)). 
Figure 6.22 shows the effect of NCL7 glass powder on cell mitochondrial activity. As can be 
observed, the presence of glass powders in direct contact, and at high concentrations, slightly 
affected rat OB mitochondrial activity (Figure 6.22 (a)). Tests performed according to indirect 
method revealed no cytotoxic effect and a positive influence of NCL7 composition on rat OB cell 
viability, which increased over the 7 days in culture. 
 
Figure 6.22: Effect of NCL7 glass powders (measured in triplicate) on formazan formation after (a) 
direct and (b) indirect contact with rat osteoblast cells, evaluated through MTT assay after 1 day and 7 
days in culture. Error bars represent the standard error of the mean (p < 0.05(*) and p < 0.001(**)). 
The last of the novel compositions, NCL8 silicate-based glass, showed a cytotoxic effect on cell 
viability after both 1 and 7 days in culture tested by direct contact. For the indirect method a 
decrease of rat OB activity was found particularly after 7 days in culture, and by increasing the 
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glass powder concentration (Figure 6.23), proving the harmful influence of this formulation on rat 
OB viability.  
 
Figure 6.23: Effect of NCL8 glass powders (measured in triplicate) on formazan formation after (a) 
direct and (b) indirect contact with rat osteoblast cells, evaluated through MTT assay after 1 day and 7 
days in culture. Error bars represent the standard error of the mean (p < 0.05(*) and p < 0.001(**)). 
Ultimately, Figure 6.24 reports the data for AW glass powder. Similarly to composition NCL7, 
also in this case glass powder in direct contact with cells, and at high concentrations slightly 
compromised their mitochondrial activity (Figure 6.24 (a)).  
However, indirect test condition (Figure 6.24(b)) showed that nevertheless an initial drop after the 
first 24 hours in culture, rat osteoblast mitochondrial activity improved after the longer time point. 
 
Figure 6.24: Effect of AW glass powders (measured in triplicate) on formazan formation after (a) direct 
and (b) indirect contact with rat osteoblast cells, evaluated through MTT assay after 1 day and 7 days in 
culture. Error bars represent the standard error of the mean (p < 0.05(*) and p < 0.001(**)).  
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In light of the MTT assay results, performed on raw glass powders, the following consideration 
can be taken: 
 NCL1, NCL3, NCL6 and NCL8 formulations showed a detrimental effect on cell 
mitochnodrial activity at all the concentrations tested, and either for direct and indirect 
contact test; 
 NCL2, NCL4 and NCL7 compositions showed similar outcomes of AW glass-ceramic; 
specifically, these compositions influenced negatively cell viability following a direct 
contact test with high concentrations of glass powders in media, wherease they showed high 
cell mitochondrial activity for the indirect condition and after 7 days in culture; 
 based on the in vitro text findings, given the high number of doping agent in each 
formulation, no significant correlations can be drawn between the in vitro glass behaviour 
and their structure. 
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6.3  Bioceramic pellets 
This section presents the results of the experimental work conducted on bulk dense structures and 
prepared following the procedure described in paragraph 5.3.2. Once the pellets were pressed, they 
were placed in a chamber furnace. In order to assess their sintering behaviour, several thermal 
treatments were performed in the range 550-850ºC for 1 hour (heating rate 10ºC/min), according 
to HSM results. 
 Morphological analysis 
SEM investigations were performed onto bioceramic pellet surfaces to evaluate the effect of 
different heating treatments on sample morphology, and to further assess their sintering level. 
Figure 6.25 to Figure 6.32 report the pellet surface of each composition after two of the several 
heating treatments that were investigated. Micrographs (a) of Figure 6.25 to Figure 6.32 show a 
poor sintering level for all the formulations, where glass particles started to aggregate, but they 
were not properly sintered. The microstructures reported in micrographs (b) of Figure 6.25 to 
Figure 6.32 demonstrate how an increase in the heating temperatures leads to an appropriate 
densification status, as a result of increased liquid phase. Particularly for NCL1, NCL3, NCL6, 
NCL7, NCL8 and AW compositions the formation of sintering necks (red arrows in the figures) 
became evident. 
 
Figure 6.25: SEM micrograph (magnification 2500x) of NCL1 pellet surface at (a) low (575ºC), and (b) 
appropriate sintering level (625ºC). 
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Figure 6.26: SEM micrograph (magnification 2500x) of NCL2 pellet surface at (a) low (650ºC), and (b) 
appropriate sintering level (700ºC). 
 
Figure 6.27: SEM micrograph (magnification 2500x) of NCL3 pellet surface at (a) low (550ºC), and (b) 
appropriate sintering level (625ºC); red arrows indicate necking formation. 
 
Figure 6.28: SEM micrograph (magnification 2500x) of NCL4 pellet surface at (a) low (600ºC), and (b) 
appropriate sintering level (625ºC). 
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Figure 6.29: SEM: micrograph (magnification 2500x) of NCL6 pellet surface at (a) low (700ºC), and 
(b) appropriate sintering level (725ºC); red arrow indicates necking formation. 
 
 
Figure 6.30: SEM micrograph (magnification 2500x) of NCL7 pellet surface at (a) low (600ºC), and (b) 
appropriate sintering level (625ºC); red arrows indicate necking formation. 
 
 
Figure 6.31: SEM micrograph (magnification 2500x) of NCL8 pellet surface at (a) low (575ºC), and (b) 
appropriate sintering level (625ºC). 
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Figure 6.32: SEM micrograph (magnification 2500x) of AW pellet surface at (a) low (830ºC), and (b) 
appropriate sintering level (850ºC); red arrow indicates necking formation. 
 Bioceramic pellets sintering conditions 
In light of the SEM microstructural observations, and after a thorough qualitative analysis, the 
heating treatment temperatures that provided the best densification degree of the bioceramic 
pellets, and hence mechanically competent structures are shown in Table 6.4 below. 
Table 6.4: Bioceramic pellets sintering temperatures. 
CODE COMPOSITION 
SINTERING 
TEMPERATURE (°C) 
NCL1 Silicate-based 625 
NCL2 Silicate-based 700 
NCL3 Borate-based 625 
NCL4 Borate-based 625 
NCL6 Phosphate-based 725 
NCL7 Silicate-based 625 
NCL8 Silicate-based 625 
AW Silicate-based 850 
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 X-ray diffraction analysis before and after sintering 
XRD spectra for all 7 compositions and AW, before and after sintering, are reported in Figure 6.33 
to Figure 6.40. NCL1, NCL3, NCL4, and NCL8 formulations maintained the same amorphous 
status also after the sintering treatment (see Figure 6.33, Figure 6.35, Figure 6.36 and Figure 6.39). 
Crystalline phases developed during the sintering treatments of NCL2 formulation (Figure 6.34) 
were identified as diopside phase (ICDD ref. code 01-073-6374). 
.   
Figure 6.33: XRD patterns of NCL1 composition: (a) glass powder and (b) pellet sintered at 625ºC. 
 
 
Figure 6.34: XRD patterns of NCL2 composition: (a) glass powder and (b) pellet sintered at 700ºC (● 
diopside).  
    
122 
  
 
Figure 6.35: XRD patterns of NCL3 composition: (a) glass powder and (b) pellet sintered at 625ºC. 
 
Figure 6.36: XRD patterns of NCL4 composition: (a) glass powder and (b) pellet sintered at 625ºC. 
NCL6 sample was not completely amorphous before sintering. Peaks corresponding to calcium 
sodium phosphate were detected on NCL6 glass powder (Figure 6.37(a)).  
 
Figure 6.37: XRD patterns of NCL6 composition: (a) glass powder and (b) pellet sintered at 725ºC, (● 
calcium sodium phosphate and  sodium calcium magnesium phosphate).  
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The heat treatment contributed to the further development of a crystalline phase, as shown in Figure 
6.37(b), with the growth of a sodium calcium magnesium phosphate phase (ICDD ref. code 00-
045-0136). 
Figure 6.38 displays the XRD pattern of the NCL7 formulation. This glass was almost amorphous, 
as a very low amount of Ag was detected before the sintering treatment. The intensity of Ag peaks 
(ICDD ref. code 04-003-1425) increased after sintering. 
 
Figure 6.38: XRD patterns of NCL7 composition: (a) glass powder and (b) pellet sintered at 625 C, ( 
silver). 
 
Figure 6.39: XRD patterns of NCL8 composition: (a) glass powder and (b) pellet sintered at 625ºC. 
Figure 6.40 shows the XRD results of the glass powder and sintered A-W pellet. Although the 
crystalline phases remained the same (hydroxylapatite and β-wollastonite), after the sintering process 
the sintered material showed more intense peaks (Figure 6.40(b)) with respect to the raw glass-
powder (Figure 6.40(a)), confirming the glass-ceramic nature of this formulation.  
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Figure 6.40: XRD patterns of AW composition: (a) glass powder and (b) pellet sintered at 850ºC,  
(  hydroxylapatite,  β-wollastonite). 
 Sintering behaviour  
Figure 6.41 reports the volumetric shrinkage (%) of the novel bioceramic pellets calculated 
according to the formula described in paragraph 5.4.6, and following the sintering conditions 
reported in Table 6.4. For all materials the volumetric shrinkage was between 29% and 36%.  
 
Figure 6.41: Average volumetric shrinkage (%) for sintered pellets (n=5). Error bars represent the 
standard error of the mean. 
  
(  
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 Mechanical properties  
A representative stress-strain curve of the sintered bioceramic pellets, assessed in compression 
using a Tinius Olsen universal testing machine, is reported in Figure 6.42. The curve indicated that 
the stress increased linearly with increasing compressive strain. 
 
Figure 6.42: Representative stress-strain curve obtained during compression tests performed on the 
sintered bioceramic pellets.  
The averaged compressive stress at 20% (σ20) of the strain, and compressive modulus (Ec) data are 
shown in Figure 6.43. All the seven bioceramic pellets had a σ20 higher than the one of AW, with 
NCL8 showing the highest value (286±11MPa). According to the results obtained (Figure 6.43(a)), 
a part from composition NCL7, the silicate-based glasses (NCL1, NCL2 and NCL8) showed a 
small but significant increase for both Ec and σ20 compared to AW. No significant differences were 
found for phosphate and borate-based formulations. 
Regarding the compressive modulus (Figure 6.43(b)), very significant differences (p < 0.001) were 
observed for the NCL1 and NCL8 compositions, and significant differences (p <0.05) for NCL2 
and NCL3 compositions in comparison to AW glass-ceramic. However, all the glasses showed σ20 
values in excess of 150MPa, and modulus values in excess of 1.2GPa.  
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Figure 6.43: a) Averaged compressive stress (for εc=20%) and b) compressive modulus values of dry 
bioceramic pellets (n=5). Error bars represent the standard error of the mean (p<0.05(*) and 
p<0.001(**)). 
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6.4  Selection of glass compositions as potential bone tissue-like substitutes 
Considering the stringent criteria necessary for the design of 3D bone-like substitutes (previously 
presented in Table 3.1), the development of novel biomaterials for bone tissue repair remains a 
highly challenging task. However, those set of requirements can be considered an essential 
guideline for accepting or improving a material response according to specific clinical situation 
demands. Along with appropriate physico-chemical properties necessary to match the 
characteristics of the host tissue (i.e. degradation rate, surface chemistry) (Reis and Román, 2004; 
Mitra et al., 2013), a crucial aspect for the effective success of bone substitutes for load-bearing 
applications is a good balance between porosity of the structure and its mechanical proprieties (Chu 
et al., 2002; Hsin and Yiwei, 2011; Loh and Choong, 2013). As described in Table 3.1, a highly 
interconnected porous structure is essential to enable fluid flow, cell migration, bone ingrowth and 
vascularization (Liu et al., 2013). However, porosity affects the mechanical behaviour of the 
structure, since strength and stiffness gradually decrease when the volume fraction of pores 
increases (Vitale-Brovarone et al., 2010). 
In light of the results presented in paragraph 6.3.5, which showed the mechanical performance of 
the new formulations in form of dense bioceramic pellets, similar properties were found with 
respect to the widely applied AW glass-ceramic (Kokubo, 2008), particularly for NCL4, NCL6 and 
NCL7 compositions. Hence, all the formulations could be considered potential biomaterials for 
bone repair applications. However, since a biomaterial should perform its function without 
exhibiting any immune response in the host tissue, another important aspect, that it is worth to 
consider, concerns the in vitro biocompatibility (Hutmacher, 2000; Hutmacher, 2001). Particularly, 
the cytotoxicity of novel developed biomaterials is a key issue that should be addressed prior to 
pre-clinical trials (Hollinger, 2011). In paragraph 6.2.6 the in vitro cytotoxicity data resulting from 
raw glass powders were presented. The results of the tests revealed that for the direct method, and 
high concentration of glass powder (10mg/l), cell mitochondrial activity was significantly affected 
by the presence of the glass particles. On the other hand, the indirect method indicated that after 7 
days in culture and at the highest concentration tested NCL2, NCL4 and NCL7 showed no 
significant differences with respect to the control (similarly to AW glass-ceramic behaviour). On 
the basis of the MTT results, and considering the assumption according to which the 
biocompatibility of new materials is a key concern for the following clinical application, only 
NCL2, NCL4 and NCL7 formulations were selected for further characterisation.  
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6.5  Bioactivity evaluation 
This paragraph presents the results obtained from SBF testing on selected bioceramic pellets 
(NCL2, NCL4, NCL7 and AW). 
The SEM micrographs and EDS analysis of the top surface of NCL2 dense pellets before 
immersion in SBF solution and after 7 days of soaking are shown in Figure 6.44(a-b) and Figure 
6.44(c-d) respectively. No signs of precipitate formation were detected on the sample surface after 
7 days of soaking. 
 
Figure 6.44: a) morphological (5Kx mag) and b) compositional analysis of the marked region of NCL2 
bioceramic pellet before the immersion in SBF. c) morphological (5Kx mag) and d) compositional 
analysis (at %) of the marked region of NCL2 bioceramic pellet after 7 days of immersion in SBF.  
However, after 28 days in immersion, NCL2 specimens developed a homogeneous rough layer on 
their surface (Figure 6.45(a-b)), even though no HCA formation was detected (see EDS spectra in 
Figure 6.45(c)). 
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Figure 6.45: a) morphological (5Kx mag) analysis with b) higher magnification inset (20Kx mag), and 
c) compositional analysis (at %) of the marked precipitates observed on NCL2 bioceramic pellet after 28 
days of soaking in SBF. 
Regarding NCL4 composition, Figure 6.46 shows the SEM micrographs and EDS compositional 
analysis of the top surface, before (Figure 6.46(a-b)) and after 7 days (Figure 6.46(c-d)) of soaking 
in SBF solution. As suggested by the SEM analysis and EDS spectra, globular shaped agglomerates 
rich in calcium and phosphorous (Ca/P=0.76) (Figure 6.46(d)) precipitated on the sample surface, 
during the 7 days of immersion.  
 
Figure 6.46: a) morphological (5Kx mag) and b) compositional analysis of the marked region of NCL4 
bioceramic pellet before the immersion in SBF. c) morphological (5Kx mag) and d) compositional 
analysis (at %) of the marked region of NCL4 bioceramic pellet after 7 days of immersion in SBF.   
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After 28 days of immersion, more granular structures (see white arrows in Figure 6.47(b)) were 
observed on the NCL4 pellets surface, with the Ca/P ratio that moved from 0.76 at day 7 to 1.08 at 
day 28 (see spectra in Figure 6.47(c)). 
 
Figure 6.47: a) morphological (5Kx mag) analysis with b) higher magnification inset (20Kx mag), and 
c) compositional analysis (at %) of the marked precipitates observed on NCL4 bioceramic pellet after 28 
days of soaking in SBF (white arrows indicate the granular structures developed on the pellet surface). 
The top surface SEM imaging and the corresponding EDS spectra for NCL7 bioceramic pellets, 
before and after 7 days of soaking in SBF, are reported in Figure 6.48(a-b) and Figure 6.48(c-d) 
respectively. Also in this case no apatite formation was detected after 7 days. Although, similarly 
to NCL4 composition, globular shaped agglomerates were identified on the sample surface, with a 
Ca/P ratio of 1.10, as reported in the EDS analysis (see Figure 6.48(d)). However, Figure 6.48(c) 
documents the formation of micro-cracks (indicated by the red arrows in the figure), and the 
presence of a thin silica-rich layer, which usually forms during the first steps of the bioactivity 
process. 
In fact, after 28 days of immersion in SBF, the micro-cracks development on the pellets surface 
(see Figure 6.49(a)) became more pronounced. Calcium phosphate agglomerates with a 
cauliflower-like shape precipitated on the NCL7 sample surface, as can be observed in Figure 
6.49(b). In addition, the Ca/P ratio of the precipitates increased from 1.1 at day 7 to 1.4 at day 28 
(Figure 6.49(c)), which may be considered an HA precursor, thus indicating the potential bioactive 
behaviour of NCL7 composition.  
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Figure 6.48: a) morphological (5Kx mag) and b) compositional analysis of the marked region of NCL7 
bioceramic pellet before the immersion in SBF. c) morphological (5Kx mag) and d) compositional 
analysis (at %) of the marked region of NCL7 bioceramic pellet after 7 days of immersion in SBF (the 
red arrows indicate the micro-cracks formation on the pellet surface). 
 
 
Figure 6.49: a) morphological (5Kx mag) analysis with b) higher magnification inset (20Kx mag), and 
c) compositional analysis (at %) of the marked precipitates observed on NCL7 bioceramic pellet after 28 
days of soaking in SBF (the red arrows indicate the micro-cracks formation on the pellet surface).  
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Regarding AW composition (Figure 6.50), the upper surface of the pellets after one week of 
immersion (see Figure 6.50(c)) was homogenously covered by a thin layer of apatite enriched in 
Ca and P (see Figure 6.50(d)), proving the quick bioactive process that characterised this material.  
 
Figure 6.50: a) morphological (5Kx mag) and b) compositional analysis of the marked region of AW 
bioceramic pellet before the immersion in SBF. c) morphological (5Kx mag) and d) compositional 
analysis (at %) of the marked region of AW bioceramic pellet after 7 days of immersion in SBF (the red 
arrows indicate the micro-cracks formation on the pellet surface). 
SEM analysis together with the EDS spectra of AW after 28 days in SBF immersion are shown in 
Figure 6.51. The high bioactive potential of AW glass-ceramic has already been widely 
investigated in the literature (Magallanes-Perdomo et al., 2011; Park and Ozturk, 2013). However, 
in this study the extensively documented bioactive properties of AW formulation, were proved by: 
i) the precipitation of a homogeneous needle-like layer rich in Ca and P (see Figure 6.51(a)), ii) the 
micro-cracks formation (Figure 6.51(b)), and iii) most importantly by the Ca/P ratio of around 1.62 
(Figure 6.51(c)) that is nearly equal to the composition of human bone hydroxyapatite (Ca/P=1.67) 
(Palmer et al., 2008).  
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Figure 6.51: a) morphological (5Kx mag) analysis with b) higher magnification inset (20 Kx mag), and 
c) compositional analysis (at %) of the marked precipitates observed on NCL7 bioceramic pellet after 28 
days of soaking in SBF (the red arrows indicate the micro-cracks formation on the pellet surface). 
In addition to the semi-quantitative analysis performed, a quantitative elemental characterisation 
of the sample surfaces before and after soaking in SBF was assessed by XPS, in order to evaluate 
the atomic concentration of the main elements (Si, Ca and P) potentially involved in the bioactivity 
process. The XPS analysis evidenced that after 28 days of soaking in SBF, silicon content 
decreased for all the investigated compositions (Figure 6.52 and Figure 6.53). Conversely, the 
atomic concentration of calcium and phosphorous slightly increased for all the pellets, as 
consequence of the formation of CaP precipitates on their top surface. Specifically, for NCL2 
phosphorous (at.%) remained almost steady (~9.5 after 28 days in immersion), while for the other 
compositions it reached values above 40%. The concentration of calcium instead increased beyond 
30% for all the formulations. 
 
Figure 6.52: Atomic concentration of Si, Ca and P on the upper surface of a) NCL2 and b) NCL4 
bioceramic pellets after immersion in SBF at different time points.  
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Figure 6.53 : Atomic concentration of Si, Ca and P on the upper surface of a) NCL7 and b) AW 
bioceramic pellets after immersion in SBF at different time points. 
Ion leaching variation of Si, Ca, and P from bioceramic pellets, soaked in SBF solution at different 
time intervals, was evaluated using ICP – OES analysis. As evidenced in Figure 6.54(a), for NCL2 
the concentration of Ca and P released in solution was almost constant for the all immersion time 
points; instead Si increased gradually up to day 14 and then started to decrease slowly. For NCL4 
bioceramic pellets (see Figure 6.54(b)) the release of Ca increased rapidly during the early stage of 
immersion and then remained around 110mg/l until the end of the soaking time, whereas P 
concentration decreased rapidly from 100mg/l to 25mg/l after 1 day of soaking, and then 
maintained a level around this value up to 28 days of soaking in SBF. Si release increased up to 3 
days in immersion, then after a steady profile between day 3 and 7, it showed a “zig-zag” variation 
up to day 28. 
 
Figure 6.54: Release profiles of Si, Ca and P ions for a)NCL2 and b) NCL4 bioceramic pellets 
immersed in SBF solution at different time intervals.  
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Figure 6.55 reports the results for composition NCL7 and AW formulations. The variation of Ca 
and P for NCL7 samples had a quite specular profile as well as a similar range of values. The 
release of silicon from NCL7 composition in SBF solution showed a gradual increase from 0 to 28 
days. For AW composition (Figure 6.55(b)) Ca content decreased rapidly during the early stage, 
and then fluctuated around 22mg/l with the increasing immersion time. P reached 116mg/l after 24 
hours in immersion, and then declined slowly to 96.5mg/l at day 28. After a slow growth with a 
peak at day 7 (36.8mg/l), silicon dropped to almost zero at day 28.  
 
Figure 6.55: Release profiles of Si, Ca and P ions for a)NCL7 and b) AW bioceramic pellets immersed 
in SBF solution at different time intervals. 
The in vitro biodegradation behaviour of the fabricated pellets was further studied by measuring 
the weight loss of the samples, up to 28 days in SBF immersion, as function of the storage time 
(Figure 6.56).  
 
Figure 6.56: Averaged weight loss (±SE) of NCL2, NCL4, NCL7 and AW pellets after soaking in SBF 
solution.  
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As expected, the weight loss for NCL4 samples was higher with respect to the other specimens, 
confirming that borate-based glasses have a faster dissolution rate, in accordance with the literature 
(Yao et al., 2007; Liu et al., 2010; Deliormanli, 2013; Wang et al., 2014). NCL7 and AW showed 
a similar trend all over the considered interval, with a mass loss around 12% and 14% respectively, 
after 28 days of soaking, whereas no marked sign of degradation was found for NCL2 formulation. 
The degradation process of a bioactive glass takes place by ionic exchange of soluble ions, which, 
depending on the glass composition, influence the pH of the surrounding media (Rahaman et al., 
2011). In order to evaluate the hydrolytical stability of the bioceramic pellets after immersion in 
SBF, the pH changes during the 28 days of immersion were assessed.  
Figure 6.57 reports the pH values measured during 28 days of immersion. As it can be observed, 
all the compositions were characterised by a low pH variation over the period, which ranged 
between 7.44 and 7.74. 
 
Figure 6.57: Averaged pH value (±SE) of SBF solution for NCL2, NCL4, NCL7 and AW samples.  
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Chapter 7.  Results: manufacturing of 3D porous glass-
derived substitutes 
7.1 Introduction 
The use of AM technology for the production of bone-like substitutes has been predicted to increase 
in the coming years, primarily focusing on the development of medical implants that can be 
customised according to patient and clinical needs. Among the different computer-aided fabrication 
techniques, indirect powder-based 3D printing is such a versatile technology that has been widely 
used to produce scaffolds from a broad variety of materials (Bose et al., 2013). The advantages of 
this method, in the field of bone tissue engineering, derive from i) the flexibility in material usage 
and ii) the possibility of printing objects with defined geometry, controlled and interconnected 
structure without the use of any toxic solvent (Utela et al., 2010; Butscher et al., 2011; Bose et al., 
2013). Several studies in the literature investigated the potential of powder-based 3DP technology 
to process ceramic-based materials alone or in combination with other blended compounds for 
bone tissue applications, however the lack of appropriate mechanical properties is still their major 
limitation (Lee et al., 2005; Leukers et al., 2005; Irsen et al., 2006b; Utela et al., 2006a; Vorndran 
et al., 2008; Butscher et al., 2012; Cox et al., 2015). 
The main objectives of the last part of this work are: 
i) to manufacture 3D porous glass-derived substitutes via powder-based 3DP technology, using the 
three novel glass formulations that showed appropriate mechanical and biological properties during 
the first two stages of the study,  
ii) to characterise them in terms of physico-chemical, mechanical and biological performance. 
For powder-based 3D printing systems, grain size and grain size distribution of the starting 
materials are crucial factors for the physical characteristics of the final 3D printed parts. 
Specifically, they must be taken into account during the manufacturing of porous tissue substitutes, 
since they directly influence porosity, which in turn has been seen to impact cell attachment, 
proliferation and differentiation, and equally importantly the resulting mechanical properties of the 
implant (Spath et al., 2015). 
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In the current study, a ZCorp 310 3D printer was used as processing route to create 3D bone-like 
substitutes based on blends of glass powder - MD (70:30 w/w) as precursor materials. The particle 
range (between 0 and 53 µm) of the raw materials was chosen according to the work performed by 
Alharbi, where different blend of AW-MD were used to investigate the feasibility of powder-based 
3DP technology, and its potential utility for bone tissue engineering applications (Alharbi, 2015). 
7.2 Indirect 3D printed bioceramic substitutes 
Figure 7.1 displays the microstructures of NCL2, NCL4, NCL7 and AW green bodies resulting from 
the indirect 3D printing process. As can be observed from Figure 7.1(b), composition NCL4 showed 
a very brittle and less compact structure with respect to the other formulations and resulted not 
suitable for further processing and characterisation.  
 
Figure 7.1: SEM micrographs of 3D printed green bodies: a) NCL2, b) NCL4, c) NCL7 and d) AW 
samples.  
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 Sintering optimisation 
Once the green bodies were printed, the indirect stage of the process started. Different thermal 
treatments were performed and optimised on both NCL2 and NCL7 compositions in order to obtain 
mechanically competent 3D porous parts with appropriate structural integrity. Figure 7.2 displays 
the three sintering profiles evaluated for NCL2 3D printed green bodies. The heat treatment 1 was 
a one-step treatment, on the basis of the results obtained from the HSM, and already evaluated for 
the sintering of dense bioceramic pellets. For the heat treatment 2, an intermediate step at 400°C 
was investigated to allow a better nucleation of the glass particles; however, many micro-cracks 
developed in the structures during the sintering process. 
 
Figure 7.2: Heat treatments and corresponding profiles that were investigated for NCL2 3D printed 
green bodies.  
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Hence, considering the presence of the polymer-based binder, the thermal cycle was modified to 
remove completely the sacrificial porogen without losing the sample integrity. A third and longer 
(5°C/min) step was added to the previous heat treatment in order to permit the burning-out of the 
binder and the gradual consolidation of the bioceramic structure. Similar considerations were 
adopted for composition NCL7, for which the corresponding heating profiles are illustrated in 
Figure 7.3. The maximum heating temperature, in this case was 625°C. In the end, the heat 
treatment 3 in Figure 7.2 and in Figure 7.3 was selected as the more appropriate for the sintering 
of NCL2 and NCL7 3D printed green parts respectively. 
 
Figure 7.3: Heat treatments and corresponding profiles that were investigated for NCL7 3D printed 
green bodies.  
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For all the heat treatments each step consisted of heating the green bodies (with specific heating 
rate) up to desired temperature, followed by dwelling for 1 hour. At the end of each treatment the 
samples were left to cool down in the furnace chamber.  
The sintering conditions of AW were selected on the basis of previous studies, and are reported in 
Figure 7.4 below (Xiao et al., 2008). 
 
Figure 7.4: Heat treatment and corresponding profile for AW 3D printed green bodies. 
 Morphological evaluation 
  Macrostructural observation 
Figure 7.5, Figure 7.6 and Figure 7.7 display NCL2, NCL7 and AW 3D printed structures 
respectively before (micrograph(a)) and after (micrograph(b)) the sintering. This qualitative 
comparison highlights that the green bodies showed a good level of integrity already after the 
printing process, and that the post-processing phase led to a more connected and harder structures 
with no shape distortion.  
 
Figure 7.5: NCL2 3D printed samples: a) before and b) after the sintering process. 
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Figure 7.6: NCL7 3D printed samples: a) before and b) after the sintering process. 
 
Figure 7.7: AW 3D printed samples: a) before and b) after the sintering process. 
As expected, the thermal treatments, during which the liquid and solid binders were burned off, 
produced a reduction of the sample dimensions between 49% and 57%. However, no significant 
differences were measured for the shrinkage values of the two compositions in comparison to AW 
scaffolds (Figure 7.8). 
 
Figure 7.8: Average volumetric shrinkage (%) for sintered NCL2, NCL7 and AW 3D printed samples. 
Error bars represent the standard error of the mean. 
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  Microstructural observation 
SEM analysis was performed on NCL2, NCL7 and AW 3D printed structures to evaluate the effect 
of sintering treatment on samples morphology. Figure 7.9 shows the top surface (micrograph(a)) 
and cross section (micrograph(b)) of NCL2 3D printed structure, following the heat treatment 3 
described previously in Figure 7.2. Figure 7.9 reveals that thermal treatment led to neck formation 
(see red arrows), driven by the mix of small and big particles, and to a diffuse strut roughness, 
which was enhanced by the presence of many micro-particles, as demonstrated by surface 
morphology of the green body (see Figure 7.1 (c)).  
 
Figure 7.9: SEM micrographs of a) upper surface and b) cross section of NCL2 3D printed structure 
after sintering (red arrows indicate necking formation). 
The upper surface and internal structure of NCL7 3D printed scaffold, after sintering, are shown in 
Figure 7.10.  
 
Figure 7.10: SEM micrographs of a) top surface and b) cross section of NCL7 3D printed structure 
after sintering (red arrows indicate necking formation).  
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If compared to the green body, the sintered structure exhibited a very high degree of densification, 
demonstrating that a good level of sintering was achieved, since it was impossible to identify the 
original sharp grain boundaries of the glass powders. Furthermore, the resulting morphology 
consisted in a smooth and also interconnected 3D network.  
Figure 7.11 reports the surface and internal morphology of sintered 3D printed AW sample. The 
thermal treatment led to a consolidate structure, characterised by a rough and dense surface with 
fine crystalline grains. Figure 7.11(b) highlights the presence of a distributed micropore-based 
network (pore size about 20µm). 
 
Figure 7.11: SEM micrographs of a) top surface and b) cross section of AW 3D printed structure after 
sintering (red arrows indicate necking formation). 
 Porosity and microarchitecture of the scaffolds 
On the basis of the results reported in Figure 7.12, which compare open and total porosity of NCL2, 
NCL7 and AW 3D printed parts after sintering, open porosity values varied between 15% and 23%, 
while total porosity values were found to vary from 28% to 38%. Significant differences were 
observed for NCL2 open porosity values in comparison to those of NCL7 3D printed scaffolds. No 
significant differences were found for the new compositions with respect to AW glass-ceramic; 
even though, NCL2 showed the lowest porosity and AW the highest, whereas NCL7 sintered 
samples exhibited an intermediate porosity level. 
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Figure 7.12: Averaged open and total porosity values for sintered NCL2, NCL7 and AW 3D printed 
parts. Error bars represent the standard error of the mean (p < 0.05(*)). 
These outcomes were confirmed by the micro-CT analysis, performed to evaluate the 
microarchitecture of the 3D printed sintered scaffolds. 3D reconstructions together with the 
representation of three spatial views (XY, XZ and YZ) of the bioceramic-derived structures are 
shown in Figure 7.13, Figure 7.14 and Figure 7.15 for NCL2, NCL7 and AW scaffolds 
respectively. 
Both porosity and interconnectivity are known to be desirable requirements of engineered 
scaffolds, necessary for the proper diffusion of nutrients and for metabolic waste removal (Salgado 
et al., 2004). 
Although the same glass powder/maltodextrin ratio was used to make all the bioceramic samples, 
composition NCL2 exhibited lower micro-porosity, showing a heterogeneous distribution of the 
pores. Additionally, in Figure 7.13(c-d) the presence of macro-channels, which crossed the 
structure, can be observed.  
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Figure 7.13: NCL2 scaffold: (a) 3D reconstruction and (b), (c) and (d) spatial views (XY, XZ and YZ) 
obtained through micro-CT analysis. 
Conversely, NCL7 micro-CT data (Figure 7.14) revealed an architecture characterised by a 
homogeneous widespread network of micro and macro-pores, which presence is crucial for fluid 
flow, cell migration, bone ingrowth and vascularisation. According to the different spatial views 
represented in Figure 7.14(b-c-d), a good level of interconnectivity throughout the structure was 
achieved. 
3D representation of NCL7 was found highly similar to AW-based structure. In good agreement 
with previous studies (Alharbi, 2015), AW samples were successfully sintered showing a 
homogeneous distribution of micro and macro pores along with an interconnected architecture 
(Figure 7.15(b-c-d)).  
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Figure 7.14: NCL7 scaffold: (a) 3D reconstruction and (b), (c) and (d) spatial views (XY, XZ and YZ) 
obtained through micro-CT analysis. 
 
Figure 7.15: AW scaffold: (a) 3D reconstruction and (b), (c) and (d) spatial views (XY, XZ and YZ) 
obtained through micro-CT analysis.  
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 Mechanical properties 
In order to assess the mechanical characteristics of the NCL2, NCL7 and AW 3D printed 
bioceramic structures, a three-point bending test was performed (Figure 7.16), according to the 
ASTM C1161 – 13 standard, using an INSTRON 5567 testing machine.  
 
Figure 7.16: Illustrative images of 3D sintered bars after the three-point bending test. 
The mechanical property values of the printed samples were evaluated from the stress-strain curves, 
resulting from the bending test (Figure 7.17). 
 
Figure 7.17: Representative stress-strain curve for 3D printed porous ceramic bars, resulting from the 
three-point bending test (red arrows indicate the cracking phenomena during the test).  
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The stress-strain curves presented similar trends, characterised by an almost linear profile with 
some stress oscillation (see red arrows in Figure 7.17), likely due to pore collpsing or either porous 
structure cracking during the test. 
Figure 7.18 reports the flexural strength and modulus values calculated for NCL2, NCL7 and AW 
structures. NCL2 was characterised by the highest mechanical properties. However, no significant 
differences were found for the novel 3D printed scaffolds in comparison to AW, whereas NCL2 
scaffolds showed flexural strength values significantly higher than NCL7 bars.  
 
Figure 7.18: Average flexural strength and flexural modulus for NCL2, NCL7 and AW 3D printed 
scaffolds evaluated through three-point bending test. Error bars represent standard error of the mean 
(p < 0.05(*)). 
A summary of the mechanical properties values for NCL2, NCL7 and AW printed bars is reported 
in Table 7.1. According to these data, even though the starting materials were different, it can be 
concluded that using the same glass powder-porogen ratio, 3D printed structures with comparable 
mechanical properties can be obtained. 
Table 7.1: Summary of the mechanical properties (mean±SE) for 3D printed NCL2, NCL7 and AW 
porous scaffolds assessed by three-point bending test. 
SAMPLE 
FLEXURAL 
STRENGTH (MPa) 
FLEXURAL 
MODULUS (GPa) 
NCL2 35.84±2.5 13.47±1.7 
NCL7 26.08±2.1 11.20±0.9 
AW 28.64±3.2 10.86±1.1 
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 In vitro cellular tests 
Figure 7.19 reports the effect of 3D printed scaffolds on rat OB mitochondrial activity tested by 
MTT colorimetric assay up to 7 days in culture.  
According to the absorbance values shown in Figure 7.19, no significant differences were detected 
for the novel 3D printed scaffolds in comparison to 3D printed AW after each considered time 
point.  
Furthermore, it can be highlighted that, although NCL2 showed a slightly increase of absorbance 
values after 7 days in culture, compared to those after 3 days, the absorbance values for NCL2 
scaffolds after 7 days were significantly lower (p<0.001) than those measured for the control 
sample (CTRL), represented by the polysterene culture plate, and 3D printed NCL7 scaffolds. 
 
Figure 7.19: Effect on formazan formation by NCL2, NCL7 and AW 3D printed scaffolds (n=6), 
evaluated through MTT assay after 24 hours, 3 days and 7 days in culture. Error bars represent the 
standard error of the mean (p < 0.05(*), p < 0.001(**)). 
 
Additionally, Table 7.2 displays the pH values of the conditioning media and the results obtained 
from the ICP analysis, considering the common elements of the three compositions (Si, P, Ca and 
Mg) after 7 days of immersion in DMEM solution. Acellular DMEM solution alone was used as 
control.  
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Table 7.2: pH values and ionic concentrations of the different DMEM extracts obtained from NCL2, 
NCL7 and AW specimens at specific time points. 
 NCL2 NCL7 AW DMEM 
 24 h 3 d 7 d 24 h 3 d 7 d 24 h 3 d 7 d 24 h 3 d 7 d 
pH (mg/l) 8.17 7.99 7.96 8.27 8.05 7.88 8.19 8.08 7.99 7.16 7.10 7.05 
Si (mg/l) 5.49 2.11 1.59 22 16.8 34.1 1.49 13.15 16.85 0.25 0.25 0.25 
P (mg/l) 3.7 2.5 2.7 5.2 8.2 10.5 4.6 0.5 2.6 29.5 29.5 29.5 
Ca (mg/l) 4.8 2.3 4.6 2.6 9.7 22.9 10.4 17.8 28.8 65.1 65.1 65.1 
Mg (mg/l) 2.1 0.8 0.7 2.1 0.8 4 2.2 2.2 2 19.8 19.8 19.8 
 
Novel 3D printed scaffolds, immersed in DMEM (having an initial pH of 7), produced a pH 
increase, in particular after 24 hours of soaking. The pH values, whose variation is commonly 
caused by the ion exchange phenomena between the samples and DMEM solution, started to 
decrease slowly after 3 days in culture for both NCL2 and NCL7. However, the pH values ranged 
between 7.88 and 7.96 after seven days, similarly to AW glass-ceramic.  
According to Table 7.2, which reports the ionic concentration of the pure extracts, calculated by 
subtracting the DMEM ionic content, there are no remarkable correlations between incubation time 
and concentration of ions released in DMEM solution. However, NCL7 resulted in the highest 
values for silicon and phosphorous values release in DMEM solution, while AW produced the 
highest released of calcium ions.  
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 Antibacterial test 
In order to evaluate the possible antibacterial properties of NCL7 composition, due to the presence 
of silver in its formulation, an inhibition zone test was performed on raw powders, sintered pellets 
and 3D printed scaffolds using S. aureus.  
As reported in Figure 7.20, no inhibition zone for bacterial growth was detected for raw powders 
and bioceramic pellets after 24h in incubation.  
 
Figure 7.20: Illustrative image of the zone inhibition test after 24 h incubation, performed on: NCL7 
and AW glass powders (bottom) and bioceramic pellets (top) using S. aureus. 
According to the qualitative analysis performed on the agar plate containing the porous samples 
(Figure 7.21(a)), also no antibacterial activity was revealed by AW specimens (see inset Figure 
7.21(b)), since no antibacterial agents were present in the AW main composition. 
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Surprisingly, a different behaviour was found for the porous NCL7 scaffolds, when compared to 
the dense bioceramic pellets. As shown in Figure 7.21(b), only NCL7 3D printed samples were 
able to create a zone where the bacterial growth was slightly inhibited. Although the halo was 
limited with respect to the positive control, the test revealed the potential antibacterial activity of 
porous NCL7-derived scaffolds, presumably due to silver ions diffusion in the area close to the 
sample. 
 
Figure 7.21: Inhibition halo test by using S. aureus strain to evaluate the antibacterial effect of NCL7 
and AW 3D printed scaffold: a) general view of the agar plate, b) magnification of AW sample and c) 
magnification of NCL7 sample showing the inhibition zone that limited bacterial growth.  
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Chapter 8.  Discussion 
8.1  Introduction 
In this research project eight new bioceramic formulations were developed using: 
i) silicon dioxide, phosphorous pentoxide and boron trioxide as network formers due to their 
widely demonstrated bioactive potential (Hench, 1998a; Hench, 1998b), distinctive resorbable 
properties (Knowles, 2003; Abou Neel et al., 2009b), and tailorable degradation rate (Huang et al., 
2006; Yao et al., 2007); 
ii) a range of different doping agents (i.e. MgO, MnO2, Al2O3, CaF2, 5Fe2O3, ZnO, CuO, Cr2O3) 
to tailor the properties of the main formulation (Dietrich et al., 2009; Fielding and Bose, 2013; 
Miola et al., 2014; Stähli et al., 2015; Tarafder et al., 2015; Vyas et al., 2015; Zhao et al., 2015). 
The aim of the study was the processing and characterisation of these novel developed glass 
formulations as potential biomaterials for bone tissue repair and regeneration, according to the 
following objectives: 
OB1: development of a series of novel glass compositions containing specific doping agents; 
OB2: evaluation of the physico-chemical and biological properties of the glass powders; 
OB3: evaluation of the physico-chemical, mechanical and in vitro bioactive properties of dense 
sintered bioceramic pellets; 
OB4: optimisation of the methodology for the fabrication of 3D porous glass-derived substitutes; 
OB5: evaluation of the physico-chemical, mechanical and biological properties of the 3D porous 
sintered substitutes. 
These objectives were all achieved, however limitations in the properties meant that not all the 
glass formulations were carried through to the later stages. 
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Table 8.1 provides a summary of the key outcomes, which will be discussed in more detail in the 
following sections. 
Table 8.1: Summary of the key outcomes deriving from the processing and characterisation of the novel 
glass formulations. 
CODE RATIONALE COMMENTS 
NCL1 
(SiO2-based) 
Osteogenic properties, mainly determined 
by the presence of a high amount of silica. 
Cytotoxic. 
NCL2 
(SiO2-based) 
Osteogenic properties and tailored 
degradation rate, mainly for load bearing 
applications. 
Good mechanical properties. Slow 
dissolution rate. 
NCL3 
(B2O3-based) 
Improved degradation rate and 
appropriate level of bioactivity as well as 
mechanical properties. 
Cytotoxic. 
NCL4 
(B2O3-based) 
Tailored degradation rate and osteogenic 
effects. 
Good mechanical properties as dense 
material. Quick degradation rate. 
NCL5 
(P2O5-based) 
Resorbable properties with controlled 
degradation rate. 
Did not form melt at 1500 ºC. 
NCL6 
(P2O5-based) 
Resorbable properties with controlled 
degradation rate, and improved 
mechanical strength. 
Cytotoxic. 
NCL7 
(SiO2-based) 
Antibacterial properties, mainly 
determined by the presence of silver 
oxide, and a good level of bioactivity. 
Good mechanical properties and 
bioactive potential. Scaffolds 
inhibited bacterial growth. 
NCL8 
(SiO2-based) 
Osteogenic properties and tailored 
degradation rate for non-load bearing 
applications. 
Cytotoxic. 
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8.2  Glass melting behaviour 
The NCL5 phosphate-based formulation did not form a liquid at 1500ºC, therefore the process was 
terminated and this composition was not pursued. The high melting temperature required was in 
contrast with other studies, which stated that phosphate–based glasses can be prepared at relatively 
low temperatures (Abou Neel et al., 2009b). It is considered that the complexity of NCL5 
composition (10 oxides in total), in comparison to other phosphate-based formulations developed 
in the literature (typically 6 oxides) (Navarro et al., 2004; Leonardi et al., 2010; Novajra et al., 
2011; Vitale-Brovarone et al., 2011), might have increased the melting point of NCL5 glass.  
8.3  Sintering temperature selection and sintering behaviour  
The selection of the appropriate sintering temperature, usually defined as the temperature where 
the maximal densification rate is reached (Venturelli, 2011; Bretcanu et al., 2014), is a key step 
during the manufacturing process to consolidate ceramic-based structures (Dorozhkin, 2010; 
Palmour et al., 2013).  
A summary of the potential sintering temperature ranges, derived from HSM analysis, and the 
optimal sintering temperatures selected for dense pellets and porous scaffolds is reported in Table 
8.2. The silicate-based and phosphate-based glasses showed larger sintering intervals when 
compared to borate-based glasses. However, no specific correlations were found among the 
different compositions. This might be due to the complex structure of the novel glasses, containing 
different network formers in diverse molar percentages. 
Table 8.2: Glass formulations sintering intervals obtained by HSM, and optimal sintering temperatures 
for dense pellets and porous scaffolds. 
 
NCL1 NCL2 NCL3 NCL4 NCL6 NCL7 NCL8 AW 
HSM sintering 
interval (ºC) 
575-785 600-730 555-625 550-650 580-775 575-785 500-730 800-1225 
Optimal sintering 
temperature (ºC) 
(dense pellets) 
625 700 625 625 725 625 625 850 
Optimal sintering 
temperature (ºC) 
(porous scaffolds) 
- 700 - - - 625 - 1150 
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From a qualitative point of view, the HSM thermographs (reported in paragraph 6.2.3 and obtained 
under the same heating conditions) revealed that silicate-based glasses (specifically, NCL1, NCL2, 
NCL7 and NCL8) displayed a similar thermal profile, characterised by an increase in the samples 
dimensions after the maximum shrinkage temperature. These results are in good agreement with 
the findings reported by Baino et al., which found that a silicate-based glass after a first 
densification step exhibited a significant volumetric expansion (Baino et al., 2013). Similar 
shrinkage profiles were observed for borate-based glasses (NCL3 and NCL4) and the AW 
composition, which showed an “elbow” in their curves, as reported in Figure 6.5. These findings 
support the work published by Arstila et. al, who suggested that the elbow indicated the possible 
sintering interval of the analysed compound (Arstila et al., 2005; Arstila et al., 2008). Regarding 
the NCL6 phosphate-based glass, although this composition has a network former content similar 
to another glass reported in the literature (45% P2O5, 3% SiO2, 26% CaO, 7% MgO, 15% Na2O 
and 4% K2O) (Bretcanu et al., 2014), its shrinkage profile was more comparable to those of the 
novel borate-based compositions. This is tentatively attributed to the presence of the network 
modifiers in the formulation. 
Appropriate sintering temperatures can be selected only by a thorough post-processing evaluation, 
which includes: i) the production of sintered structures using different thermal treatments and ii) 
subsequent morphological characterisation using SEM or micro-CT analyses (Baino and Vitale-
Brovarone, 2011; Vivanco et al., 2011; Bretcanu et al., 2014).  
On the basis of the data obtained from the HSM analysis, different thermal treatments were 
investigated and optimised to increase the liquid phase of the dense pellets and improve their 
densification status. It is interesting to note that, although an optimisation process was needed, the 
outcomes from the heating microscopy were a very useful guide in predicting the optimal sintering 
temperatures of bioceramic pellets: the temperatures that led to optimal consolidated structures 
were all in the range of sintering temperatures provided by the HSM.  
Moving from compact bioceramic pellets to 3D porous scaffolds, the sintering conditions required 
a further optimisation process (Baino et al., 2013; Bretcanu et al., 2014). As 3D porous scaffolds 
have a different internal structures, if compared to dense pellets, it was necessary to burn-out the 
solid binder, which entails further shrinkage of the structure and thus a major reduction of the final 
volume. The optimal sintering temperatures for NCL2 and NCL7 scaffolds were consistent with 
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those applied for the sintering of dense bioceramic pellets. However, as reported in Chapter 7, a 
gradual adjustment of porous structure sintering conditions needed to be performed. Specifically, 
following the same heating treatments as implemented on the NCL2 and NCL7 bioceramic pellets, 
the solid binder was not completely burnt off. Therefore, a 2 steps sintering treatment was 
developed. However, also in this case the 3D printed parts were poorly consolidated, showing weak 
structural integrity. A 3 steps heat treatment for both NCL2 and NCL7 scaffolds was necessary in 
order to obtain mechanically competent 3D porous parts with appropriate densification degree. 
Particularly, during the first step of the treatment (up to 200°C) the temperature was increased to 
remove completely the sacrificial porogen. The second step was added in order to allow the gradual 
consolidation of the bioceramic structure, and finally the last step was required to reach the optimal 
sintering of the bioceramic structures. 
Additionally, observing the sintering behaviour of AW glass-ceramic, the data in Table 8.2 show 
how moving from dense to porous structures the sintering conditions of the material were affected. 
Specifically, the optimal sintering temperature of dense AW was 850ºC, in agreement with the 
HSM data presented by Faeghi-Nia (Faeghi-Nia et al., 2009), while the 3D porous AW required 
an increase of the optimal sintering conditions up to 1150ºC, based on the protocol developed by 
Xiao and subsequently applied by Alharbi (Xiao et al., 2008; Alharbi, 2015). Comparing the heat 
treatments of NCL2 and NCL7 scaffolds with respect to AW (3 steps vs 2 steps), a further stage 
during the sintering process was necessary in order to reach a satisfactory densification of the novel 
bioceramic-based samples. Hence, it can be concluded that the best sintering conditions, assessed 
by a thorough post-processing analysis, are significantly influenced by the glass composition 
(Novajra et al., 2015).  
8.4  Crystal structure evolution 
XRD analysis indicated that only NCL6 and NCL7 (as raw materials) showed a glass-ceramic 
behaviour, whereas the other formulations produced XRD patterns characterised by a broad peak 
detected at 2θ values between 25° and 30° (Figure 6.3), typical of completely amorphous bioglasses 
(Boccaccini et al., 2007).  
Comparing the XRD patterns of the glass powders with those of the sintered bioceramic pellets, 
few considerations can be drawn. First of all, the XRD analysis confirmed the amorphous nature 
of NCL1, NCL2, NCL3, NCL4 and NCL8 compositions even after sintering; the thermal process 
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did not affect the crystallinity of NCL7 glass-ceramic, which still showed a crystalline phase 
corresponding to pure silver. The post sintering XRD pattern for NCL2 silicate-based glass 
revealed the presence of a crystalline phase identified as diopside. Diopside is a Mg-containing 
compound, which have already been investigated as biomaterials for bone repair in form of powder 
and dense bulk ceramic (Nonami and Tsutsumi, 1999). Furthermore, diopside-derived scaffolds 
were found to possess good and stable mechanical properties upon immersion in physiological 
solution due to their low degradation rate (Wu et al., 2010). Additionally, the sintering process 
increased the crystallinity of NCL6 glass sample; in fact, as the XRD pattern reported (see Figure 
6.37), the initial calcium sodium phosphate phase was complemented by a sodium calcium 
magnesium phosphate phase after NCL6 thermal treatment. As presented in chapter 2, the use of 
calcium phosphates is a longstanding area of interest for bone tissue applications due to their high 
similarity with human bone (Dorozhkin, 2010).  
The XRD patterns of AW glass-ceramic revealed the same crystalline phases (hydroxylapatite 
complemented with β-wollastonite) before and after the sintering process (Xiao et al., 2008). 
However, the sintered material showed more intense peaks (Figure 6.40(b)) with respect to the raw 
glass-powder (Figure 6.40(a)), confirming the glass-ceramic nature of this formulation. These 
results are different from those of Magallanes-Perdomo et al., who worked with raw AW powder 
which was completely amorphous, and showed that thermal treatment of the powders at 1100ºC 
for 1 hour produced two crystalline phases, apatite and wollastonite respectively. It is thought that 
differences in the glass production method will have affected the crystallisation behaviour of the 
compound. Hence, it can be concluded that through a careful optimisation of the post-processing 
conditions, it is possible to consolidate AW powder which is completely amorphous and AW 
powder that is partially crystalline, with similar phase composition in the sintered material. 
8.5  Morphological analysis  
The morphology of the starting glass powders was evaluated through SEM analysis, after the 
grinding and sieving processes. Glass particles were found to have an average size of 20µm and 
less than 53µm, and the tendency to agglomerate. From a qualitative perspective, the raw powders 
showed a microstructure very similar to AW glass-ceramic and also to other glasses produced by 
the melting route (Baino et al., 2013). Moving from glass powders to dense materials, SEM 
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observations showed homogenous and microporous structures of compact sintered pellets with no 
internal cracks. 
The microstructures achieved from the processing by indirect 3D printing of NCL2 and NCL7 were 
porous with different topographies, but with high surface roughness similar to AW-based scaffolds 
obtained by the same processing route. Additionally, micro-CT investigations offered a more 
accurate assessment of 3D printed glass-derived scaffolds. 3D reconstructions of NCL2, NCL7 and 
AW printed bioceramic structures are shown in Figure 7.13, Figure 7.14 and Figure 7.15 
respectively. Although the same glass powder/maltodextrin ratio was used, the NCL2 composition 
exhibited lower micro-porosity with a heterogeneous distribution of the pores. NCL7 micro-CT 
images revealed an interconnected architecture very similar to 3D printed AW, and characterised 
by a homogeneous widespread network of micro (~20µm) and macro-pores (~150µm), which are 
fundamental for fluid flow, cell migration, bone ingrowth and vascularisation (Liu et al., 2007; Loh 
and Choong, 2013). Overall, the NCL7 and AW scaffolds showed the most promising structures 
for clinical application. 
8.6  Ion release potential and cytotoxicity evaluation 
The ionic release ability of the novel formulations was assessed by immersing the raw glass 
powders (10 mg/l) in deionised water. A summary of the ion release concentrations for Si, P, B, 
Ca and Mg, which are the common elements present in almost all the formulations, and derived 
from the ion release data presented in Chapter 6, is reported in Figure 8.1. It is interesting to observe 
that, except for NCL2 composition, the amount of silicon released in solution after 28 days of 
soaking, was proportional to the molar content present in the main formulation. Furthermore, boron 
was released much quicker than silicon for NCL3, NCL4 and NCL6 composition, in accordance 
with the findings reported by previous researchers (Huang et al., 2006). The data reported in Figure 
8.1 further demonstrate the widely proved reactive nature of B2O3-based glasses. Moreover, it was 
found that phosphorus concentration (Figure 8.1) did not increase with immersion time for all the 
glasses, except for NCL6 phosphate-based formulation.  
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Figure 8.1: Ionic concentrations of Si, P, B, Ca and Mg released into deionised water from all the 
formulations, without refreshing the solutions and at different time points (1, 7, 14 and 28 days). 
Additionally, concerning the pH of the solutions, it is well-known that changes in pH values can 
cause severe damage to OB cells, which prefer a more physiological environment (pH ~ 7.5) (El-
Ghannam et al., 1997). The pH values resulting from the immersion of the raw glass powders in 
deionised water were monitored up to 28 days. All the glasses, even with refreshes of the media, 
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showed pH levels above 8.5, which can be considered a severe condition for cell viability. 
However, the values were comparable to those of AW, therefore the pH rise might be due to the 
high reactivity of glass powders. These results are consistent with the work of other researchers, 
which found that fine Bioglass® powders (average particle size ~2µm), immersed in different 
solutions, produced a rapid increase in pH already after 6 hours of soaking; in particular, the pH of 
deionised water solution reached a value of 10 after the first 30 seconds of immersion (Cerruti et 
al., 2005) 
Following these considerations and looking at the overall data reported in Figure 8.1, no 
meaningful correlations between the cytotoxic effect of the novel formulations and their ionic 
release potential of Si, P, B, Ca and Mg can be derived. Cell viability was significantly affected by 
the presence of the glass powders in the media in particular at high concentrations. These findings 
are consistent with the results obtained by Santocildes-Romero et al., who found that the addition 
of Sr-doped bioactive glass powders (≥ 6.7mg/ml) to culture medium, significantly reduced MSCs 
viability. However, for NCL1, NCL3, NCL6 and NCL8 compositions the cell mitochondrial 
activity was inhibited even for the indirect method for all three concentrations tested. Considering 
that no remarkable variation in pH values up to 7 days were detected, it can be stated: 
 for NCL1 and NCL3 glass formulations, considering the low concentrations of the majority 
of the doping agents, it is most likely that the release of vanadium from both these 
compositions might have had a negative effect on cell mitochondrial activity(Sakai et al., 
2002); 
 for NCL6 composition, since not many dopants were present in this formulation, and 
because the release of Co, Cu and Cr after 28 days in immersion was quite low, it is most 
likely that the high level of phosphorus and boron concentration was the cause of the 
detrimental effect of this glass; 
 considering the doping agents of NCL8 formulation and comparing their effect with those 
of the other compositions, no clear reasons for the toxicity of this glass were found; hence, 
the negative effect might be due to the combination of the different oxides present in the 
main formulation; 
 for NCL2 composition the slow release of the doping agents seems to positively influence 
the cell viability; conversely, the high reactive nature of NCL4 borate-based glass helped 
the release of strontium at higher level (in comparison to NCL1 glass), which has been 
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demonstrated to increase proliferation as well as differentiation of osteoblast cells 
(Gentleman et al., 2010; Hesaraki et al., 2010) 
 the positive effect of the NCL7 formulation seems to derive from the combined effect of 
titanium, iron and copper, which enhance OB proliferation and activity(Mourino et al., 
2012). 
According to the results of the MTT assay performed on 3D porous structures, no obvious reason 
for the differences in behaviour can be derived from the formulations alone, but the AW and NCL7 
materials showed the best results for apatite formation in SBF, which will be discussed in the next 
section, and this bioactive response might have influenced cellular behaviour (Dyson et al., 2007; 
Alharbi, 2015; Lee et al., 2015). 
8.7 Apatite-forming ability 
No apatite needle-like precipitates were visible on the surface of the three novel compositions, after 
immersion in SBF. On the contrary, AW glass-ceramic was completely covered after 7 days in 
immersion, demonstrating its widely proved bioactive behaviour (Zhang et al., 2009; Magallanes-
Perdomo et al., 2011; Park and Ozturk, 2013). However, globular shaped aggregates were found 
on the surface of NCL4 and NCL7 bioceramic pellets after 7 days in immersion, which particularly 
for the NCL7 composition increased after 28 days. Furthermore, for NCL7 pellets the Ca/P ratio 
changed from 1.1 at day 7 up to 1.4 at day 28, as demonstrated by EDS and XPS analysis. These 
precipitates might be considered HCA precursors (octacalcium phosphate) (Dorozhkin, 2010), and 
therefore suggest the capability of NCL7 composition to induce bioactivity.  
Fu et al. suggested that the morphology of sample surfaces, after immersion in SBF, changed from 
needle-like for silicate-based scaffolds to approximately globular shape for borate-based scaffolds 
(Fu et al., 2010a). On the basis of the SBF testing results conducted in this study, NCL4 and AW 
compositions can therefore be said to have behaved as expected. Conversely, the cauliflower shape 
of NCL7 precipitates was not in accordance with the findings reported by previous studies (Huang 
et al., 2006; Magallanes-Perdomo et al., 2011; Deliormanli, 2013). A possible explanation for this 
might be the presence of iron in the NCL7 main formulation, which could have affected the 
morphology of the precipitates (Zhang et al., 2013). If this was the case, it would mean that the 
differences in precipitate morphology, after immersion in SBF solution, are composition 
dependent. 
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The Ca/P ratio of NCL7 precipitates after 28 days in immersion was lower than the one for AW, 
but the formation of micro-cracks on NCL7 surface was more pronounced than the AW-derived 
pellets (see Figure 8.2). Crack development is usually a common morphological feature due to the 
dual reaction of formation of a silica-rich film and growth of the calcium-phosphate HCA layer, 
which is typical of bioactive materials (Hench, 1991). This suggests that the NCL7 formulation 
may be considered a bioactive material. 
 
Figure 8.2: (a) NCL7 and (b) AW bioceramic pellet after soaking in SBF for 28 days (the red arrows 
indicate the micro-cracks formation on the pellet surface).  
Regarding NCL2 bioceramic pellets, no structural changes were detected, apart from that after 28 
days of soaking in SBF the surface appeared homogeneously covered by a thin white layer rich in 
calcium.  
According to the literature, the structure of a glass plays a crucial role in determining its bioactivity 
(Goel et al., 2012). Specifically, the incorporation of intermediate oxides and the reduction of P2O5 
content in the glass network can reduce bioactive behaviour (Groh et al., 2014). Hence, the complex 
formulation of NCL2 glass may explain the absence of even HA precursors. However, it has been 
also demonstrated that bioactivity tests in vitro, using SBF solution, can lead to false positive and 
false negative results when compared to in vivo trials (Bohner and Lemaitre, 2009), and so no 
strong conclusion can be drawn. 
Another aspect that needs to be considered when a biomaterial is immersed in SBF solution is its 
biodegradation rate. Usually glass-based structures undergo degradation process at a rate defined 
by the kind of network former (Fu et al., 2010a). In good agreement with the literature, and as 
anticipated by the ion leaching phenomena, after 28 days of immersion in SBF borate-based 
samples were characterised by comparatively greater weight loss (Yao et al., 2007; Xin et al., 
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2010). Silicate-derived structures showed the lowest degradation rate (Huang et al., 2006). 
Particularly, for NCL2 the negligible weight loss is consistent with the low degradation rate showed 
by its diopside crystalline phase upon immersion in physiological fluids, as previous studies 
demonstrated (Wu et al., 2010). These findings indicate that NCL2-based structures, with their 
high mechanical strength and slower degradation rate (compared to traditional bioactive ceramics) 
could potentially be used for bone-tissue repair where a controlled slow degradation is desirable.  
Additionally, the pH variation of the NCL2, NCL4 and NCL7 compositions during bioactivity tests 
in SBF solution was monitored up to 28 days. Conversely to the pH trends resulting from the 
immersion of the raw glass powders in deionised water, it was observed that the pH varied between 
7.4 and 7.7. These values are considered optimal for in vitro cell culture (El-Ghannam et al., 1997), 
and are consistent with those of Vitale-Brovarone et. al., who evaluated pH variation of dense 
silicate-based glasses in SBF solution, and reported pH levels around 7.75 (Vitale-Brovarone et 
al., 2008). 
8.8  Novel glass formulations printability 
When processed by ZCorp 310 3D printer, the NCL2 and NCL7-based green parts resulted in stable 
structures similar to AW. On the contrary, NCL4-based green bodies were very weak and powdery, 
and difficult to handle. A possible explanation for this might be related to the poor flowability of 
NCL4-based blend, which as stated by Cox et al. directly affects the material printability (Cox et 
al., 2015). The poor printability of NCL4 formulation, in comparison to the other compositions, 
was qualitatively observed during the spreading phase of the printing process. NCL4 blend particles 
tended to agglomerate resulting in a non-homogenous powder layer.  
8.9  Mechanical properties 
Table 8.3 shows that the moduli of the dense bioceramics were close to that of dense AW. However, 
porosity and interconnectivity are known to be desirable requirements of tissue engineered 
structures, necessary for correct diffusion of nutrients and for the removal of metabolic waste 
(Salgado et al., 2004; Polo-Corrales et al., 2014). Total porosity values for 3D printed NCL2, 
NCL7 and AW scaffolds are reported in Table 8.4 in comparison to human cortical and trabecular 
bone. All the 3D printed structures had porosity levels higher than cortical bone and lower than 
trabecular bone (Goldstein, 1987; Keaveny and Hayes, 1993), with no significant differences 
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between the three materials. However, depending on the clinical need, it might be possible to reach 
a porosity level closer to cortical or trabecular bone simply redesigning the precursor characteristics 
(i.e. particle size and powder/binder ratio) (Goldstein, 1987; Keaveny and Hayes, 1993; Jones and 
Hench, 2003b). Furthermore, using a 3D printing approach, it has been shown that combined 
macro- and micro-porous structures can be created (Dyson et al., 2007; Alharbi, 2015). 
Table 8.3: Compressive modulus (mean±SE) of AW and dense bioceramic pellets. 
 Compressive 
Modulus (GPa) 
Porosity (%) 
AW 1.29 ± 0.03 < 2 % 
NCL1 1.54 ± 0.01 < 2 % 
NCL2 1.43 ± 0.03 < 2 % 
NCL3 1.53 ± 0.04 < 2 % 
NCL4 1.37 ± 0.02 < 2 % 
NCL6 1.24 ± 0.01 < 2 % 
NCL7 1.32 ± 0.06 < 2 % 
NCL8 1.68 ± 0.01 < 2 % 
 
Table 8.4: Total porosity values (vol %) of 3D printed scaffolds (n=5) compared to human bone. The 
data represent the mean ± SE (* (Goldstein, 1987)). 
NCL2 NCL7 AW Cortical bone  Trabecular bone 
28.7±1.5 35.3±2.0 38.4±3.7 5-10*  50-90* 
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It has been considered that for powder-based 3D printing systems, grain size and relative 
distribution of the starting materials are crucial factors for the physical characteristics of the final 
3D printed parts. Particularly, these parameters directly influence porosity, which in turn has been 
seen to impact cell behaviour (attachment, proliferation and differentiation), as well as the resulting 
mechanical properties of the implant (Spath et al., 2015). However, one of the major critical aspects 
in developing load-bearing scaffolds for bone tissue is the conflicting balance between porosity 
and mechanical properties.  
Considering the data reported in Table 8.5, the scaffolds fabricated in the current work had flexural 
strength higher than trabecular bone (10-20MPa) and lower than human cortical bone (135-
193MPa) (Fu et al., 2011). Furthermore, the NCL2 and NCL7 3D printed scaffolds showed similar 
properties to AW scaffolds (Table 8.5). It is of value to highlight that, using a powder-based indirect 
3DP technology and novel glass formulations, porous bone-like substitutes with load-bearing 
capability and tailorable porosity have been manufactured. 
8.10 NCL7 antibacterial properties 
The results of the antibacterial tests performed on NCL7 silver-doped composition were presented 
in the last part of Chapter 7. The porous 3D printed NCL7 scaffolds were able to create a zone 
where the bacterial growth was slightly inhibited, which was absent for the dense bioceramic 
pellets. A possible explanation of this effect might be the higher surface area that the porous 
materials offered with respect to the dense pellets, and presumably the greater release of Ag ions 
(Sepulveda et al., 2002; Fu et al., 2011; Kolmas et al., 2014). However, the resulting halo, assessed 
qualitatively via the inhibition test, was limited in comparison to the positive control. As Kolmas 
stated, the method of material synthesis plays a crucial role during the release of doping ions 
(Kolmas et al., 2014). Specifically, they found that the direct incorporation of Ag ions into the 
structure of HA lowered their release. Furthermore, dose dependent antibacterial activity was 
observed for silver-substituted HA, for which higher levels of silver (1.1wt%) led to a more 
effective bactericidal response (Lim et al., 2013). Hence, it is possible that the antibacterial 
properties of NCL7 formulation would also be enhanced by increasing the Ag content.  
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Table 8.5: Mechanical properties (mean±SE) of 3D printed scaffolds via powder-based indirect 3DP. 
Material 
Sintering 
conditions 
Total porosity 
(vol%) 
Flexural 
strength (MPa) 
Reference 
NCL2 700ºC/1h 28.7±1.5 35.9±2.5 - 
NCL7 625ºC/1h 35.3±2.0 26.1±2.1 - 
AW 1150ºC/1h 38.4±3.7 28.6±3.2 - 
AW 1150ºC/1h 35.3±1.9 35.6±4.7 (Alharbi, 2015) 
β-TCP/Bioglass 1000ºC - 14.9±3.6 
(Bergmann et al., 
2010) 
HA/AW 
1200ºC/3h 
1300ºC/3h 
51.5±1.2 
2.5±0.1 
21.0±0.1 
76.8±4.3 
(Suwanprateeb et al., 
2009) 
HA 1200ºC/2h  21.2±2.2 (Seitz et al., 2005) 
TCP 134ºC/2h 28-35% 3.9-5.2 
(Klammert et al., 
2010) 
 
8.11 Summary 
Over the last four decades, considerable progress has been made to develop load-bearing substitutes 
for diseased, injured or missing bone. Particularly, the science of glass and glass-ceramic together 
with the last developments in additive manufacturing technology have greatly contributed to 
address some of the current open problems, mainly poor reproducibility of the grafts, degree of 
performance needed and strategy for a cost-effective manufacturing process (Ventola, 2014). 
However, although numerous research efforts have been made “the design of advance bioactive 
biomaterials that can share load with host bone, transmit the load to the cells, and then degrade 
as the bone repairs” is a frontier that need to be crossed (Hench and Jones, 2015).  
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Taken all together, the results of this research work indicated the possibility to design novel 
bioceramic formulations by adding specific and functional doping agents in order to tailor their 
properties towards a specific mechanical and biological response. Particularly, ICP analysis proved 
the high reactive nature of borate-based glass, and the quicker release of boron in comparison to 
silicon and phosphorous. Furthermore, the data obtained from the HSM represented a useful 
preliminary guide in the selection of the appropriate sintering temperature for glass-derived 
structures. Finally, this study demonstrated the excellent capabilities of powder-based 3DP 
technology to produce 3D bioceramic substitutes, which feature similar properties, such as surface 
roughness, porosity, interconnectivity, mechanical properties. Moreover in vitro biocompatibility 
of 3D printed bioceramic-derived structures, by using different ceramic-based precursors, has been 
investigated. Additionally, the use of a binder jetting 3DP technology for the manufacturing of 
porous structures as potential bone-like substitutes, led to establish that the glass composition 
significantly impacts the printability of powdered materials, as demonstrated by NCL4 
formulation. Hence, a thorough optimisation process is required before the manufacturing phase 
starts. 
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Chapter 9.  Conclusion and future work 
9.1  Conclusions 
Eight innovative glass compositions, based on silicate, phosphate and borate network formers, were 
initially proposed for this research work and three of these (NCL2, NCL4 and NCL7 compositions) 
are considered to have promise in load bearing musculoskeletal applications: 
 NCL2 has good mechanical properties and slow degradation rate; 
 NCL4 has the highest biodegradation rate of the three, however, NCL4 glass composition 
significantly influenced the printability of the powder-based precursors; 
 NCL7 was more able to form HCA precursors than NCL2 and NCL4-derived pellets, and 
in the form of a porous scaffold inhibited bacterial growth. 
According to the main findings of whole research project, the following conclusions can be drawn: 
 the NCL6, NCL7 and AW compositions were glass-ceramic in nature, whilst the NCL1, 
NCL2, NCL3, NCL4 and NCL8 formulations were completely amorphous; 
 the sintering treatment contributed to the development of diopside crystalline phase for 
NCL2 composition, modifying the nature of the material from glass to glass-ceramic after 
the sintering; 
 hot stage microscopy provides an effective and informative method to support the 
development of new material sintering conditions; 
 the borate-based formulations showed the fastest ion release and degradation rates, with the 
silicate-based compositions showing the lowest degradation rate; 
 all the formulations, processed as dense bioceramic structures, showed mechanical 
properties comparable to those of dense AW glass-ceramic; 
 the NCL7-based bioceramic structures showed a better ability to form HCA precursors than 
NCL2 and NCL4-based materials; 
 binder removal as part of a sintering cycle can be best achieved through the use of a multi-
step sintering treatment. 
 indirect powder-based 3DP offers an effective route for the production of porous 
bioceramic scaffolds. 
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Overall, this research work demonstrated: 
i) the potential of NCL2 and NCL7 glass formulations as smart materials in the field of bone tissue 
repair and regeneration, with surface roughness, porosity and interconnectivity, mechanical 
properties and in vitro biocompatibility similar to 3D printed AW-derived structures. 
ii) the possibility to process glass powder blends by using a versatile and cost-effective additive 
manufacturing technology for the production of customised “off-shelf” bone tissue engineered 
substitutes. 
9.2  Future work 
The findings of the present study complemented those of previous researchers, and contributed to 
extend the knowledge on the use of ceramic materials with tailorable properties for orthopaedic 
applications. Nevertheless, future research work that will be valuable to perform is suggested 
below.  
 Biodegradation rate: 
the degradation rate of bioglass formulations depends not only on their compositions but 
also on surface area, geometry of the specimens and pH of the environment (Fu et al., 
2010a) (Huang et al., 2006). Therefore, a set of new experimental conditions, based on 
different geometries (both rectangular and cylindrical shape), level of porosity, and initial 
pH values of the solution might be useful to be explored in static and dynamic conditions 
(Pilia et al., 2013). Furthermore, additional studies need to be performed to prove the 
potential of NCL2 and NCL4 formulations as controlled drug delivery systems. 
 Bioactivity: 
bioactivity tests in SBF using 3D printed structures should be carried out to establish the 
potential bone-bonding behaviour of 3D porous materials.  
 Printability: 
the effects of processing parameters (such as precursor particle distribution, layer thickness 
and binder saturation level) on mechanical properties of 3D printed structures before and 
after sintering could be further investigated. Additionally, the printability of the NCL4 
formulation, as function of different processing parameters, needs to be further assessed. 
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 Antibacterial properties: 
i) further tests, based on the quantitative evaluation of Ag released during the 
antibacterial test need to be performed; 
ii) in order to deeply investigate the efficiency of the antibacterial activity of the NCL7 
composition different types of bacteria need to be carried out; 
iii) development and characterisation of new glass compositions with different Ag 
content could be further evaluated.  
 In vivo tests: 
since in vitro tests cannot replicate the complex environment of the human body, animal 
studies to assess whether or not the novel materials are suitable for bone tissue repair and 
regeneration applications should be performed.   
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